| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Immunology |
Recent Updates
Recently added Catalysts
Immutep Limited$0.42
-0.01 (-1.55%)
C 52Pipeline Score Undervalued Biotech · Clinical
Market Cap
62.99 M
EPS
-0.37
P/E Ratio
-
Value Trade
283.98 K
7.6 %
Week
-18.2 %
1 Month
-83.01 %
3 Month
-71.42 %
6 Month
-89.55 %
5 Year
-98.96 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
191.99 K
52 Week Range
0.29 - 3.53
% held by Insiders
0.84 %
% held by Institutions
1.77 %
Enterprise Value
-2.31 M
Total Shares
147.37 M
Short %
3.04 %
Float Shares
146.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immutep Limited
1348Total events
0Upcoming
251Tier-1 (high impact)
2012 – 2026Coverage
Event history 1348
Q3 2026
Q3 2026
▲Enrollment Completeeftilagimod alfaTrial
Patient enrolment completion expected in Q3 2026
non-small cell lung cancersource ↗
Q3 2026
◆Enrollment Completeeftilagimod alfaTrial
Full patient enrolment expected
first line non-small cell lung cancersource ↗
Jun 4, 2026
◆Poster PresentationIMP761Presentation
IMP761 Phase I data to be presented at EULAR 2026
Autoimmune diseasessource ↗
Jun 4, 2026
▲Primary Endpoint MetIMP761Clinical Data
Phase I single ascending dose part met primary endpoint of safety and tolerability
autoimmune diseasessource ↗
Jun 3, 2026
●Oral PresentationIMP761Presentation
Presentation of IMP761 details at EULAR 2026 Congress
autoimmune diseasessource ↗
Jun 2026
▼Milestone Paymenteftilagimod alfaCorporate
US$10 million payment due to Dr. Reddy's by June 2026 per license agreement
May 30, 2026
◆Poster Presentationeftilagimod alfaPresentation
Poster presentation at ASCO 2026: Efti induced lymphocyte activation linked to improved survival
late-stage cancer (NSCLC, HNSCC, MBC, melanoma)source ↗
May 28, 2026
▲Full Resultseftilagimod alfaClinical Data
Systematic evaluation of 5 trials shows efti + SOC improves OS in ALC responders
late-stage cancer (NSCLC, HNSCC, MBC, melanoma)source ↗
Apr 30, 2026
▼Trial Discontinuedeftilagimod alfaTrial
TACTI-004 Phase III trial discontinued following IDMC recommendation after interim futility analysis
first-line non-small cell lung cancersource ↗
Apr 30, 2026
▼Enrollment Pausedeftilagimod alfaTrial
Enrollment halted in TACTI-004 due to trial discontinuation
first-line non-small cell lung cancersource ↗
Drug Pipeline Intelligence
C52
Pipeline Score $388M
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored6.2x
rNPV / MCap Top 79%
Micro Cap (rank 192 of 911)
Percentile RankImmutep Limited carries a moderate pipeline score (52/100), with $5.2B risk-adjusted pipeline value, led by eftilagimod alfa in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (Phase 3), across $143B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eftilagimod alfa Monoclonal antibody | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | NCT06726265 | 48% | $3.3B | ACTIVE NOT_RECRUITING | 756 | FAST | B (73) | Sep 1, 2029 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IMP761 | autoimmune diseases | Phase 1 | 2026-06-04 | statistically significant pharmacodynamic activity at 7 mg/kg; p = 0.029 Read More | Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 Read More | |
IMP761 | autoimmune diseases | Phase 1 | 2026-06-04 | statistically significant pharmacodynamic activity at 7 mg/kg; p = 0.029 Read More | Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 Read More | |
IMP761 | autoimmune diseases | Phase 1 | 2026-06-04 | statistically significant pharmacodynamic activity at 7 mg/kg; p = 0.029 Read More | Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMMP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMMP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMMPIMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
Bernstein Liebhard LLP has announced a deadline of July 6, 2026, for investors to join a class action lawsuit against Immutep Limited. The lawsuit alleges that the company made materially false and misleading statements regarding its business operations and financial stability, leading to inflated stock prices. As a result, many investors incurred significant financial losses when the truth about the company's operations was revealed. Affected shareholders are encouraged to take legal action if they purchased shares during the specified period.
Read more →IMMPImmutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
Immutep Limited announced positive interim Phase I data for its LAG-3 agonist antibody, IMP761, which showed favorable safety and pharmacodynamic activity in healthy volunteers. The study met its primary endpoint and demonstrated significant immunosuppressive effects, supporting further clinical investigation in autoimmune diseases. Additional updates are expected in H2 CY2026.
Read more →IMMPSystemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Immutep Limited announced positive results from five clinical trials evaluating eftilagimod alfa in late-stage cancer patients. The combination of eftilagimod alfa with standard-of-care therapies led to a significant increase in overall survival, particularly among patients showing an immune response. The findings suggest a strong link between immune activation and improved clinical outcomes across various cancer types.
Read more →IMMP▼ -6.9%on this news
IMMUTEP CLASS ACTION LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Immutep Ltd. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against Immutep Ltd., concerning false and misleading statements made by the company about its TACTI-004 trial. The lawsuit specifically addresses claims that Immutep concealed crucial risk factors regarding the trial's efficacy and safety endpoints. Investors who suffered losses between March 24, 2025, and March 12, 2026, are encouraged to consider their legal options. The firm also provides contact information for investors interested in participating in or learning more about the lawsuit.
Read more →IMMPIMMUTEP ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Immutep Ltd. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Immutep Ltd. The lawsuit alleges that the company made false and misleading statements about the TACTI-004 trial, which misrepresented the trial's efficacy and safety prospects. Investors who acquired Immutep's ADRs during the specified period are encouraged to contact the law firm. The lawsuit indicates that internal data suggested a significant risk of trial failure, which was not communicated to investors.
Read more →IMMPIMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has initiated a securities class action lawsuit on behalf of investors who purchased American Depositary Receipts of Immutep Limited between March 24, 2025, and March 12, 2026. The lawsuit accuses the company of making false and misleading statements about its business and financial health, which led to inflated stock prices. When the actual situation was disclosed, investors experienced substantial financial losses. Affected shareholders are encouraged to contact the law firm to discuss their rights and possible participation in the class action.
Read more →IMMP▼ -5.6%on this news
ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY26 Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trial Root cause an
Immutep has decided to discontinue the TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer based on a recommendation from the Independent Data Monitoring Committee. The interim futility analysis indicated that patients receiving the treatment were underperforming compared to those on a placebo. Although this outcome was disappointing, Immutep continues to explore other avenues for its clinical programs, including ongoing trials like INSIGHT-003, which show favorable results. The company's financial position remains solid with a cash balance of approximately A$110.6 million.
Read more →IMMPImmutep Receives Nasdaq Notice of Bid Price Deficiency
Immutep Limited has received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement of $1.00 per share. The company has a compliance period of 180 days to regain this status. While the notification does not affect current trading, there is uncertainty about whether compliance will be achieved within the given timeframe.
Read more →IMMPImmutep Quarterly Activities Report Q3 FY26
Immutep Limited has announced the discontinuation of its TACTI-004 Phase III trial following an interim futility analysis by the Independent Data Monitoring Committee. The analysis revealed that patients receiving the combination of eftilagimod alfa, KEYTRUDA, and chemotherapy were underperforming compared to the control group. Despite this setback, the company reported a strong cash position and positive results from other ongoing trials, including IMP761 and EFTISARC-NEO.
Read more →IMMPImmutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Immutep Limited announced that an abstract has been accepted for presentation at the ASCO 2026 Annual Meeting. The abstract focuses on the impact of eftilagimod alfa on lymphocyte activation and survival outcomes in metastatic cancer patients. The presentation will showcase data linking immune activation markers to improved survival rates. The event will take place from May 29 to June 2, 2026, in Chicago.
Read more →IMMP▲ +72.8%on this news
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
Immutep Limited has received FDA Orphan Drug Designation for eftilagimod alfa to treat Soft Tissue Sarcoma, a rare cancer. This designation supports the development of therapies for rare diseases and provides potential regulatory benefits. The decision is backed by promising results from the Phase II EFTISARC-NEO trial, which demonstrated significant efficacy in tumor response.
Read more →IMMPImmutep Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm is investigating potential securities claims against Immutep Ltd. due to allegations of misleading business information. The investigation follows the announcement that a pivotal Phase III trial for eftilagimod alfa was discontinued based on interim analysis results, leading to a significant drop of 82.6% in the stock price. Investors who suffered losses may be eligible for compensation through a proposed class action without upfront costs. Immutep is now working on an orderly wind down of the trial in accordance with regulatory guidelines.
Read more →IMMPImmutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
Immutep has successfully completed the single ascending dose portion of its Phase I study for IMP761, a LAG-3 agonist aimed at treating autoimmune diseases. The drug was well tolerated with no safety concerns reported. The study is now progressing to the multiple ascending dose phase, with results to be presented at the EULAR conference in June 2026.
Read more →IMMPImmutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Immutep Limited following a significant decline in stock price. The investigation is prompted by the company's announcement that the Phase III TACTI-004 trial, evaluating eftilagimod alfa in treatment for non-small cell lung cancer, is unlikely to achieve its primary endpoints. This led to an 85-90% drop in stock price after a recommendation for trial discontinuation. Investors who suffered losses are encouraged to reach out to Johnson Fistel for details on potential recovery.
Read more →IMMP▼ -82.4%on this newsshared move
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Immutep Limited has announced the discontinuation of the TACTI-004 Phase III study evaluating eftilagimod alfa in first-line non-small cell lung cancer. The Independent Data Monitoring Committee recommended this decision following a futility analysis. Despite this setback, Immutep plans to continue developing its pipeline and reassess its capital allocation priorities.
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2025 (previous corresponding period: half-year ended 31 December 2024) To be read in conjunction with the 30 J
Immutep Limited reported its half-year financial results for the period ending December 31, 2025. The company experienced a net loss after tax of A$44,859,721, a significant increase compared to the previous year's loss. Total revenues increased by 6%, but a marked decline in other income, alongside decreased net tangible assets per share, raises concerns about the company's financial health. Despite the losses, Immutep reported positive developments in its clinical trials for efti, particularly in key oncology indications.
Read more →IMMPImmutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Immutep Limited has reached 50% enrolment in the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. The trial aims to establish a new standard of care and has enrolled 378 patients across 27 countries. The company anticipates completing enrolment by Q3 2026.
Read more →IMMP▼ -8.1%on this news
ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY26 Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America,
Immutep Limited has reported significant progress in its Q2 FY26 Quarterly Activities Report, primarily highlighting a strategic collaboration with Dr. Reddy's for the commercialization of eftilagimod alfa (efti) outside North America. The collaboration includes an upfront payment and potential milestone payments, indicating strong financial prospects. Additionally, the company detailed the ongoing progress of its Phase III TACTI-004 trial, which shows promise in treating advanced non-small cell lung cancer. Furthermore, data from various trials, including INSIGHT-003 and EFTISARC-NEO, demonstrate encouraging efficacy and safety profiles for efti.
Read more →IMMPImmutep Quarterly Activities Report Q2 FY26
Immutep Limited has reported significant advancements in its Q2 FY26 activities, including a strategic collaboration with Dr. Reddy's for the development of efti, a novel immunotherapy. The company is making strong progress in its Phase III TACTI-004 trial for non-small cell lung cancer and has received positive feedback from the FDA regarding efti's dosing. However, the INSIGHT-005 Phase I study was discontinued due to recruitment difficulties.
Read more →IMMPImmutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
Immutep Limited has reported positive results from its Phase I study of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The trial demonstrated good safety and efficacy, with significant immunosuppressive effects observed. The study's success has generated increased interest in the drug, which targets conditions like rheumatoid arthritis and Type 1 diabetes. Further updates are expected in 2026.
Read more →IMMPImmutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the
Immutep Limited announced significant operational progress in its Phase III TACTI-004 trial, which evaluates the combination of eftilagimod alfa, KEYTRUDA, and chemotherapy for advanced non-small cell lung cancer. The trial has successfully enrolled 289 patients, accounting for over 38% of the target enrollment of 756. With more than 120 clinical sites across 27 countries activated, the company anticipates completing patient enrollment in the third quarter of 2026. The CEO expressed satisfaction with the trial's progress and the strong interest in the study following a recent licensing agreement.
Read more →IMMP▲ +26.1%on this news· ran to +46% by day 3
Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in al
Immutep Limited and Dr. Reddy's Laboratories announced a strategic collaboration for the development and commercialization of the immunotherapy Eftilagimod Alfa outside North America, Europe, Japan, and Greater China. As part of the agreement, Dr. Reddy's will pay Immutep an upfront amount of USD 20 million and has the potential to contribute further milestone payments totaling up to USD 349.5 million. Eftilagimod Alfa, currently under evaluation in a Phase III trial for non-small cell lung cancer, demonstrates the potential to serve as a first-in-class treatment option in oncology. The collaboration is viewed as a significant milestone for Immutep, enhancing its ability to maximize value in licensed markets.
Read more →IMMP▼ -7.6%on this news· ran to +23% by day 3shared move
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Immutep announced that new data from the AIPAC-003 Phase II trial will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial evaluated eftilagimod alfa in combination with paclitaxel for metastatic breast cancer patients. Results showed promising response rates, but tolerability issues were noted at the higher dosing level. The study aligns with FDA's Project Optimus initiative, defining the optimal biological dose for future clinical programs.
Read more →IMMPTranslational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
Immutep Limited presented positive results from the EFTISARC-NEO Phase II trial at CTOS 2025, demonstrating a median 51.5% tumor hyalinization/fibrosis in patients with resectable soft tissue sarcoma. The trial evaluated the combination of eftilagimod alfa, radiotherapy, and KEYTRUDA, achieving significant pathologic response rates. Early data also indicated strong immune activation, suggesting potential for broader applications of efti in cancer treatment.
Read more →IMMPASX/Media Release Immutep Receives A$4.6 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA - 3 November 2025 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunoth
Immutep Limited announced that it has received approximately A$4.6 million in research and development tax incentives from the French Government. This funding will be used to support the ongoing global clinical development of its immunotherapy products, eftilagimod alfa and IMP761. The tax incentive reflects Immutep's eligibility under the French "Crédit d'Impôt Recherche" scheme for R&D activities conducted in Europe. The company also qualifies for rebates from the Australian government's R&D tax incentive program.
Read more →IMMPImmutep Receives A$4.6 million R&D Tax Incentive from French Government
Immutep Limited has announced the receipt of a €2.59 million (approximately A$4.57 million) research and development tax incentive from the French Government. This funding, part of the Crédit d'Impôt Recherche scheme, supports R&D activities conducted in Europe. The funds will be allocated to the global clinical development of Immutep's therapies, eftilagimod alfa and IMP761.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY26 Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build m
Immutep Limited provided an update on its Quarter 1 FY26 activities, focusing on the ongoing TACTI-004 Phase III trial for eftilagimod alfa in non-small cell lung cancer. The trial is showing robust enrollment growth with over 170 patients already randomized and more than 100 clinical sites activated globally. Additionally, supportive feedback from the FDA has paved the way for further development in head and neck cancers, while encouraging data presentations at major oncology conferences have bolstered confidence in their ongoing trials. The company remains financially stable with a strong cash position.
Read more →IMMPImmutep Quarterly Activities Report Q1 FY26
Immutep Limited has provided its quarterly activities report for Q1 FY26, highlighting significant progress in its clinical trials, particularly the TACTI-004 Phase III trial for lung cancer, which has enrolled over 170 patients. The company received positive FDA feedback for its efti treatment in head and neck cancer and presented encouraging data at major oncology conferences. Despite a strong cash position, the company reported net cash outflows during the quarter.
Read more →IMMPPrimary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Immutep Limited announced positive results from the EFTISARC-NEO Phase II trial at the ESMO Congress 2025. The trial evaluated eftilagimod alfa combined with radiotherapy and KEYTRUDA for resectable soft tissue sarcoma, achieving a median tumor hyalinization/fibrosis of 51.5%, significantly surpassing the target of 35%. The study also reported a favorable safety profile.
Read more →IMMPTwo Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
Immutep Limited presented two posters at ESMO Congress 2025, showcasing promising data from the INSIGHT-003 trial, which demonstrated strong response rates for the combination therapy of eftilagimod alfa, KEYTRUDA, and chemotherapy in first-line non-small cell lung cancer. The data is particularly encouraging for patients with low PD-L1 expression. Additionally, the TACTI-004 Phase III trial was highlighted, aiming to further evaluate this combination therapy across various patient populations.
Read more →IMMPImmutep Announces Successful Completion of FDA Project Optimus Requirements
Immutep Limited has successfully completed the FDA's Project Optimus requirements, receiving positive feedback regarding the optimal biological dose of 30mg for its immunotherapy, eftilagimod alfa (efti). This milestone is crucial for the ongoing Phase III trial TACTI-004, which evaluates efti in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. The company aims to bring this novel treatment to market for cancer patients worldwide.
Read more →IMMPImmutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
Immutep announced a significant update regarding its TACTI-004 Phase III trial for eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. The trial has successfully enrolled over 170 patients, allowing for a futility analysis to be conducted in early 2026. The company remains optimistic about the trial's potential to improve treatment outcomes in this high-need patient population.
Read more →IMMP▲ +6.2%on this news
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
Immutep Limited has announced a Phase II trial to evaluate neoadjuvant eftilagimod alfa (efti) in early-stage HR+/HER2-negative breast cancer. The trial, led by the George Washington University Cancer Center, aims to assess the efficacy of efti combined with standard chemotherapy. Up to 50 patients will be treated, with the goal of achieving high rates of pathological complete response. Efti is designed to activate the immune system to better combat cancer.
Read more →IMMPImmutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Immutep Limited announced that its EFTISARC-NEO Phase II trial has been accepted for oral presentation at the CTOS 2025 Annual Meeting. This trial is the first to assess eftilagimod alpha in combination with radiotherapy and KEYTRUDA for soft tissue sarcoma patients. The study highlights the urgent need for effective treatments in this orphan disease.
Read more →IMMPImmutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2025 Previous corresponding period
Immutep Limited reported its preliminary final results for FY25, highlighting both significant achievements and challenges. The company has transitioned into a Phase III biotechnology firm, showcasing strong execution on clinical programs and promising trial data. However, a notable increase in losses and external challenges, such as regulatory uncertainty and supply chain issues, impact its financial outlook. Despite these hurdles, Immutep ended the year with a strong cash position, facilitating continued progress in clinical trials.
Read more →IMMPImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS 1 SYDNEY, AUSTRALIA August 5th, 2025 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep
Immutep Limited has received favorable feedback from the FDA regarding the clinical development of its immunotherapy, eftilagimod alfa, for treating recurrent/metastatic head and neck cancer patients with PD-L1 expression below 1. The feedback highlights the potential of efti in combination with KEYTRUDA, especially for a segment of patients with a high unmet medical need. Future development paths could include a randomized registrational trial or a smaller single-arm study, with plans to accelerate the clinical process under the FDA's Project FrontRunner initiative. CEO Marc Voigt expressed optimism about the comprehensive support received from the FDA and emphasized the ongoing focus on other clinical trials, such as the pivotal Phase III study for non-small cell lung cancer.
Read more →IMMPImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Immutep has received positive feedback from the FDA regarding the clinical development of eftilagimod alfa (efti) for treating recurrent/metastatic head and neck cancer patients with PD-L1 expression below 1. The FDA supports further development of efti in combination with KEYTRUDA, highlighting the significant unmet medical need in this patient population. Immutep is considering various clinical development paths, including potential accelerated approval options.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY25 The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients
Immutep Limited has released its quarterly activities report for Q4 FY25, highlighting significant progress in its pivotal TACTI-004 Phase III trial for first-line non-small cell lung cancer (1L NSCLC). The trial, evaluating efti in combination with KEYTRUDA and chemotherapy, is building momentum with 78 clinical sites approved across 23 countries. The company reported positive initial data from its Phase I trial of IMP761 for autoimmune diseases and a robust cash balance of approximately A$129.69 million. However, an increase in net cash used for research and development activities has raised some concerns regarding operational expenditures.
Read more →IMMPImmutep Quarterly Activities Report Q4 FY25
Immutep Quarterly Activities Report Q4 FY25
Read more →IMMPImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Read more →IMMPImmutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Read more →IMMP▼ -5%on this news
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases Initial pharmacological data from placebo-controlled, double-blind Phase I study shows signi
Immutep Limited has reported positive initial efficacy and safety data from a Phase I study of its first-in-class LAG-3 agonist antibody, IMP761, aimed at treating autoimmune diseases. The study, which is double-blind and placebo-controlled, indicates substantial T cell suppression at the highest dose without any treatment-related adverse events. Given these encouraging results, Immutep plans to continue exploring higher dosing levels. The ongoing trial is being conducted in the Netherlands, and further data is expected to be released in late 2025.
Read more →IMMPImmutep s Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma Novel combination with efti has met the trial s primary endpoint of tumour hyalinization/fibrosis in
Immutep Limited's Efti, when combined with radiotherapy and KEYTRUDA (pembrolizumab), has met its primary endpoint in the EFTISARC-NEO Phase II trial for soft tissue sarcoma, achieving a tumour hyalinization/fibrosis rate significantly above historical data. The trial's success indicates the potential for improved survival outcomes in patients with this aggressive cancer type. Results will be presented at a future medical meeting, highlighting the importance of this research within the oncology field.
Read more →IMMP▲ +8.2%on this news
Immutep s Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-lin
Immutep Limited announced promising results from its INSIGHT-003 trial, where the combination of eftilagimod alpha (efti) with KEYTRUDA and chemotherapy achieved a 60.8% response rate and a 90.2% disease control rate in patients with first-line non-small cell lung cancer. This trial evaluated the efficacy of efti in patients, particularly those with low PD-L1 expression, who represent a significant portion of the NSCLC population. CEO Marc Voigt expressed confidence in efti becoming a new standard of care based on these results and historical comparisons. Additional updates from the study are anticipated at future medical conferences.
Read more →IMMP▲ +45.6%on this news
Immutep s Efti in Combination with KEYTRUDA (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS 1 Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall
Immutep Limited has reported promising results for its immunotherapy drug Efti in combination with KEYTRUDA for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with PD-L1 expression below 1. The Phase IIb trial TACTI-003 showed a median overall survival of 17.6 months, significantly better than existing treatment options. Efti has already received Fast Track designation from the FDA, and the company plans to discuss potential paths to approval with regulators. The therapy was also noted for its favorable safety profile, enhancing its potential for broader application in treating cancer.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY25 First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone Pivotal TACTI-004 trial design presented at
Immutep Limited has announced significant developments in its clinical trials, particularly the dosing of the first patient in the Phase III TACTI-004 trial for non-small cell lung cancer. The trial aims to evaluate the efficacy of eftilagimod alfa in combination with anti-PD-1 therapy and chemotherapy. Additionally, the company presented the trial's design at the European Lung Cancer Congress, receiving positive feedback from investigators. With approvals for the trial now in 19 countries, Immutep also reported a solid financial position, enhancing its capacity to advance its research programs.
Read more →IMMPImmutep Quarterly Activities Report Q3 FY25
Immutep Quarterly Activities Report Q3 FY25
Read more →IMMP▼ -5.6%on this news· ran to -20% by day 3
Immutep to Participate in Upcoming Investor Conferences
Immutep Limited, an immunotherapy company specializing in cancer and autoimmune diseases, has announced its participation in upcoming investor conferences. The company will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, and at The Citizens Life Sciences Conference on May 8, 2025, among others. This engagement is part of Immutep's strategy to enhance their market presence and showcase their advancements in LAG-3 therapeutics to stakeholders.
Read more →IMMPFirst Patient Dosed in Immutep s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep
Immutep has successfully dosed the first patient in its TACTI-004 Phase III trial, evaluating the efficacy of eftilagimod alfa combined with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. This trial aims to provide a new standard of care for patients with significant unmet medical needs. The trial will enlist approximately 756 patients across over 150 sites globally, focusing on improving progression-free and overall survival rates. Positive results could lead to impactful changes in treatment practices for lung cancer patients.
Read more →IMMPImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2024 (previous corresponding period: half-year ended 31 December 2023) To be read in conjunction with the 30 J
Immutep Limited has announced its half-year financial results for the period ending December 31, 2024, reporting a 77% increase in total revenue and other income totaling A$7,276,004. However, the company also noted a 5% rise in net loss after tax, which reached A$22,377,429. In the clinical domain, encouraging results from trials of its key product candidate, efti, in combination with KEYTRUDA were presented, indicating potential effectiveness in non-small cell lung cancer and head and neck squamous cell carcinoma. The company remains focused on advancing its promising product portfolio.
Read more →IMMP▼ -5.7%on this news
ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY25 Marking Immutep s transition to a Phase III biotech, the Company s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) r
Immutep Limited has reported significant progress in its clinical developments, particularly announcing the initiation of the Phase III TACTI-004 trial for eftilagimod alfa in first-line non-small cell lung cancer (1L NSCLC). This transition marks a pivotal moment as the company moves forward with global regulatory approvals for the trial in over 25 countries. Additionally, encouraging results from the TACTI-003 Phase IIb trial highlight promising overall survival rates in patients with head and neck cancer. The company is well-funded, ensuring sustained research efforts into 2026.
Read more →IMMPImmutep Quarterly Activities Report Q2 FY25
Immutep Quarterly Activities Report Q2 FY25
Read more →IMMPPatient Enrolment Completed for EFTISARC-NEO Phase II Trial
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Read more →IMMPPatient Enrolment Completed for INSIGHT-003
Patient Enrolment Completed for INSIGHT-003
Read more →IMMPImmutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 Favourable safety profile for world s first LAG-3 agonist, IMP761, with no treatment related adverse events to date Additional saf
Immutep Limited announced positive initial safety data from its first-in-human Phase I trial of IMP761, a novel LAG-3 agonist. The study, which is placebo-controlled and double-blind, saw no treatment-related adverse events among the first three dosing cohorts of healthy participants. This trial aims to assess both safety and pharmacological efficacy of IMP761, which is designed to address autoimmune diseases by enhancing immune regulation. Further safety data and PK/PD assessments are expected in the first half of 2025.
Read more →IMMPImmutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Read more →IMMP▼ -5.3%on this newsshared move
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pem
Immutep Limited announced promising clinical results from its TACTI-003 Phase IIb trial at the ESMO Immuno-Oncology 2024 congress. The trial evaluates eftilagimod alpha (efti) combined with MSD's KEYTRUDA in patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 expression below 1. The new data shows significant improvements in overall survival, progression-free survival, and durability when compared to historical anti-PD-1 therapy results. The findings suggest a potential breakthrough for an underserved patient population that currently has limited treatment options.
Read more →IMMPImmutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA
Immutep Limited has announced the initiation of the TACTI-004 Phase III clinical trial for first-line metastatic non-small cell lung cancer (NSCLC). The trial, which has received regulatory approval from the Australian Therapeutic Goods Administration, aims to evaluate the efficacy of eftilagimod alfa in combination with KEYTRUDA and chemotherapy. The study will involve approximately 750 patients across over 150 clinical sites worldwide, with expectations to enroll the first patient by the first quarter of 2025. Immutep is optimistic that this trial will significantly impact treatment options for lung cancer patients.
Read more →IMMPPositive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patie
Immutep Limited presented positive data from its Phase II EFTISARC-NEO trial at the CTOS 2024 Annual Meeting, highlighting the efficacy of eftilagimod alpha in combination with pembrolizumab and radiotherapy for patients with soft tissue sarcoma. The trial reported that 71.4% of patients achieved a significant pathologic response, while the combination resulted in a median hyalinization/fibrosis rate three times higher than that of standard radiotherapy. The ongoing study aims to enroll a total of 40 patients by Q1 2025, primarily funded by a Polish government grant.
Read more →IMMP▲ +11.8%on this newsshared move
Immutep s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical contro
Immutep Limited has announced positive results from the INSIGHT-003 Phase I trial, highlighting the efficacy of its immunotherapy, efti, in combination with KEYTRUDA and chemotherapy for treating metastatic non-squamous non-small cell lung cancer. The trial, which followed up on 21 patients for a minimum of 22 months, reported a median overall survival of 32.9 months and a 24-month overall survival rate of 81.0%. Remarkably, the data suggests that efti may enhance the treatment outcomes for patients with low PD-L1 expression, a group typically less responsive to existing therapies. Immutep is optimistic about advancing to the upcoming TACTI-004 study.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY25 Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concludin
Immutep Limited has reported positive FDA feedback regarding its TACTI-004 Phase III trial, which evaluates its drug efti in combination with KEYTRUDA for treating first-line non-small cell lung cancer. The company also announced encouraging results from its TACTI-003 Phase IIb trial, showcasing a significant objective response rate and strong safety profile. With a solid cash balance of approximately A$172.3 million, Immutep is well-positioned to continue advancing its clinical trials and support future growth. Additionally, the company gained recognition by entering the ASX300 index, further enhancing its market visibility.
Read more →IMMPImmutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Read more →IMMPImmutep Quarterly Activities Report Q1 FY25
Immutep Quarterly Activities Report Q1 FY25
Read more →IMMPImmutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Read more →IMMPImmutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Read more →IMMPImmutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer SYDNEY, AUSTRALIA
Immutep Limited has completed patient enrollment for the randomized Phase II portion of the AIPAC-003 clinical trial, focusing on metastatic breast cancer. The trial involves 65 patients who have exhausted other therapy options and will assess the efficacy of eftilagimod alpha in combination with paclitaxel. This research is pivotal in determining the optimal dosage and furthering treatment options for patients with breast cancer. Upcoming updates will follow after data collection and analysis.
Read more →IMMPASX/Media Release Immutep Receives A$3.6 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 24 September 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company d
Immutep Limited has announced the receipt of an A$3.6 million research and development tax incentive from the French Government. This funding, part of the Crédit d'Impôt Recherche scheme, will aid in the development of its LAG-3 related immunotherapy treatments aimed at cancer and autoimmune diseases. The company also benefits from cash rebates under the Australian Federal Government's R&D tax incentive program. These financial resources will facilitate the ongoing global clinical development of its investigational products.
Read more →IMMPImmutep Receives A$3.6 million R&D Tax Incentive from French Government
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
Read more →IMMPNew Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Read more →IMMP▼ -12.5%on this newsshared move
Immutep s Efti in Combination with MSD s KEYTRUDA Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2
Immutep Limited has announced positive results from its TACTI-003 Phase IIb trial, featuring eftilagimod alpha (efti) in combination with Merck's KEYTRUDA for patients with recurrent or metastatic head and neck cancer. The trial demonstrated improved efficacy, including higher response rates and maintained safety, particularly in patients with high PD-L1 expression. Presented at the ESMO Congress 2024, these findings signify a promising advance in immunotherapy for challenging cancer types. Immutep aims to pursue potential regulatory pathways based on these positive outcomes.
Read more →IMMPINDEX ANNOUNCEMENT S&P Dow Jones Indices Announces September 2024 Quarterly Rebalance of the S&P/ASX Indices SYDNEY, SEPTEMBER 6, 2024: S&P Dow Jones Indices announced today the changes in the S&P/ASX Indices, effective
S&P Dow Jones Indices has announced the changes to the S&P/ASX Indices, effective before the trading open on September 23, 2024. Notably, Immutep Limited is set to be included in the S&P/ASX 300 Index along with several other companies. Meanwhile, some companies like Domino's Pizza Enterprises Limited will be removed. The changes reflect the September quarterly review and are crucial for market participants.
Read more →IMMPImmutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2024 Previous corresponding period
Immutep Limited released its preliminary final report for the year ended June 30, 2024, indicating an increase in overall losses to AUD 42.7 million, though other income rose to AUD 7.8 million. The report highlights significant progress in clinical trials for efti, particularly in oncology, emphasizing partnerships and positive clinical data. Despite the revenue increase, the lack of dividends and the financial losses raise concerns about the company's short-term stability. The report also notes the challenging market conditions for biotech companies in the early months of 2024.
Read more →IMMPASX/Media Release Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in
Immutep Limited announced that a late-breaking abstract has been selected for oral presentation at the 2024 ESMO Congress in Barcelona. The presentation will showcase results from the TACTI-003 Phase IIb trial, which assesses the efficacy of eftilagimod alpha in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This high-profile presentation emphasizes the potential of novel LAG-3 immunotherapies in improving treatment outcomes for cancer patients. The study's implications for clinical practice and ongoing research advancements are significant.
Read more →IMMPImmutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
Read more →IMMPASX/Media Release Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody IMP761 is designed to enhance the brake function of LAG-3 on T cells to restore balance to t
Immutep Limited has announced the successful dosing of the first participant in a Phase I clinical trial for IMP761, a first-in-class agonist LAG-3 antibody. This study, intended to assess the safety and pharmacological effectiveness of IMP761, will involve 49 healthy volunteers and is being conducted by the Centre for Human Drug Research in the Netherlands. Preliminary results, including safety data, are expected by the end of the year, with pharmacokinetics and pharmacodynamics assessments to follow in early 2025. IMP761 shows potential in treating autoimmune diseases by silencing dysregulated memory T cells.
Read more →IMMP▲ +8.5%on this newsshared move
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY24 Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in
Immutep Limited released its quarterly activities report for Q4 FY24, highlighting significant advancements in its immunotherapy programs. The company formed a pivotal clinical trial collaboration with MSD to evaluate efti combined with KEYTRUDA and chemotherapy in metastatic non-small cell lung cancer, expected to enroll around 750 patients. Positive feedback was received from both the FDA and the Spanish AEMPS regarding the trial design. Immutep also reported successful results from the TACTI-003 Phase IIb trial in head and neck cancer, showing improved response rates compared to KEYTRUDA monotherapy.
Read more →IMMPImmutep Quarterly Activities Report Q4 FY24
Immutep Quarterly Activities Report Q4 FY24
Read more →IMMP▲ +7.4%on this news
ASX/Media Release Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase
Immutep Limited announced a successful meeting with the FDA regarding its TACTI-004 Phase III trial design for eftilagimod alfa (efti) in treating first-line metastatic non-small cell lung cancer (NSCLC). The trial will combine efti with KEYTRUDA and standard chemotherapy and aims to enroll around 750 patients. This feedback marks a significant milestone in Immutep's development process, potentially paving the way for a new standard of care in NSCLC treatment. The upcoming trial is designed to evaluate the drug's efficacy and safety across various PD-L1 expression levels.
Read more →IMMPImmutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Read more →IMMPImmutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
Read more →IMMPASX/Media Release Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases Study expected to enrol first participants during Q3 CY2024 SYDNEY,
Immutep Limited has secured regulatory clearance to commence a Phase I clinical study for IMP761, the first therapeutic LAG-3 agonist antibody, aimed at treating autoimmune diseases. This study, set to enroll 49 healthy volunteers, will assess the safety, pharmacokinetics, and pharmacodynamics of the drug. Preclinical data supports the potential of IMP761 to silence aggressive T cells and restore immune balance. Initial enrollment is anticipated in Q3 2024, with first results expected later in the year.
Read more →IMMP▲ +14.9%on this newsshared move
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression Efti in combination with KEYTRUDA (pembrolizumab) achieved a 35.5% response rate in evaluable p
Immutep Limited reported positive results from its TACTI-003 Phase IIb trial, where the combination of eftilagimod alfa (efti) and KEYTRUDA yielded a 35.5% response rate in recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. This marks a considerable improvement over the historical response rates associated with anti-PD-1 monotherapy. The trial also indicated a high disease control rate and no new safety concerns, reinforcing the potential viability of this chemotherapy-free treatment approach. Further discussions with regulatory agencies regarding the path forward for this combination are anticipated.
Read more →IMMP▲ +5.3%on this news
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA July 3rd, 2024
Immutep Limited has announced an upcoming oral presentation at the ESMO Virtual Plenary session scheduled for July 11, 2024, highlighting new clinical data from the TACTI-003 Phase IIb trial. The presentation will focus on patients with negative PD-L1 expression and will be led by Dr. Robert Metcalf. The company will also host a webcast on July 12 to discuss the results in more detail, showcasing the therapeutic potential of its LAG-3 immunotherapy, Eftilagimod alfa, in treating head and neck squamous cell carcinoma.
Read more →IMMP▼ -32.5%on this news
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer Efti in combination with KEYTRUDA (pembrolizumab) in first line head and neck squamous cell carcinoma (1L HNSCC)
Immutep Limited announced positive topline results from the TACTI-003 Phase IIb trial evaluating eftilagimod alfa (efti) combined with KEYTRUDA for treatment of first-line recurrent/metastatic head and neck squamous cell carcinoma. The trial revealed a ~34% overall response rate across all evaluable patients, indicating higher efficacy compared to KEYTRUDA monotherapy. Notably, efti's performance included improvements among patients with negative PD-L1 expression. The results underline efti's potential to broaden the efficacy of anti-PD-1 therapies in broader patient populations, with plans for further discussions with regulatory agencies to explore future pathways.
Read more →IMMPNOT FOR DISTRIBUTION OR RELEASE TO U.S. WIRE SERVICES IN THE UNITED STATES 24 June 2024 Immutep completes underwritten retail entitlement offer Immutep Limited ACN 009 237 889 (ASX: IMM) ( Immutep or the Company ) is ple
Immutep Limited announced the successful completion of its Retail Entitlement Offer, which raised approximately A$10.6 million. This was part of a larger fully underwritten Offer that included an institutional component, with a total amount raised reaching A$100.2 million. The Retail Entitlement Offer attracted 1,963 applications with a take-up rate of 62% from eligible retail shareholders. Immutep's Chairman expressed optimism regarding the company's future, particularly in relation to its late-stage clinical trials for efti in lung cancer.
Read more →IMMPASX/Media Release Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer SYDNEY, AUSTRALIA 25 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
Immutep Limited has entered into an exclusive license agreement with Cardiff University for the development and commercialization of next-generation anti-LAG-3 small molecules targeting cancer treatment. The new collaboration arises from years of research and aims to create oral therapies that could be more affordable than existing monoclonal antibodies. The partnership benefits from the expertise of prominent scientists at Cardiff University and its successful history in innovative therapeutic research. This agreement is seen as a significant step toward advancing Immutep's pipeline and solidifying its presence in the competitive LAG-3 landscape.
Read more →IMMPImmutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Read more →IMMP▲ +8.8%on this news
June 2024 Immutep successfully completes institutional placement and institutional component of entitlement offer Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce
Immutep Limited has successfully completed its institutional placement and entitlement offer, raising approximately A$89.6 million. The institutional offer saw a take-up rate of about 100% from eligible investors. The company continues to push forward with its late-stage clinical trials for its cancer therapy, efti, which has reported strong efficacy and safety results. As they move closer to seeking marketing authorization in the U.S., the company is preparing to initiate a retail component of the offer, set to open shortly.
Read more →IMMP▼ -12.1%on this newsshared move
Immutep successfully completes institutional placement and institutional component of entitlement offer
Immutep successfully completes institutional placement and institutional component of entitlement offer
Read more →IMMP▼ -12.1%on this newsshared move
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA (pembrolizumab) in Pivotal Phase III Trial Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD s an
Immutep Limited has announced a collaboration with MSD to conduct a Phase III trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA and chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC). This trial, named TACTI-004, aims to establish a new treatment standard by improving response rates across all NSCLC patient types. It follows previous successful trials and aims to include around 750 patients worldwide. Both companies will retain commercial rights to their respective compounds under this agreement.
Read more →IMMPImmutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination t
Immutep Limited presented promising results from the safety lead-in phase of the AIPAC-003 trial at the ESMO Breast Cancer 2024 Congress. The trial focused on the efficacy and safety of a 90 mg dose of eftilagimod alpha in combination with paclitaxel for metastatic breast cancer patients who had previously failed standard therapies. The study observed a 50% overall response rate, including one complete response, and a favorable safety profile with no severe adverse events reported. Further data from the ongoing randomized Phase II portion of the trial is expected in 2024.
Read more →IMMPASX/Media Release Positive Initial Clinical Data Reported from Immutep s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma Novel triple combination of efti with radiother
Immutep Limited has reported positive initial results from the EFTISARC-NEO Phase II trial, evaluating eftilagimod alpha in combination with radiotherapy and KEYTRUDA for soft tissue sarcoma patients. Notably, 67% of participants exhibited near-complete responses after the treatment. The trial is an important first step in assessing this novel combination's effectiveness in a neoadjuvant setting. The study continues to enroll patients, with further data expected to be presented at a medical conference later this year.
Read more →IMMPPositive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY24 First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% over
Immutep Limited released its Q3 FY24 activities report, highlighting positive developments in its clinical trials for the cancer therapy efti. The first clinical data from the AIPAC-003 trial in metastatic breast cancer indicated that the 90mg dosing of efti was safe with a 50% overall response rate. Additionally, the company maintains strong cash reserves of approximately $95.4 million as it continues advancing its product candidates. The report also mentions the termination of its collaboration with GSK, though it is not expected to materially affect the company's finances.
Read more →IMMPImmutep Quarterly Activities Report Q3 FY24
Immutep Quarterly Activities Report Q3 FY24
Read more →IMMPImmutep Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA (pembrolizumab) in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients w
Immutep Limited reported positive preliminary topline results from its TACTI-003 Phase IIb trial, evaluating eftilagimod alpha (efti) in combination with KEYTRUDA for patients with first-line metastatic head and neck squamous cell carcinoma (HNSCC) exhibiting negative PD-L1 expression. The trial demonstrated an overall response rate of 26.9% and a disease control rate of 57.7%, which reflects favorable outcomes compared to historical data. This combination therapy could offer significant benefits for a patient population currently in need of effective treatment alternatives, having also received FDA Fast Track designation.
Read more →IMMPASX/Media Release Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3
Immutep Limited has announced a partnership with the Centre for Human Drug Research (CHDR) to conduct a first-in-human Phase I clinical trial for IMP761, a novel LAG-3 agonist antibody. This trial aims to assess safety, pharmacokinetics, and pharmacodynamics in approximately 49 healthy volunteers, following all necessary regulatory approvals. The research involves advanced immunological models to evaluate the therapeutic potential of IMP761 in treating autoimmune diseases. With promising preclinical data indicating its effectiveness, the trial is a significant step toward developing innovative immunotherapy treatments.
Read more →IMMPImmutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Read more →IMMPImmutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Read more →IMMP▲ +11.1%on this news
Immutep Announces First Clinical Data from 90mg Dosing of Efti Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated Encouraging initial efficacy in
Immutep Limited has announced preliminary data from its Phase II/III AIPAC-003 trial evaluating 90mg dosing of eftilagimod alpha (efti) in combination with paclitaxel for metastatic breast cancer. The safety lead-in from the trial shows that the combination therapy is safe and well tolerated, with no serious adverse events reported. Encouragingly, the initial efficacy results indicate a 50% overall response rate among six patients, including one complete response. The ongoing randomized portion of the trial aims to further assess the safety and efficacy of this higher efti dosage compared to lower doses.
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2023 (previous corresponding period: half-year ended 31 December 2022) To be read in conjunction with the 30 J
Immutep Limited reported its half-year financial results for the period ending December 31, 2023, showcasing a 59% increase in total revenue to A$4,110,397. However, the net loss attributable to members rose by 3%, reaching A$21,228,191 compared to A$20,623,250 for the same period last year. The company is advancing its lead immunotherapy candidate, efti, towards potential marketing approvals in various cancer indications, having received positive regulatory feedback in Europe and the USA. Immutep aims to commence a pivotal trial for efti in 2024, further bolstered by Fast Track designations from the FDA.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY24 Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lu
Immutep Limited has released its Quarterly Activities Report for Q2 FY24, highlighting promising clinical data from the TACTI-002 Phase II trial, which shows a median Overall Survival of 35.5 months for first line non-small cell lung cancer patients using efti in combination with KEYTRUDA. The report also covers advancements in several other trials, including TACTI-003 and AIPAC-003, with ongoing recruitment and data expected in 2024. The company remains financially robust with a cash balance of approximately $103.7 million.
Read more →IMMPImmutep Quarterly Activities Report Q2 FY24
Immutep Quarterly Activities Report Q2 FY24
Read more →IMMPFirst Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Read more →IMMPImmutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA
Immutep Limited has received constructive feedback from the Paul-Ehrlich-Institut regarding its planned TACTI-004 Phase III trial for the treatment of metastatic non-small cell lung cancer with efti. The PEI supports evaluating efti in combination with anti-PD-1 therapy in a chemotherapy-free regimen or as part of a triple combination therapy. Immutep anticipates announcing the final trial design in the first quarter of next year, reflecting confidence in the promising safety and efficacy data from previous trials.
Read more →IMMPASX/Media Release Immutep Receives A$2.6 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 7 December 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company dev
Immutep Limited has announced that it received a cash payment of approximately A$2.6 million from the French Government under the Crédit d'Impôt Recherche scheme. This incentive is intended to reimburse 30% of the eligible research and development spending conducted in the European Union during the 2022 calendar year. The funds are earmarked to aid the ongoing clinical development of the company's products, eftilagimod alpha and IMP761. Additionally, Immutep has previously secured a cash rebate of A$1.13 million from the Australian Federal Government for its R&D activities in the same financial year.
Read more →IMMPImmutep Receives A$2.6 million R&D Tax Incentive from French Government
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Read more →IMMPImmutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Read more →IMMPImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Read more →IMMPASX/Media Release Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma A total of 171 head and neck squamous cell carc
Immutep Limited announced the completion of patient enrollment in the TACTI-003 Phase IIb trial, which evaluates eftilagimod alpha (efti) in combination with KEYTRUDA for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). A total of 171 patients were enrolled across multiple centers in the US, Europe, and Australia. The primary endpoint focuses on the overall response rate, with data expected to be reported in the first half of 2024. This trial represents a key step in developing novel immunotherapies for a challenging cancer type.
Read more →IMMPImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Read more →IMMPASX/Media Release Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer No safety or tolerability issues in open-label,
Immutep Limited has announced the successful completion of the safety lead-in for its AIPAC-003 Phase II/III trial, which evaluates eftilagimod alpha in combination with paclitaxel for metastatic breast cancer. There were no safety or tolerability issues, as confirmed by the independent Data Monitoring Committee. Subsequently, the trial is set to enter the randomized Phase II portion with plans for up to 58 evaluable patients, aiming to determine the optimal biological dose of the drug. This trial marks an important advance in the company's research into innovative cancer therapies.
Read more →IMMPASX/Media Release Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells
Immutep Limited announced promising new biomarker data from its TACTI-002 Phase II trial for its cancer treatment, eftilagimod alpha (efti), in patients with non-small cell lung cancer (NSCLC). The data reveals significant increases in Th1 serum biomarkers, which are linked to the drug's success as a first-line therapy. Efti has demonstrated a 35.5-month median overall survival for patients with certain PD-L1 expressions. This information will be presented at the Society for Immunotherapy of Cancer's annual meeting, further solidifying efti's potential in enhancing immune response in cancer therapy.
Read more →IMMPImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Read more →IMMPImmutep to Participate in November Investor Events
Immutep to Participate in November Investor Events
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY24 Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS 1%
Immutep Limited reported promising results from its ongoing development programs, highlighting the efficacy of efti in combination with KEYTRUDA for non-small cell lung cancer (NSCLC), achieving a median overall survival of 35.5 months. The company received encouraging regulatory advice from both the EMA and FDA, indicating no further toxicology studies are needed for efti's marketing application. Additionally, the company reported a robust cash position, allowing for continued investment in clinical trial programs. Future trials, including TACTI-004, are set to commence in 2024.
Read more →IMMPImmutep Quarterly Activities Report Q1 FY24
Immutep Quarterly Activities Report Q1 FY24
Read more →IMMPImmutep Receives ~A$1.13 Million R&D Tax Incentive
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 25 October 2023 Immutep receives ~A$1.13 million R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to a
Immutep Limited has announced that it received approximately A$1.13 million from the Australian Federal Government's R&D tax incentive program. The rebate is related to expenditures incurred during the 2022 fiscal year for its TACTI-002 and TACTI-003 clinical studies involving its lead compound eftilagimod alpha. Additionally, Immutep is set to utilize this non-dilutive funding to enhance its ongoing clinical trials. The company also benefits from the French CIR tax incentive through its subsidiary in the European Union.
Read more →IMMPASX/Media Release Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line
Immutep Limited reported successful clinical data from the INSIGHT-003 trial at ESMO Congress 2023. The trial evaluates the combination of eftilagimod alpha, anti-PD-1 therapy (pembrolizumab), and doublet chemotherapy for treating metastatic non-squamous non-small cell lung cancer (NSCLC). The data revealed a significant Overall Response Rate of 71.4% and median Progression Free Survival of 10.1 months, particularly in patients with low PD-L1 expression. These results suggest that the therapy may offer new treatment options for a subgroup of patients traditionally unresponsive to existing therapies.
Read more →IMMP▼ -7.4%on this newsshared move
ASX/Media Release Immutep s Efti in Combination with KEYTRUDA Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer Median Overall Survival reaches 35.5 months in first-line
Immutep Limited announced promising results from the TACTI-002 Phase II trial, which evaluated eftilagimod alpha (efti) in combination with KEYTRUDA for treating metastatic non-small cell lung cancer (NSCLC). With a median overall survival of 35.5 months, the trial indicated that efti is effective for patients regardless of their PD-L1 expression levels. Increased efficacy and safety, particularly in low PD-L1 expressing patients, were highlighted, positioning efti favorably in the competitive immunotherapy landscape. The company is preparing to advance into a Phase III trial next year based on these positive results.
Read more →IMMP▼ -7.4%on this newsshared move
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Read more →IMMPImmutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Read more →IMMPASX/Media Release Immutep Announces Publication of Abstracts at ESMO Congress 2023 New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday,
Immutep Limited has announced the publication of abstracts containing new data from its TACTI-002 and INSIGHT-003 trials at the 2023 ESMO Congress. The TACTI-002 trial, which evaluates the combination of eftilagimod alpha and KEYTRUDA in non-small cell lung cancer (NSCLC), has shown encouraging initial survival benefits across various patient groups. New overall survival data will be detailed during a mini oral session by Dr. Enric Carcereny on October 21, 2023. Meanwhile, the INSIGHT-003 trial has demonstrated a promising 67% overall response rate, further establishing Immutep's therapeutic potential in treating NSCLC.
Read more →IMMPImmutep Announces Publication of Abstracts at ESMO Congress 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
Read more →IMMPImmutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Read more →IMMPASX/Media Release Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved SYDNEY, A
Immutep Limited has announced that it has received regulatory authorization for the commercial manufacturing of its immunotherapy, Eftilagimod Alpha (efti), at a 2000L scale for clinical trial use. This significant achievement enables the company to proceed with trials across several European countries, including Germany and the UK. The company has confirmed that comparability between the scales of manufacturing has been successfully established, allowing for the integration of the 2000L process into ongoing and future studies.
Read more →IMMPCommercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Read more →IMMPImmutep to Participate in September Investor Conferences
Immutep to Participate in September Investor Conferences
Read more →IMMPASX/Media Release Immutep Receives Positive Scientific Advice from European Medicines Agency SYDNEY, AUSTRALIA 1 August 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechno
Immutep Limited has received positive scientific advice from the EMA for its soluble LAG-3 protein, efti, which is moving towards marketing authorization without the need for further toxicity studies. The advice reflects the EMA's assessment of existing clinical data, indicating that additional animal studies would not provide relevant information. Furthermore, Immutep has garnered positive feedback from the FDA for ongoing clinical trials, including those targeting non-small cell lung cancer and metastatic breast cancer. This news signifies an encouraging step in the development of innovative cancer therapies by Immutep.
Read more →IMMPImmutep Receives Positive Scientific Advice from European Medicines Agency
Immutep Receives Positive Scientific Advice from European Medicines Agency
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY23 Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st
Immutep Limited provided a quarterly report highlighting advancements in its late-stage clinical trials for eftilagimod alpha (efti) and IMP761. The company received positive feedback from the FDA regarding its TACTI-004 Phase III trial, which supports its planned registrational study for treating non-small cell lung cancer (NSCLC). Furthermore, significant progress was made in the TACTI-002 and INSIGHT-003 trials, with encouraging overall survival and response rates reported. Immutep's ongoing development efforts were bolstered by a successful funding round, securing A$80 million.
Read more →IMMPImmutep Quarterly Activities Report Q4 FY23
Immutep Quarterly Activities Report Q4 FY23
Read more →IMMPImmutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
Read more →IMMPASX announcement First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma SYDNEY, AUSTRALIA 28 July 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company )
Immutep Limited has announced the successful enrollment and dosing of the first patient in the EFTISARC-NEO Phase II trial, which investigates the use of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for soft tissue sarcoma. This trial represents a pioneering approach as it focuses on a chemotherapy-free treatment regimen, aiming to address the high unmet medical need in this aggressive disease category. The study, supported by a Polish government grant, plans to enroll up to 40 patients and is conducted by leading oncologists in Poland. The trial will provide valuable insights into the tumor microenvironment changes induced by the novel therapy.
Read more →IMMPFirst Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Read more →IMMPASX/Media Release Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor SYDNEY, AUSTRALIA 27 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage bi
Immutep Limited has secured a third United States patent for its lead immunotherapy candidate, Eftilagimod Alpha, in combination with PD-1 pathway inhibitors. This patent builds upon previously granted patents and safeguards the innovative treatment methods for cancer. The company continues to expand its patent estate to support its clinical development pipeline and investment strategy. Efti is being evaluated for treating various solid tumors and has received Fast Track Designation in specific cancer indications from the FDA.
Read more →IMMPImmutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Read more →IMMPImmutep Completes A$80 Million Capital Raise
Immutep Completes A$80 Million Capital Raise
Read more →IMMPASX/Media Release Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3 SYDNEY, AUSTRALIA 20 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology
Immutep Limited announced that the United States Patent Office has granted a patent for their first-in-class agonist antibody, IMP761, which targets LAG-3 for the treatment of autoimmune diseases. This patent follows similar grants in Japan and Europe. The company aims to advance IMP761 towards first-in-human clinical trials, having developed a GMP-compliant manufacturing process and engaged Charles River Laboratories for a GLP toxicology study. Pre-clinical findings indicate that IMP761 may effectively silence autoimmune memory T cells, showing promise in its therapeutic potential.
Read more →IMMPImmutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Read more →IMMPImmutep to Participate at the Jefferies Healthcare Conference
Immutep to Participate at the Jefferies Healthcare Conference
Read more →IMMPASX/Media Release Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression l
Immutep Limited released positive final data from the Part C of the TACTI-002 Phase II trial at ASCO 2023, showing efficacy of eftilagimod alpha plus pembrolizumab in 2nd line treatment of head and neck squamous cell carcinoma (HNSCC). This combination therapy achieved an overall response rate of 29.7% and a complete response rate of 13.5%, regardless of PD-L1 expression. Long-lasting responses were observed, and the safety profile was favorable with minimal treatment discontinuation due to adverse reactions. These results strengthen the potential of this dual immunotherapy approach for managing difficult-to-treat cancer patients.
Read more →IMMPJune 2023 Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) ( Immutep or the Company ), is please
Immutep Limited has successfully completed an institutional placement and the institutional component of its entitlement offer, raising approximately A$80 million. The company aims to utilize these funds to support its clinical programs through Q1 2026, specifically highlighting several ongoing trials for cancer and autoimmune disease treatments. The successful funding positions Immutep to expand its clinical research and explore new drug trials, including the potential Phase I trial for IMP761. This financial backing underscores the company's commitment to advancing its innovative therapeutics pipeline.
Read more →IMMPImmutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Read more →IMMPImmutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Read more →IMMPASX/Media Release Immutep Selects Charles River Laboratories for IMP761 s GLP Toxicology Study Appointment of Charles River Laboratories ( Charles River ) to run Immutep s preclinical toxicology study evaluating the safe
Immutep Limited has appointed Charles River Laboratories to conduct a GLP toxicology study for IMP761, a novel LAG-3 agonist antibody targeting autoimmune diseases. This toxicology study is a critical step in the development of IMP761 as it moves towards clinical trials, projected for the first half of the following year. Early preclinical results are encouraging, showing significant reductions in cytokine secretion in relevant disease models, signaling potential effectiveness in treating these conditions.
Read more →IMMP▼ -5.6%on this newsshared move
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
Read more →IMMP▼ -7.4%on this newsshared move
ASX/Media Release Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line
Immutep Limited announced the publication of abstracts for the ASCO 2023 Annual Meeting, highlighting data from Part C of its TACTI-002 Phase II trial involving eftilagimod alpha in metastatic cancer patients. The presentation will feature final results in head and neck squamous cell carcinoma, while another abstract for the AIPAC-003 Phase III trial was also shared. Eftilagimod alpha is under evaluation for multiple solid tumors and shows promise due to its favorable safety profile and innovative mechanism of action.
Read more →IMMP▼ -6.1%on this newsshared move
ASX/Media Release Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer SYDNEY, AUSTRALIA 25 May 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-sta
Immutep Limited has announced that it successfully dosed the first patient in its AIPAC-003 Phase II/III trial for metastatic breast cancer. This trial will evaluate eftilagimod alpha (efti) in combination with paclitaxel at multiple clinical sites across Europe and the USA. The trial aims to improve clinical outcomes focusing on overall survival, building on the encouraging results of prior trials. If successful, this study may lead to further regulatory actions and expanded treatment options for patients with breast cancer. The achievement is regarded as a significant milestone for the company.
Read more →IMMP▼ -6.1%on this newsshared move
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
Read more →IMMP▼ -6.1%on this newsshared move
ASX/Media Release Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung c
Immutep Limited announced favorable clinical data from the INSIGHT-003 trial, evaluating its LAG-3 immunotherapy, eftilagimod alpha, in combination with standard anti-PD-1 therapy and chemotherapy for non-small cell lung cancer. The trial reports a 67% overall response rate and a 91% disease control rate in patients, particularly highlighting efficacy in patients with lower PD-L1 expression. The trial will expand enrollment to 50 patients based on these promising results, with further data expected to be presented at a medical conference later this year.
Read more →IMMP▲ +6.5%on this newsshared move
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Read more →IMMP▲ +6.5%on this newsshared move
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Read more →IMMP▲ +64.8%on this news
ASX/Media Release Immutep s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer Immuno-oncology combination of eftilagimod alpha (efti) and th
Immutep Limited has reported promising results from its Phase II TACTI-002 trial, showcasing that its investigational therapy efti, used in combination with pembrolizumab, significantly improves overall survival in patients with first-line non-small cell lung cancer. The interim results indicate a median overall survival of 25 months for patients expressing PD-L1, with a notable response rate. This combination therapy demonstrated an encouraging safety profile and the potential for deeper, longer-lasting responses in cancer treatment, prompting further clinical exploration.
Read more →IMMPImmutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Read more →IMMPASX/Media Release Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA 16 May 2023 I mmutep Limited (ASX: IMM; NASDAQ: IMMP)
Immutep Limited has received positive feedback from the FDA regarding its late-stage clinical development plans for eftilagimod alpha (efti) in treating non-small cell lung cancer (NSCLC). The FDA supported a registrational trial after examining encouraging Phase II trial data. This next trial, named TACTI-004, will assess efti in combination with anti-PD-1 therapy. The company's leadership expresses confidence that these developments will pave the way for new treatment options for cancer patients.
Read more →IMMPImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Read more →IMMPImmutep to Participate in the JMP Securities Life Sciences Conference
Immutep to Participate in the JMP Securities Life Sciences Conference
Read more →IMMPImmutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma
Read more →IMMPASX/Media Release Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will
Immutep Limited has received regulatory approval to initiate the INSIGHT-005 trial, evaluating eftilagimod alpha in combination with BAVENCIO for patients with metastatic urothelial carcinoma. This trial aims to provide a new treatment option for patients who are ineligible for platinum-based chemotherapy. Previous studies have shown promising results for the combination therapy, suggesting significant potential for improving patient outcomes. The trial will enroll up to 30 patients and will be conducted in Frankfurt as part of a broader investigator-initiated research program.
Read more →IMMPImmutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q3 FY23 Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cance
Immutep Limited announced the initiation of its AIPAC-003 Phase II/III trial, evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer. The trial commenced following regulatory approvals and is anticipated to enroll its first patient in Q2 CY2023. Additionally, Immutep reported positive results from the TACTI-002 trial in lung cancer patients and made significant advancements in its other clinical programs. The company remains well funded, with a cash balance sufficient to support operations into FY24.
Read more →IMMPImmutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting
Read more →IMMPImmutep Quarterly Activities Report
Immutep Quarterly Activities Report
Read more →IMMPImmutep Appoints Dr. Florian Vogl as Chief Medical Officer
Immutep Appoints Dr. Florian Vogl as Chief Medical Officer
Read more →IMMPASX/Media Release Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a po
Immutep Limited has announced the launch of an investigator-initiated Phase II trial for eftilagimod alpha in combination with pembrolizumab and radiotherapy for soft tissue sarcoma patients. This trial is being conducted to address a significant unmet medical need in treating this rare and aggressive cancer. The trial will evaluate the safety and efficacy of this chemotherapy-free approach to enhance immune responses in patients. Funding from the Polish government highlights the credibility and potential impact of the study in oncology.
Read more →IMMPImmutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Read more →IMMPASX/Media Release Immutep Announces Changes to the Board SYDNEY, AUSTRALIA 11 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechnology company developing novel LAG-3
Immutep Limited has announced the appointment of Lis Boyce as a Non-Executive Director to its board, filling the vacancy left by Lucy Turnbull following the unfortunate passing of Grant Chamberlain in January 2022. Boyce, a seasoned corporate lawyer with a notable background in the Life Sciences and Healthcare sectors, is expected to bring significant expertise in corporate governance and strategic collaborations. The board has expressed its appreciation for Turnbull's efforts during a difficult transition, highlighting a commitment to advancing their innovative immunotherapy solutions.
Read more →IMMPImmutep Announces Changes to the Board
Immutep Announces Changes to the Board
Read more →IMMPASX/Media Release Immutep Announces Positive Final Data in 2 nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 Efti plus pembrolizumab achieved mOS of 9.9 months a
Immutep Limited reported promising final data from the TACTI-002 Phase II trial at the European Lung Cancer Congress 2023, showcasing the efficacy of eftilagimod alpha combined with pembrolizumab in metastatic non-small cell lung cancer patients resistant to standard PD-1/PD-L1 therapies. The treatment yielded a median overall survival of 9.9 months, outperforming typical outcomes observed with chemotherapy. Furthermore, the combination demonstrated a favorable safety profile and significant tumor response in patients, indicating potential for broader application in cancer therapies. The results suggest further investigation is warranted to enhance treatment options for patients with limited alternatives.
Read more →IMMPASX/Media Release Immutep Announces Expansion of Triple Combination Therapy in 1 st Line Non-Small Cell Lung Cancer Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and c
Immutep Limited announced the expansion of its INSIGHT-003 trial, which evaluates the combination of eftilagimod alpha (efti) with standard-of-care treatments for 1st line non-small cell lung cancer (NSCLC). The trial will increase its patient enrollment from 20 to 50, building on promising initial safety and efficacy results. Early data indicates a high overall response rate of 72.7% among treated patients. This expansion will help generate more clinical data and guide future registrational studies for efti in NSCLC treatment.
Read more →IMMPImmutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Read more →IMMPImmutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Read more →IMMPImmutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Read more →IMMP▲ +5.1%on this news
ASX/Media Release Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and w
Immutep Limited has announced the initiation of a Phase II/III trial, AIPAC-003, to assess the efficacy of eftilagimod alpha in combination with paclitaxel for treating metastatic HER2-neg/low breast cancer. The trial has received regulatory approval in the US and Spain, with patient enrollment expected to begin in early Q2 2023. The dual treatment aims to build on previous efficacy data and targets a broader breast cancer patient population, including triple-negative cases. This integrated clinical trial design reflects feedback from both the FDA and EMA, indicating a proactive approach to regulatory compliance.
Read more →IMMPImmutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2022 (previous corresponding period: half-year ended 31 December 2021) To be read in conjunction with the 30 J
Immutep Limited released its Appendix 4D Half-Year Financial Report for the period ending December 31, 2022. The report indicated a 9.4% decline in total revenue to A$2,582,728, alongside a significant increase in net loss by 26.8% to A$20,623,250. Despite these financial challenges, the company has received Fast Track designations from the US FDA for its lead product candidate, eftilagimod alpha (efti), indicating positive progress in late-stage clinical trials targeting several types of cancer. The company reported a cash position of $68.38 million, providing a strong runway for ongoing development activities.
Read more →IMMPImmutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Read more →IMMPASX/Media Release Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1 st Line NSCLC 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of ef
Immutep Limited announced that its INSIGHT-003 trial has reached its enrolment target of 20 patients with 1st line non-small cell lung cancer (1L NSCLC). The trial evaluates the efficacy of Immutep's lead candidate, eftilagimod alpha (efti), in a triple combination therapy with anti-PD-1 therapy and chemotherapy. Initial results showed an objective response rate of 72.7% and promise for patients with low PD-L1 scores. Additional data from the trial is expected to be presented in 2023 to further inform their treatment strategy.
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Q2 FY23 Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lu
Immutep Limited has announced its Quarterly Activities Report for Q2 FY23, highlighting significant developments in its product candidates efti and IMP761. The company has received a second Fast Track designation from the US FDA for efti, aimed at treating 1st line non-small cell lung cancer (NSCLC). Clinical data shows encouraging results, including a response rate of 40.4% from the TACTI-002 trial. Immutep is scaling up manufacturing capabilities and expanding trial populations, particularly in metastatic breast cancer and soft tissue sarcoma.
Read more →IMMPASX/Media Release Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer SYDNEY, AUSTRALIA 4 January 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
Immutep Limited has announced a significant achievement in its TACTI-003 Phase IIb trial for first-line head and neck cancer treatments, successfully enrolling over 50% of the target 154 patients. The trial evaluates the efficacy of its soluble LAG-3 protein, eftilagimod alpha, in conjunction with Merck's PD-1 therapy, KEYTRUDA. The enrollment is ongoing across multiple clinical sites in the US, Australia, and Europe, and the company anticipates full recruitment by mid-2023. The encouraging progress includes a recommendation from the Independent Data Monitoring Committee to continue the trial due to favorable safety data.
Read more →IMMPASX/Media Release Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer Agreement with FDA on Phase II/III trial design positions the Compa
Immutep Limited has announced a successful follow-up meeting with the US FDA regarding its clinical development plans for eftilagimod alpha in combination with chemotherapy for metastatic breast cancer. The FDA and Immutep have agreed on a Phase II/III trial design, which will allow for an integrated approach in the treatment regimen. The trial will now include patients with triple-negative breast cancer, thereby broadening its impact. The Phase II trial is expected to commence in early 2023, further emphasizing the potential of efti in oncology.
Read more →IMMPImmutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Read more →IMMPImmutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Read more →IMMP▲ +5.8%on this news
ASX/Media Release Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRA
Immutep Successfully Achieves Commercial Scale in Manufacturing of 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics AUSTRALIA 8 December, 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage
Read more →IMMPImmutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Read more →IMMPASX/Media Release Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease Achievement Allows IND-enabling Studies in 1H 2023 and Subsequent Clinical Testing
Immutep Announces GMP Manufacturing Process Developed for IMP761, LAG-3 Agonist for Autoimmune Disease IND-enabling Studies in 1H 2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases SYDNEY, AUSTRALIA 06 December 2022 Immutep Limited (A
Read more →IMMP▼ -9.3%on this newsshared move
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Read more →IMMP▲ +5.4%on this newsshared move
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Read more →IMMP▲ +5.1%on this newsshared move
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer SYDNEY, AUSTRALIA 29 November 2022 Immut
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 14 November 2022 Immutep receives Australian R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to annou
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Australian R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal
Read more →IMMPASX/Media Release Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting Overall response ra
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer
Read more →IMMPASX/Media Release Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022 First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022 First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC patients The triple
Read more →IMMPThe purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they conta
Global Webcast Presentation (ASX: IMM, NASDAQ: IMMP) Update on new TACTI-002 Phase II and initial INSIGHT-003 Phase 1 data presented at SITC 2022 A Global Leader in LAG-3 Therapeutics in Oncology and Autoimmune Disease Date & Time Thursday, 10 November 2022, at 5 pm U.S. ET Frid
Read more →IMMPImmutep Receives Australian R&D Tax Incentive
Immutep Receives Australian R&D Tax Incentive
Read more →IMMP▼ -7.6%on this newsshared move
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Read more →IMMP▼ -7.6%on this newsshared move
ASX/Media Release Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination SYDNEY, AUSTRALIA 9 November 2022 Immutep Limited (ASX: IMM;
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination SYDNEY, AUSTRALIA 9 November 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechnology
Read more →IMMP▼ -7.6%on this newsshared move
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Read more →IMMP▼ -7.6%on this newsshared move
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Read more →IMMP▲ +9.3%on this newsshared move
ASX/Media Release Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Oral presentatio
Immutep Late-Breaking Abstract Accepted for Oral Presentation LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Oral presentation will detail new clinical data for eftilagimod alpha in combination with pembrolizumab in 1st line NSCLC pa
Read more →IMMP▲ +9.3%on this newsshared move
ASX/Media Release Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on
Read more →IMMPImmutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
Read more →IMMPImmutep to Participate in Two Upcoming Investor Conferences
Immutep to Participate in Two Upcoming Investor Conferences
Read more →IMMPImmutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Read more →IMMPASX/Media Release Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned SYDNEY, AUSTRALIA 26 October 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immute
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned SYDNEY, AUSTRALIA 26 October 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechnology company developing novel
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 25 October 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today provides an
Read more →IMMPImmutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Read more →IMMPASX/Media Release Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Initial data from INSIGHT-003 trial treating patients with various solid tumou
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemothe
Read more →IMMPASX/Media Release Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer Fast Track designation has been granted by the US FDA for efti in combinatio
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer SYDNEY, AUSTRALIA 4 October 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a clinical-stage biotechnology company developing
Read more →IMMP▲ +5.3%on this newsshared move
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Read more →IMMPImmutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
Read more →IMMPASX/Media Release Immutep Receives A$2.7 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 23 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company d
Immutep Receives A$2.7 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 23 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoim
Read more →IMMPImmutep Receives A$2.7 million R&D Tax Incentive from French Government
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Read more →IMMPASX/Media Release Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha Encouraging Phase II data supports broad therapeutic potential of eftilagim
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha SYDNEY, AUSTRALIA 14 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-
Read more →IMMPASX/Media Release Immutep Appoints LAG-3 Pioneer, Fr d ric Triebel to Board SYDNEY, AUSTRALIA 13 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing nove
Immutep Appoints LAG-3 Pioneer, Fr d ric Triebel to Board SYDNEY, AUSTRALIA 13 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease,
Read more →IMMPImmutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Read more →IMMPImmutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Read more →IMMPASX/Media Announcement Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma Expansion of the efti clinical development pipeline with a new Phas
ASX/Media Announcement Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma SYDNEY, AUSTRALIA 6 September 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announ
Read more →IMMPImmutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Read more →IMMP▼ -7.4%on this newsshared move
Immutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2022 Previous corresponding period
Preliminary final report Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2022 Previous corresponding period: Year ended 30 June 2021 FY 2021 FY 2022 Revenue from ordinary activities Up Nil to 170,369 Other inco
Read more →IMMPASX/Media Release IMMUTEP GRANTED JAPANESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 30 August 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( I
IMMUTEP GRANTED JAPANESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 30 August 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 rel
Read more →IMMPImmutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Read more →IMMPASX/Media Release Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2 nd line PD-X refractory NSCLC Encouraging efficacy results continue for patients with 2 nd l
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X refractory NSCLC SYDNEY, AUSTRALIA 1 August 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing n
Read more →IMMPImmutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favoura
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 28 July 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides an
Read more →IMMPASX/Media Release IMMUTEP GRANTED JAPANESE PATENT FOR IMP761, A FIRST-IN-CLASS IMMUNOSUPPRESSIVE ANTIBODY TARGETING LAG-3 SYDNEY, AUSTRALIA 6 July 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ),
IMMUTEP GRANTED JAPANESE PATENT FOR IMP761, A FIRST-IN-CLASS IMMUNOSUPPRESSIVE ANTIBODY TARGETING LAG-3 SYDNEY, AUSTRALIA 6 July 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for canc
Read more →IMMP▲ +7.5%on this newsshared move
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Read more →IMMP▼ -6.5%on this news
ASX/Media Release Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer SYDNEY, AUSTRALIA 27 June 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology com
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer SYDNEY, AUSTRALIA 27 June 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and
Read more →IMMPImmutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Read more →IMMPASX/Media Release Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1 st line NSCLC for PD-L1 all-comers TACTI-002 has met its primary objective for 1 st line non-small cell lung cancer (NS
positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers SYDNEY, AUSTRALIA 6 June 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatme
Read more →IMMPImmutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Read more →IMMPImmutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
Read more →IMMPASX/Media Release Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022 Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1 st line non-small cell lung ca
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022 SYDNEY, AUSTRALIA 27 May 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and aut
Read more →IMMPImmutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
Read more →IMMPImmutep to Present at Investor Conferences
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited to pr
Read more →IMMPASX/Media Release Immutep Appoints Leading Oncologists to its Clinical Advisory Board SYDNEY, AUSTRALIA 18 May 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing
Leading Oncologists to its Clinical Advisory Board SYDNEY, AUSTRALIA 18 May 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced to
Read more →IMMPImmutep Appoints Leading Oncologists to its Clinical Advisory Board
SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today the appointment of four n
Read more →IMMP▼ -5.8%on this news
ASX/Media Release Immutep presents new and significant data from the AIPAC study Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 level
new and significant data from the AIPAC study SYDNEY, AUSTRALIA 4 May 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new b
Read more →IMMP▲ +7.9%on this newsshared move
Immutep Presents New and Significant Data from the AIPAC Study
Immutep Presents New and Significant Data from the AIPAC Study
Read more →IMMP▲ +5.2%on this newsshared move
ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C New interim TACTI-002 data from 2 nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 29 April 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for and autoimmune disease, provides an update
Read more →IMMP▲ +9.6%on this newsshared move
ASX/Media Release Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting SYDNEY, AUSTRALIA 28 April 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biot
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting SYDNEY, AUSTRALIA 28 April 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments f
Read more →IMMPImmutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Read more →IMMPASX/Media Release Immutep s efti in combination with MSD s pembrolizumab shows encouraging antitumor activity in difficult to treat 2 nd line metastatic lung cancer patients All enrolled patients were 2 nd line metastati
Immutep s efti in combination with MSD s pembrolizumab shows encouraging antitumor activity in difficult to treat 2nd line metastatic lung cancer patients SYDNEY, AUSTRALIA 30 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology compan
Read more →IMMPImmutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
Read more →IMMP▼ -6.1%on this newsshared move
ASX/Media Release Immutep announces publication of TACTI-002 abstract at ESMO s European Lung Cancer Congress 2022 New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line
Immutep announces publication of TACTI-002 abstract at ESMO s European Lung Cancer Congress 2022 24 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and au
Read more →IMMP▲ +6.9%on this newsshared move
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES SECOND JAPANESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA 18 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to ann
IMMUTEP ANNOUNCES SECOND JAPANESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA 18 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce the grant of patent no. 7030750 entitled Antibody molecules to LAG-3
Read more →IMMP▲ +14%on this news· ran to +26% by day 3shared move
Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022
Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022
Read more →IMMP▲ +14%on this news· ran to +26% by day 3shared move
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Read more →IMMPASX/Media Release IMMUTEP RECEIVES CONSTRUCTIVE FEEDBACK FROM US FDA ON ITS CLINICAL DEVELOPMENT PROGRAM FOR EFTI IN METASTATIC BREAST CANCER SYDNEY, AUSTRALIA 10 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Imm
IMMUTEP RECEIVES CONSTRUCTIVE FEEDBACK FROM US FDA ON ITS CLINICAL DEVELOPMENT PROGRAM FOR EFTI IN METASTATIC BREAST CANCER SYDNEY, AUSTRALIA 10 March 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce it has received constructive
Read more →IMMP▲ +11.2%on this newsshared move
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
Read more →IMMP▼ -7.3%on this news
ASX/Media Release IMMUTEP GRANTED AUSTRALIAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 11 February 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP)
IMMUTEP GRANTED AUSTRALIAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 11 February 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3
Read more →IMMP▼ -7.3%on this news
Immutep Appoints Lucy Turnbull as Non-Executive Director
Immutep Appoints Lucy Turnbull as Non-Executive Director
Read more →IMMP▼ -7.3%on this news
IMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2021 (previous corresponding period: half-year ended 31 December 2020) To be read in conjunction with the 30 J
Half-Year Financial Report (previous corresponding period: half-year ended 31 December 2020) To be read in conjunction with the 30 June 2021 Annual Report. In compliance with Listing Rule 4.2A. ASX/Media Release (ASX: IMM) Appendix 4D Half-Year Financial Report Results for
Read more →IMMPImmutep to Present at Healthcare Investor Conferences
Immutep to Present at Healthcare Investor Conferences
Read more →IMMP▼ -6.3%on this newsshared move
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Read more →IMMP▼ -6.7%on this news
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Read more →IMMP▲ +10%on this news
Immutep to Present at February Investor Conferences
Immutep to Present at February Investor Conferences
Read more →IMMP▼ -7.1%on this news
ASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Final Overall Survival data from AIPAC Phase IIb trial reported at the SITC 2021 conference, supporting Immutep s planned Phase III clinical development
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 25 January 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides a
Read more →IMMPASX/Media Release Immutep Advances IMP761 Manufacturing SYDNEY, AUSTRALIA 16 December 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immun
Immutep Advances IMP761 Manufacturing SYDNEY, AUSTRALIA 16 December 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announ
Read more →IMMPImmutep Advances IMP761 Manufacturing
Immutep Advances IMP761 Manufacturing
Read more →IMMP▼ -8%on this news
ASX/Media Release IMMUTEP REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI STUDY, INSIGHT-003 SYDNEY, AUSTRALIA 2 December 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Com
IMMUTEP REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI STUDY, INSIGHT-003 SYDNEY, AUSTRALIA 2 December 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherap
Read more →IMMP▼ -5.8%on this newsshared move
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Read more →IMMP▼ -6.8%on this news
ASX/Media Release Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha Enrolled and dosed last patient in the expansion stage of Part A (1 st line non-small cell lun
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha SYDNEY, AUSTRALIA 19 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunother
Read more →IMMPImmutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
Read more →IMMPSITC 2021 Results: Management Update GLOBAL WEBCAST Date & Time: 8.00 am AEDT (Sydney) Wednesday 17 November 2021 4.00 pm EST (New York) Tuesday 16 November 2021 10.00 pm CET (Berlin) Tuesday 16 November 2021 Register: h
& Time: 8.00 am AEDT (Sydney) Wednesday 17 November 2021 4.00 pm EST (New York) Tuesday 16 November 2021 10.00 pm CET (Berlin) Tuesday 16 November 2021 Register: https://fnn.webex.com/fnn/onstage/g.php?MTID=ef12af93633b5d17a2e4e176fcac2f070 A replay of the webcast will also be a
Read more →IMMPASX/Media Release Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha AIPAC poster presentation includes new data and graphs showing: Very en
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC Positive New Data for LAG-3 Therapy, Eftilagimod Alpha 15 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunothera
Read more →IMMPImmutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor
Read more →IMMPImmutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Read more →IMMP▲ +7.5%on this newsshared move
ASX/Media Release Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details Data from Phase IIb AIPAC, including final Overall Survival data, re
Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details SYDNEY, AUSTRALIA - 10 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related
Read more →IMMPImmutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Read more →IMMPImmutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer
Read more →IMMPASX/Media Release IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A CHEMOTHERAPY AGENT SYDNEY, AUSTRALIA 2 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immut
IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A SYDNEY, AUSTRALIA 2 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treat
Read more →IMMPImmutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent
Read more →IMMPASX/Media Release Immutep receives positive EMA scientific advice for further clinical development of efti in MBC including Phase III Positive feedback for the general clinical development program including the planned r
Immutep receives positive EMA scientific advice for further clinical development of efti in MBC including Phase III SYDNEY, AUSTRALIA 29 October 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related imm
Read more →IMMPImmutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Read more →IMMPImmutep Quarterly Activities Report & Appendix 4C
Received competent authority and institutional review board approvals for TACTI-003 Phase IIb trial Enrolled first patient in INSIGHT-003 study in patients with various solid tumours Preparations progressing for new Phase III trial (AIPAC-003) in metastatic breast cancer Final
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Received competent authority and institutional review board approvals for TACTI-003 Phase IIb trial Enrolled first patient in INSIGHT-003 study in patie
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 28 October 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides a
Read more →IMMPImmutep to present Phase II TACTI-002 data at SITC 2021
Immutep to present Phase II TACTI-002 data at SITC 2021
Read more →IMMPASX/Media Release Immutep Receives A$3.4 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 29 September 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company d
Immutep Receives A$3.4 million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 29 September 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoim
Read more →IMMPImmutep Receives A$3.4 million R&D Tax Incentive from French Government
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
Read more →IMMP▼ -7.1%on this news
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
Read more →IMMPASX/Media Release Immutep Completes Recruitment of 2 nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 Last 2 nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 SYDNEY, AUSTRALIA 1 September 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments fo
Read more →IMMPImmutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Read more →IMMPImmutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2021 Previous corresponding period
Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2021 Previous corresponding period: Year ended 30 June 2020 FY 2020 FY 2021 Revenue from ordinary activities Down 7,48
Read more →IMMP▲ +14.6%on this newsshared move
ASX/Media Release IMMUTEP S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE SYDNEY, AUSTRALIA 31 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to advise its Chinese p
IMMUTEP S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE AUSTRALIA 31 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to advise its Chinese partner for eftilagimod alpha ( efti or IMP321 ), EOC Pharma ( EOC ) is planning to
Read more →IMMPImmutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA 27 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce t
IMMUTEP ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 SYDNEY, AUSTRALIA 27 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce the grant of patent no. ZL201580013695.X entitled Antibody molecules to LAG-
Read more →IMMPImmutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Read more →IMMPASX/Media Release Immutep Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003 SYDNEY, AUSTRALIA 5 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company
Immutep Reports Dosing of First Patient For Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003 SYDNEY, AUSTRALIA 5 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy tr
Read more →IMMPImmutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Read more →IMMPImmutep completes tranche 2 of its previously announced placement Sydney, Australia
Immutep completes tranche 2 of its previously announced placement Sydney, Australia July 30, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce it has completed the second tranche of its institutional placement (Placement), details o
Read more →IMMPNot for release to US wire services or distribution in the United States ASX/Media Release COMPLETION OF SHARE PURCHASE PLAN SYDNEY, AUSTRALIA 21 July 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Compan
Not for release to US wire services or distribution in the United States SYDNEY, AUSTRALIA 21 July 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) advises that its share purchase plan ( SPP ), details of which were announced to ASX on 21 June 2021, clos
Read more →IMMPASX/Media Release Immutep Quarterly Activities Report & Appendix 4C Immutep entered late-stage development in the newly validated LAG-3 space Data from 1st line NSCLC and 2nd line HNSCC presented at ASCO Efti to be evalu
Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA 13 July 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an u
Read more →IMMPASX/Media Release Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval receive
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC SYDNEY, AUSTRALIA 6 July 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer a
Read more →IMMPImmutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Read more →IMMPASX/Media Release Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours Exp
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy SYDNEY, AUSTRALIA 21 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunother
Read more →IMMPImmutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
Read more →IMMPImmutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
Read more →IMMPASX/Media Release Immutep Reveals a New anti-LAG-3 Research Program SYDNEY, AUSTRALIA 8 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), the leading developer of LAG-3 related immunotherapy
Immutep Reveals a New anti-LAG-3 Research Program SYDNEY, AUSTRALIA 8 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an updat
Read more →IMMPImmutep Reveals a New anti-LAG-3 Research Program
Immutep Reveals a New anti-LAG-3 Research Program
Read more →IMMPASX/Media Release Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021 Encouraging activity signals from the combination of efti and avelumab with a response rate of
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO SYDNEY, AUSTRALIA 4 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatm
Read more →IMMPASX/Media Release Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021 Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall res
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021 SYDNEY, AUSTRALIA 4 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatmen
Read more →IMMPImmutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
Read more →IMMPImmutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
Read more →IMMPASX/Media Release IMMUTEP SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 2 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP)
IMMUTEP SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 2 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immun
Read more →IMMPImmutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
Read more →IMMPASX/Media Release Immutep enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bi
Immutep enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti SYDNEY, AUSTRALIA 1 June 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer a
Read more →IMMPImmutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
Read more →IMMPASX/Media Release IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 26 May 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology
IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 26 May 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmun
Read more →IMMPImmutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Read more →IMMPImmutep to Present at the Jefferies Virtual Healthcare Conference
Immutep to Present at the Jefferies Virtual Healthcare Conference
Read more →IMMPASX/Media Release Immutep announces publication of TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 Annual Meeting SYDNEY, AUSTRALIA 20 May 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a bio
Immutep announces publication of TACTI-002 and INSIGHT-004 for ASCO 2021 Annual Meeting SYDNEY, AUSTRALIA 20 May 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer
Read more →IMMPImmutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting
Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting
Read more →IMMPASX/Media Release IMMUTEP OPERATIONAL UPDATE AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing well New data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021 TACTI-003 clinical trial
IMMUTEP OPERATIONAL UPDATE SYDNEY, AUSTRALIA 7 May 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and
Read more →IMMPImmutep Operational Update
Immutep Operational Update
Read more →IMMPASX/Media Release Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting SYDNEY, AUSTRALIA 29 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( I
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting SYDNEY, AUSTRALIA 29 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), the leading developer of LAG-3 related immunothera
Read more →IMMPImmutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 16 April 2021 Immutep receives A$1,155,055 R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announc
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) A$1,155,055 R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government
Read more →IMMPImmutep Receives A$1,155,055 R&D Tax Incentive
Immutep Receives A$1,155,055 R&D Tax Incentive
Read more →IMMPASX/Media Release IMMUTEP ACHIEVES FAST TRACK DESIGNATION FROM US FDA FOR EFTI, A SOLUBLE LAG-3 PROTEIN, IN FIRST LINE RECURRENT/METASTATIC HEAD & NECK CANCER Fast Track designation opens the potential for expedited deve
IMMUTEP ACHIEVES FAST TRACK DESIGNATION FROM US FDA FOR EFTI, A SOLUBLE LAG-3 PROTEIN, IN FIRST LINE RECURRENT/METASTATIC HEAD & NECK CANCER SYDNEY, AUSTRALIA 8 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing n
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY IN COMBINATION THERAPY SYDNEY, AUSTRALIA 7 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology com
IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY IN COMBINATION THERAPY SYDNEY, AUSTRALIA 7 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disea
Read more →IMMPImmutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Read more →IMMPImmutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Read more →IMMPASX/Media Release IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C Highlights Safely dosed the last HNSCC patient for Stage 2 of Part C of the TACTI-002 Phase II study (also designated KEYNOTE-798) Initiated enrolment o
IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C SYDNEY, AUSTRALIA 19 April 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the
Read more →IMMPImmutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference
Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference
Read more →IMMPASX/Media Release IMMUTEP ENTERS SECOND COLLABORATION WITH MSD FOR A NEW RANDOMISED PHASE IIB TRIAL IN HEAD AND NECK CANCER New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD s KE
IMMUTEP ENTERS SECOND COLLABORATION WITH MSD FOR A NEW RANDOMISED PHASE IIB TRIAL IN HEAD AND NECK CANCER SYDNEY, AUSTRALIA 16 March 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for
Read more →IMMPImmutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
Read more →IMMPASX/Media Release IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 9 March 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 9 March 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treat
Read more →IMMPImmutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Read more →IMMPASX/Media Release IMMUTEP EXPANDS PART B OF TACTI-002 STUDY Follows positive efficacy and safety review SYDNEY, AUSTRALIA 5 March 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel imm
IMMUTEP EXPANDS PART B OF TACTI-002 STUDY Follows positive efficacy and safety review SYDNEY, AUSTRALIA 5 March 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to rep
Read more →IMMPImmutep Expands Part B of TACTI-002 Study
Immutep Expands Part B of TACTI-002 Study
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Half-Year Financial Report For the Half-Year Ended 31 December 2020 (previous corresponding period: half-year ended 31 December 2019) To be read in conjunction with the 30 J
Half-Year Financial Report (previous corresponding period: half-year ended 31 December 2019) To be read in conjunction with the 30 June 2020 Annual Report. In compliance with Listing Rule 4.2A. ASX/Media Release (ASX: Appendix 4D Half-Year Financial Report Results for Annou
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES ADVANCEMENT OF PHASE II TRIAL FOR EFTILAGIMOD ALPHA IN COVID-19 PATIENTS TO RANDOMISED PORTION OF THE STUDY Independently reviewed safety run-in data prompts recommendation to initiate
IMMUTEP ANNOUNCES ADVANCEMENT OF PHASE II TRIAL FOR EFTILAGIMOD ALPHA IN COVID-19 PATIENTS TO RANDOMISED PORTION OF THE STUDY SYDNEY, AUSTRALIA 27 January 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunot
Read more →IMMPImmutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Read more →IMMPASX/Media Release IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trials TACTI-002 study expanded in lung cancer New phase
IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C SYDNEY, AUSTRALIA 22 January 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on th
Read more →IMMPUlcerative Colitis Phase II Study of GSK2831781 Discontinued
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Read more →IMMPASX/Media Release Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of ad
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study SYDNEY, AUSTRALIA 7th January 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is please
Read more →IMMPImmutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients started Further interim data from TACTI-002 expected in H1 2021 Sydney, AUSTRALIA, Jan. 07, 2021 (GLOBE
Read more →IMMPASX/Media Release IMMUTEP SECURES UNITED STATES PATENT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 30 December 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Compa
IMMUTEP SECURES UNITED STATES PATENT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR SYDNEY, AUSTRALIA 30 December 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for
Read more →IMMPImmutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Read more →IMMPImmutep Upscales Efti Manufacturing
Immutep Upscales Efti Manufacturing
Read more →IMMPASX/Media Release Immutep Upscales Efti Manufacturing SYDNEY, AUSTRALIA
Immutep Upscales Efti Manufacturing SYDNEY, AUSTRALIA December 16, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement
Read more →IMMPASX/Media Release IMMUTEP OPERATIONAL UPDATE Efti clinical trial status updates Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 SY
IMMUTEP OPERATIONAL UPDATE SYDNEY, AUSTRALIA December 15, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs.
Read more →IMMPASX/Media Release Immutep s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021 Evaluates the effi
to Start Phase II Metastatic Breast Cancer Study SYDNEY, AUSTRALIA 10 December 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EO
Read more →IMMPASX/Media Release Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer First time an antigen presenting cell (APC) activator h
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer SYDNEY, AUSTRALIA 10 December 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherap
Read more →IMMPImmutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
Read more →IMMPImmutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
Read more →IMMPASX/Media Release Immutep Announces Expansion of TACTI-002 Collaboration Trial Additional 74 patients with 1 st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indicatio
Expansion of TACTI-002 Collaboration Trial 19 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha ( efti or IMP321 ) through the expansion of its ongoing TACTI-002 study and a new
Read more →IMMPImmutep completes a A$29.6 million placement to accelerate and broaden its clinical development Immutep Limited (ASX: IMM; NASDAQ: IMMP)
Immutep completes a A$29.6 million placement to accelerate and broaden its clinical development Immutep Limited (ASX: IMM; NASDAQ: IMMP) November 19, 2020: Australian biotechnology company Immutep Limited ( Immutep or the Company ), which is listed on NASDAQ and the Australian
Read more →IMMPImmutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
Read more →IMMPImmutep Announces Expansion of TACTI-002 Collaboration Trial
Immutep Announces Expansion of TACTI-002 Collaboration Trial
Read more →IMMPASX/Media Release Immutep s Phase II TACTI-002 Study Reports Encouraging Data at SITC Overall Response Rates (ORR) in 1 st line NSCLC and 2 nd line HNSCC continue to be very favourable 5 patients with a Complete Response
Immutep s Phase II TACTI-002 Study Reports Encouraging Data at SITC SYDNEY, AUSTRALIA 10 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces encouraging new interim data from its ongoing Phase II TACTI-002 study evaluating the combination of eftilagimod alpha ( ef
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA 9 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) announces the grant of patent no. 2015
IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA 9 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) announces the grant of patent no. 2015229103 entitled Antibody molecules to LAG-3 and uses thereof by the Australi
Read more →IMMPImmutep Announces Australian Patent Grant for IMP701 Antibody
Immutep Announces Australian Patent Grant for IMP701 Antibody
Read more →IMMPImmutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
Read more →IMMPASX Announcement IMMUTEP S TACTI-002 DATA TO BE PRESENTED AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2020 ANNUAL MEETING SYDNEY, AUSTRALIA 3 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ),
IMMUTEP S TACTI-002 DATA TO BE PRESENTED AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2020 ANNUAL MEETING SYDNEY, AUSTRALIA 3 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for canc
Read more →IMMPASX/Media Release Immutep to Collaborate with LabCorp to Develop Oncology Services and Products SYDNEY, AUSTRALIA 29 th October, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel imm
Immutep to Collaborate with LabCorp to Develop Oncology Services and Products SYDNEY, AUSTRALIA 29th October, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announ
Read more →IMMPImmutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting
Immutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting
Read more →IMMPImmutep to Collaborate with LabCorp to Develop Oncology Services and Products
Immutep to Collaborate with LabCorp to Develop Oncology Services and Products
Read more →IMMPASX/Media Announcement Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients Investigator-initiated, placebo controlled and randomised Phase II study evaluating eftilagimod alpha (
ASX/Media Announcement Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients SYDNEY, AUSTRALIA 23 October 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce it has signed a Material Transfer
Read more →IMMPASX/Media Release IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C Encouraging clinical results from TACTI-002 and INSIGHT-004 trials of eftilagimod alpha Immutep completes recruitment for Stage 1 of Part B in TACTI-002
IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C SYDNEY, AUSTRALIA 22 October 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of it
Read more →IMMPImmutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients
Read more →IMMPASX/Media Release IMMUTEP GRANTED EUROPEAN PATENT FOR IMP761 SYDNEY, AUSTRALIA 21 October 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy t
IMMUTEP GRANTED EUROPEAN PATENT FOR IMP761 SYDNEY, AUSTRALIA 21 October 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the gran
Read more →IMMPImmutep Activities Report for the First Quarter of Fiscal Year 2021
Immutep Activities Report for the First Quarter of Fiscal Year 2021
Read more →IMMPImmutep Granted European Patent for IMP761
Immutep Granted European Patent for IMP761
Read more →IMMPImmutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020
Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020
Read more →IMMPThis appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to
This appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 2.7 Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX be
Read more →IMMPASX/Media Release Immutep Reports Improving Results from INSIGHT-004 Trial 41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%) Encouraging early anti-
Immutep Reports Improving Results from INSIGHT-004 Trial SYDNEY, AUSTRALIA 18 September 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congr
Read more →IMMPImmutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) and one in 1st line non-small cell lung cancer (NSCLC) Five responses in patients (both indications) with negative (< 1%) or moderate PD-L1 ex
Read more →IMMPImmutep Reports Improving Results from INSIGHT-004 Trial
Immutep Reports Improving Results from INSIGHT-004 Trial
Read more →IMMPASX/Media Release Immutep and Monash University Receive Grant Funding for LAG-3 Project SYDNEY, AUSTRALIA 31 August 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Counci
Immutep and Monash University Receive Grant Funding for LAG-3 Project SYDNEY, AUSTRALIA 31 August 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,4
Read more →IMMPImmutep and Monash University Receive Grant Funding for LAG-3 Project
Immutep and Monash University Receive Grant Funding for LAG-3 Project
Read more →IMMPImmutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2020 Previous corresponding period
Table of Contents Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2020 Previous corresponding period: Year ended 30 June 2019 FY 2019 FY 2020 Revenue from o
Read more →IMMPNew Data From Immutep’s Efti To Be Presented At ESMO
New Data From Immutep’s Efti To Be Presented At ESMO
Read more →IMMPASX Announcement IMMUTEP COMPLETES RECRUITMENT FOR STAGE 1 OF PART B IN TACTI-002 STUDY 23 patients with second line Non-Small Cell Lung Cancer (NSCLC) participating in Stage 1, Part B Total of 87 patients out of up to 1
IMMUTEP COMPLETES RECRUITMENT FOR STAGE 1 OF PART B IN TACTI-002 STUDY SYDNEY, AUSTRALIA 18 August, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is
Read more →IMMPImmutep Issues Newsletter Update to Shareholders
Immutep Issues Newsletter Update to Shareholders
Read more →IMMPImmutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study
Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study
Read more →IMMPASX/Media Release IMMUTEP GRANTED UNITED STATES PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 11 August 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biot
IMMUTEP GRANTED UNITED STATES PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 11 August 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and
Read more →IMMPImmutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Read more →IMMPASX Announcement IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C Very encouraging data for efti from the ongoing Phase II TACTI-002 trial First complete disappearance of target lesion from a patient with second line HN
IMMUTEP QUARTERLY ACTIVITIES REPORT & APPENDIX 4C SYDNEY, AUSTRALIA July 23, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA - 15 July 2020 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) announces the grant of patent no.
IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA - 15 July 2020 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) announces the grant of patent no. 10,711,060 entitled Antibody molecules to LAG-3 and uses thereof by the Unit
Read more →IMMPImmutep Announces United States Patent Grant for IMP701 Antibody
Immutep Announces United States Patent Grant for IMP701 Antibody
Read more →IMMPASX Announcement IMMUTEP COMPLETES RECRUITMENT FOR PART A OF PHASE II TACTI-002 STUDY Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC) 81 patients out of up to 109 now participating ac
IMMUTEP COMPLETES RECRUITMENT FOR PART A OF PHASE II TACTI-002 STUDY SYDNEY, AUSTRALIA June 29, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is ple
Read more →IMMPImmutep Completes Recruitment for Part A Of Phase II TACTI-002 Study
Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 22 June 2020 Immutep receives A$1,437,826 R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) A$1,437,826 R&D Tax Incentive SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Government
Read more →IMMPImmutep Receives A$1,437,826 R&D Tax Incentive
Immutep Receives A$1,437,826 R&D Tax Incentive
Read more →IMMPASX/Media Release Immutep Announces Improving Data from the Phase II TACTI-002 Study First complete response reported in 2 nd line head and neck squamous cell carcinoma (HNSCC) Improving Overall Response Rate (iORR) in H
Immutep Announces Improving Data from the Phase II TACTI-002 Study AUSTRALIA 1 June 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows improving effica
Read more →IMMPASX/Media Release Immutep Receives A$ 3.6 Million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 29 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company develo
Immutep Receives A$ 3.6 Million R&D Tax Incentive from French Government SYDNEY, AUSTRALIA 29 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is p
Read more →IMMPImmutep Reports First Results from INSIGHT-004 Study
Immutep Reports First Results from INSIGHT-004 Study
Read more →IMMPImmutep Announces Improving Data from the Phase II TACTI-002 Study
Immutep Announces Improving Data from the Phase II TACTI-002 Study
Read more →IMMPImmutep Receives US$2.4 Million R&D Tax Incentive from French Government
SYDNEY, Australia, May 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has received a €2,173,45
Read more →IMMPASX/Media Release Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting SYDNEY, AUSTRALIA 27 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30a
Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting SYDNEY, AUSTRALIA 27 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, E
Read more →IMMPImmutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting
SYDNEY, Australia, May 27, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT). CEO Marc Voigt, CSO and
Read more →IMMPASX/Media Release IMMUTEP GRANTED JAPANESE PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 7 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology
IMMUTEP GRANTED JAPANESE PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA 7 May 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmun
Read more →IMMPImmutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Read more →IMMPASX/Media Announcement Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting SYDNEY, AUSTRALIA
ASX/Media Announcement First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting SYDNEY, AUSTRALIA April 30, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce new data
Read more →IMMPNot for release to US wire services or distribution in the United States ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 29 April 2020 Immutep completes a A$12 million placement to drive development of its immuno-oncolo
Not for release to US wire services or distribution in the United States ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep completes a A$12 million placement to drive development of its immuno-oncology and autoimmune asset pipeline Immutep Limited (ASX: IMM; NASDAQ: IM
Read more →IMMPImmutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting
Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting
Read more →IMMPImmutep Reports Positive Phase II TACTI-002 Data
Immutep Reports Positive Phase II TACTI-002 Data
Read more →IMMPASX/Media Announcement Immutep Reports Positive Phase II TACTI-002 Data Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC): Improving Overall Response Rate (ORR) of 53% (earlier
ASX/Media Announcement Immutep Reports Positive Phase II TACTI-002 Data SYDNEY, AUSTRALIA April 28, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, a
Read more →IMMPASX/Media Release Enrollment completed for the INSIGHT-004 Study SYDNEY, AUSTRALIA
Enrollment completed for the INSIGHT-004 Study SYDNEY, AUSTRALIA April 22, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last pat
Read more →IMMPEnrollment completed for the INSIGHT-004 Study
Enrollment completed for the INSIGHT-004 Study
Read more →IMMPASX/Media Announcement Immutep Quarterly Activities Report & Appendix 4C Highly encouraging data from efti in ongoing TACTI-002 study AIPAC Phase IIb study reported first results Limited impact on clinical trials from CO
ASX/Media Announcement Immutep Quarterly Activities Report & Appendix 4C SYDNEY, AUSTRALIA April 20, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,
Read more →IMMPImmutep Limited , Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889 ASX/Media Announcement Immutep Advances Cell Line Development for IMP761 SYDNEY, AUSTRALIA
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ASX/Media Announcement Line Development for IMP761 SYDNEY, AUSTRALIA April 16, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that Batavia Biosciences, its manufacturi
Read more →IMMPImmutep Advances Cell Line Development for IMP761
SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress in the cell
Read more →IMMPASX/Media Announcement Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020 SYDNEY, AUSTRALIA
ASX/Media Announcement Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020 SYDNEY, AUSTRALIA April 14, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cance
Read more →IMMPImmutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
Read more →IMMPImmutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
Read more →IMMPASX/Media Announcement Immutep s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer SYDNEY, AUSTRALIA April 8 th , 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to info
ASX/Media Announcement Immutep s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer SYDNEY, AUSTRALIA April 8th, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to inform that EOC Pharma ( EOC ) and Immutep jointly discussed t
Read more →IMMPImmutep AIPAC Phase IIb Clinical Results & Update Global Webcast Slides SYDNEY, AUSTRALIA
Immutep AIPAC Phase IIb Clinical Results & Update Global Webcast Slides SYDNEY, AUSTRALIA March 26, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmu
Read more →IMMPASX/Media Announcement Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020 Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (
ASX/Media Announcement Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020 SYDNEY, AUSTRALIA March 25, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3-rel
Read more →IMMPImmutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Read more →IMMPImmutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma’s phase I study in metastatic breast cancer (MBC) Data expected throughout 2020, with study completion in Q4 CY2020 Registration trial in MBC in China is planned SYDNEY, Australia, March 19,
Read more →IMMPASX/Media Announcement Immutep s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma s phase I study in me
ASX/Media Announcement Immutep s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti SYDNEY, AUSTRALIA March 20, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to report that it has been informed its Chinese pa
Read more →IMMPAppendix 3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and Introduced 30/9/2001. Name of Entity: IMMUTEP LIMITED (ASX:I
Read more →IMMPASX/Media Announcement Immutep Receives Second IND approval for Efti from US FDA Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancer AIPAC-002 to expedite the possible use of efti for patients in
ASX/Media Announcement Immutep Receives Second IND approval for Efti from US FDA SYDNEY, AUSTRALIA March 9, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune dis
Read more →IMMPImmutep Receives Second IND Approval for Efti from US FDA
Immutep Receives Second IND Approval for Efti from US FDA
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2019 (previous corresponding period: half-year ended 31 December 2018) To be read in conjunction with the 30 Jun
For the Half-Year Ended (previous corresponding period: half-year ended 31 December 2018) To be read in conjunction with the 30 June 2019 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: IMM) Appendix 4D Interim Financial Report Results for Announ
Read more →IMMPASX/Media Announcement Immutep Reports Positive TACTI-002 Data Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1 st line non-small cell lung cancer (NSCLC) patients
ASX/Media Announcement Immutep Reports Positive TACTI-002 Data SYDNEY, AUSTRALIA February 19th, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, annou
Read more →IMMPImmutep Reports Positive TACTI-002 Data
Immutep Reports Positive TACTI-002 Data
Read more →IMMPASX/Media Release Immutep to Present TACTI-002 Interim Data at German Cancer Congress SYDNEY, AUSTRALIA February 4 th , 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company de
Immutep to Present TACTI-002 Interim Data at German Cancer Congress SYDNEY, AUSTRALIA February 4th, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, ad
Read more →IMMPImmutep to Present TACTI-002 Interim Data at German Cancer Congress
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
Read more →IMMPAppendix 4C Quarterly report for entities subject to Listing Rule 4.7B +Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
report for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16 Name of entity Immutep Limited ABN Quarter ended ( current quarter ) 90 009 237 889 31 December 2019 Consolidated statement of cash flows Current quarter $A 0
Read more →IMMPImmutep Activities Report
Immutep Activities Report
Read more →IMMPASX Announcement Immutep Corporate Presentation SYDNEY, AUSTRALIA
Immutep Corporate Presentation SYDNEY, AUSTRALIA January 10, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an updated corporate presentatio
Read more →IMMPASX Announcement IMMUTEP EXPANDS PART C OF TACTI-002 DUE TO POSITIVE DATA Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC) Part C
IMMUTEP EXPANDS PART C OF TACTI-002 DUE TO POSITIVE DATA SYDNEY, AUSTRALIA January 9, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an upda
Read more →IMMPImmutep Expands Part C of TACTI-002 Due to Positive Data
Immutep Expands Part C of TACTI-002 Due to Positive Data
Read more →IMMPRule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available.
Rule 2.7, 3.10.3, 3.10.4, 3.10.5 application for quotation of additional securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public. Introduced 01/07/96 O
Read more →IMMPASX/Media Release INSIGHT-004 CLINICAL TRIAL UPDATE Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumab No new safety signals in the first cohort, with 1 patient reporting a p
INSIGHT-004 CLINICAL TRIAL UPDATE SYDNEY, AUSTRALIA December 19, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the INSIGHT-004
Read more →IMMPINSIGHT-004 Clinical Trial Update
INSIGHT-004 Clinical Trial Update
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY SYDNEY, AUSTRALIA 14 November 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the grant of pat
IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR LAG525 ANTIBODY SYDNEY, AUSTRALIA 14 November 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the grant of patent no. 3116909 entitled Antibody molecules to LAG-3 and uses thereof by the
Read more →IMMPImmutep Announces European Patent Grant for LAG525 Antibody
Immutep Announces European Patent Grant for LAG525 Antibody
Read more →IMMPASX/Media Release IMMUTEP PRESENTS POSITIVE INTERIM DATA FROM PHASE II TACTI-002 TRIAL AT SITC Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trial Preliminary Overall Response Ra
Immutep s current lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clin
Read more →IMMPImmutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
Read more →IMMPChairman s Address 2019 Annual General Meeting Dr Russell Howard 1 November 2019 Ladies and gentleman, On behalf of the Board, as Chairman I would like to welcome you to Immutep s Annual General Meeting for 2019. Immutep
2019 Annual General Meeting Ladies and gentleman, On behalf of the Board, as Chairman I would like to welcome you to Immutep s Annual General Meeting for 2019. Immutep is an Australian biotech that has established its leadership in the development of LAG-3 related immunothera
Read more →IMMPOperational Update
Operational Update
Read more →IMMPASX/Media Release OPERATIONAL UPDATE TACTI-002 patient recruitment update Six patients now enrolled and dosed in INSIGHT-004, 6 mg cohort complete Significant eftilagimod alpha clinical data expected in coming months: AI
SYDNEY, AUSTRALIA October 28, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates.
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrol
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial SYDNEY, AUSTRALIA October 15, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy tre
Read more →IMMPImmutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data Presentations at Upcoming Industry Conferences SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data Presentations at Upcoming Industry Conferences SYDNEY, AUSTRALIA October 10, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy
Read more →IMMPImmutep Receives A$2.5 Million R&D Tax Incentive from French Government
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
Read more →IMMPImmutep Announces Data Presentations at Upcoming Industry Conferences
Immutep Announces Data Presentations at Upcoming Industry Conferences
Read more →IMMPRules 4.7.3 and 4.10.3 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity: Immutep Limited (ASX:IMM) ABN / ARBN: Financial year ended: 90 009 237 889 30 June 2019
Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Name of entity: Immutep Limited (ASX:IMM) ABN / ARBN: Financial year ended: 90 009 237 889 30 June 2019 Our corporate governance statement2 for the above period above can be These pages o
Read more →IMMPASX/Media Release Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data Requisite clinical responses achieved in cohort 1 of Part A (1 st line NSCLC) of TACTI-002 Phase I
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim SYDNEY, AUSTRALIA September 26, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for can
Read more →IMMPImmutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP TO RECEIVE 4M MILESTONE PAYMENT FROM GSK SYDNEY, AUSTRALIA 23 September 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology c
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP TO RECEIVE 4M MILESTONE PAYMENT FROM GSK SYDNEY, AUSTRALIA 23 September 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for canc
Read more →IMMPImmutep to Receive £4M Milestone Payment from GSK
Immutep to Receive £4M Milestone Payment from GSK
Read more →IMMPASX/Media Release IMMUTEP ANNOUNCES JAPANESE PATENT GRANT FOR LAG525 ANTIBODY SYDNEY, AUSTRALIA 17 September 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the grant of pa
IMMUTEP ANNOUNCES JAPANESE PATENT GRANT FOR LAG525 ANTIBODY SYDNEY, AUSTRALIA 17 September 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the grant of patent no. 6576962 entitled Antibody molecules to LAG-3 and uses thereof by th
Read more →IMMPImmutep Announces Japanese Patent Grant for LAG525 Antibody
Immutep Announces Japanese Patent Grant for LAG525 Antibody
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP GRANTED EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN CANCER SYDNEY, AUSTRALIA 22 August 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a bio
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP GRANTED EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN CANCER SYDNEY, AUSTRALIA 22 August 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatme
Read more →IMMPImmutep Limited Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2019 Previous corresponding period
Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Immutep Limited ABN: 90 009 237 889 Reporting period: Year ended 30 June 2019 Previous corresponding period: Year ended 30 June 2018 Revenue from ordinary activities Down 95 % to $ 139,782 Other income
Read more →IMMPImmutep Granted European Patent for Eftilagimod Alpha in Cancer
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
Read more →IMMPNot for release to US wire services or distribution in the United States ASX/Media Release IMMUTEP RAISES A$10M VIA PLACEMENT AND UNDERWRITTEN ENTITLEMENT OFFER Approximately A$10 million being raised to drive developmen
Not for release to US wire services or distribution in the United States A$10M VIA PLACEMENT AND UNDERWRITTEN ENTITLEMENT OFFER SYDNEY, AUSTRALIA July 9, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or Company ), a biotechnology company developing novel immunotherap
Read more →IMMPASX Release IMMUTEP COMPLETES A$6M
IMMUTEP COMPLETES A$6M ENTITLEMENT OFFER SYDNEY, AUSTRALIA August 6, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce the completion of its fully underwritten pro rata non-renounceable entitlement offer ( Entitlement Offer ) of new
Read more →IMMPImmutep Completes A$6M Entitlement Offer
Immutep Completes A$6M Entitlement Offer
Read more →IMMPImmutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
Read more →IMMPMarket Announcement 5 July 2019 Immutep Limited (ASX: IMM) Trading Halt Description The securities of Immutep Limited ( IMM ) will be placed in trading halt at the request of IMM, pending it releasing an announcement. Un
Immutep Limited (ASX: IMM) Trading Halt The securities of Immutep Limited ( IMM ) will be placed in trading halt at the request of IMM, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commen
Read more →IMMPImmutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Read more →IMMPASX/Media Release Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer 226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of efti
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer SYDNEY, AUSTRALIA June 25, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cance
Read more →IMMPImmutep to Host Key Opinion Leader Call
Immutep to Host Key Opinion Leader Call
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANTED FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY SYDNEY, AUSTRALIA 21 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANTED FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY AUSTRALIA 21 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immuno
Read more →IMMPImmutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
Read more →IMMPImmutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
Read more →IMMPASX/Media Release Immutep Completes Recruitment of Initial Cohort in 1 st Line NSCLC Patients for TACTI-002 Trial Recruitment for 2 nd line (PD-1 refractory) NSCLC and 2 nd line HNSCC cohorts of the TACTI-002 trial, cond
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial SYDNEY, AUSTRALIA June 13th, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer an
Read more →IMMPASX/Media Release INSIGHT: First Patient Dosed in the 4 th arm called INSIGHT-004 Highlights First patient received first dose in INSIGHT-004, a phase I clinical trial Evaluates the combination of eftilagimod alpha with
INSIGHT: First Patient Dosed in the 4th arm called INSIGHT-004 SYDNEY, AUSTRALIA June 6, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces tha
Read more →IMMPINSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
Read more →IMMPASX/Media Release Immutep Presentation at ASCO 2019 SYDNEY, AUSTRALIA 3 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for
Presentation at ASCO 2019 SYDNEY, AUSTRALIA 3 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to confirm that it was involved in two p
Read more →IMMPImmutep Presentation at ASCO 2019
Immutep Presentation at ASCO 2019
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY SYDNEY, AUSTRALIA 23 May 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or th
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR EFTILAGIMOD ALPHA IN 23 May 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and au
Read more →IMMPImmutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma SYDNEY, AUSTRALIA May 17 , 2019 Immutep Limited (ASX: IMM; NASD
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma SYDNEY, AUSTRALIA May 17, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology com
Read more →IMMPImmutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Upcoming Industry Conference Participation SYDNEY, AUSTRALIA May 10 , 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotech
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Upcoming Industry Conference Participation SYDNEY, AUSTRALIA May 10, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments f
Read more →IMMPImmutep Announces Upcoming Industry Conference Participation
Immutep Announces Upcoming Industry Conference Participation
Read more →IMMPASX/Media Release Operational Update Highlights Recruitment for the AIPAC study expected to be completed in Q2 2019 15 patients enrolled in TACTI-002 Phase II collaboration study with MSD Trial protocol approved for the
SYDNEY, AUSTRALIA April 30, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update for the ongoing development of its product candidates.
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast SYDNEY, AUSTRALIA March 27, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunoth
Read more →IMMPImmutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN CANCER SYDNEY, AUSTRALIA 22 March 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Comp
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN CANCER SYDNEY, AUSTRALIA 22 March 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunothe
Read more →IMMPImmutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present IMP761 Preclinical Results in Global Webcast SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present IMP761 Preclinical Results in Global Webcast SYDNEY, AUSTRALIA March 19, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatme
Read more →IMMPImmutep to Present IMP761 Preclinical Results in Global Webcast
Immutep to Present IMP761 Preclinical Results in Global Webcast
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn s and Colitis Organisation SYDNEY, AUSTRALIA 8 March 2019 Immutep Limited (ASX: IMM
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn s and Colitis Organisation SYDNEY, AUSTRALIA 8 March 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma Presented at the World Immunotherapy Congress USA 2019 SYDNEY,
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma Presented at the World Immunotherapy Congress USA 2019 SYDNEY, AUSTRALIA 6 March 2019 Immutep Limited (ASX: IMM; NASDAQ:
Read more →IMMPImmutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
Read more →IMMPImmutep doses First Patient in TACTI-002 Phase II Trial
Immutep doses First Patient in TACTI-002 Phase II Trial
Read more →IMMPASX/Media Release Immutep doses First Patient in TACTI-002 Phase II Trial The First Patient has been dosed at START Madrid- FJD in Spain Clinical trial sites are active and more will be activated and commence recruitment
Immutep doses First Patient in TACTI-002 Phase II Trial SYDNEY, AUSTRALIA March 6, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), announces the first patient has been dosed with the combination of Keytruda and efti for TACTI-002, a Phase II clinical
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Oppenheimer s 29th Annual Healthcare Conference SYDNEY, AUSTRALIA 04 March 2019 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company),
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Oppenheimer s 29th Annual Healthcare Conference SYDNEY, AUSTRALIA 04 March 2019 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy tr
Read more →IMMPImmutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2018 (previous corresponding period: half-year ended 31 December 2017) To be read in conjunction with the 30 Jun
Interim Financial Report (previous corresponding period: half-year ended 31 December 2017) To be read in conjunction with the 30 June 2018 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: IMM) Appendix 4D Interim Financial Report Results for Annou
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Upcoming Industry Conferences SYDNEY, AUSTRALIA 26 February 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology c
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Upcoming Industry Conferences SYDNEY, AUSTRALIA 26 February 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for canc
Read more →IMMPImmutep to Present at Upcoming Industry Conferences
Immutep to Present at Upcoming Industry Conferences
Read more →IMMPInvestor Update JANUARY 2019 IN THIS ISSUE: MESSAGE FROM THE CEO INDUSTRY CONFERENCES AND POSTER PRESENTATIONS OPERATIONAL PROGRESS PARTNERING UPDATE FINANCING UPDATE OUTLOOK MARC VOIGT Message from the CEO Welcome to th
03 Investor Update JANUARY 2019 IN THIS ISSUE: MESSAGE FROM THE CEO INDUSTRY CONFERENCES AND POSTER PRESENTATIONS OPERATIONAL PROGRESS PARTNERING UPDATE FINANCING UPDATE OUTLOOK MARC VOIGT Message from the CEO Welcome to the first investor update of 2019 following a very meanin
Read more →IMMPASX/Media Release IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION, SERVICE AND SUPPLY AGREEMENT WITH CYTLIMIC New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha ( efti or IMP321 ) as part of a canc
IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION, SERVICE AND SUPPLY AGREEMENT WITH CYTLIMIC 7 January 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that it has entered into a clinical trial collaboration agreement, a supply ag
Read more →IMMPImmutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
Read more →IMMPImmutep Limited ABN 90 009 237 889 Prospectus For the issue by the Company of 2,080,000 Warrants convertible into 208,000,000 Warrant Shares (in aggregate) at an exercise price of US$0.025 per Warrant Share. This Prospec
the issue by the Company of 2,080,000 Warrants convertible into 208,000,000 Warrant Shares (in aggregate) at an exercise price of US$0.025 per Warrant Share. This Prospectus has been prepared for the purpose of facilitating secondary trading of any Warrant Shares issued upon the
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 21 December 2018 Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b) Sydney, Australia - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) On 19 Decembe
ASX/Media Release (Code: ASX: IMM; NASDAQ: Listing Rules 3.10.5A and 7.1A.4(b) Sydney, Australia - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) On 19 December 2018, the Company announced that it had entered into a securities purchase agreement with certa
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital - - - Extends the Company s cash runway into mid-2020, during which t
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital SYDNEY, AUSTRALIA December 19, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology compa
Read more →IMMPImmutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
Read more →IMMPSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ), dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ), dated as of December 18, 2018, is between Immutep Limited, of Level 12, 95 Pitt Street, Sydney 2000, New South Wales, Australia, an Australian public company incorporated under the laws of the C
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP SECURES EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH THERAPEUTIC ANTIBODIES FOR TREATING CANCER SYDNEY, AUSTRALIA November 29, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a bio
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP GRANTED EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 OR PD-L1
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP GRANTED EUROPEAN PATENT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 OR PD-L1 INHIBITOR SYDNEY, AUSTRALIA November 28, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology compan
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4 th Annual ICI Europe Summit SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit SYDNEY, AUSTRALIA November 27, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ),
Read more →IMMPNew Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
Read more →IMMPASX Announcement 16 November 2018 Results of Annual General Meeting The results of Immutep Limited (ASX:IMM) Annual General Meeting held earlier today are set out in the attached document. All resolutions were passed on
Results of Annual General Meeting The results of Immutep Limited (ASX:IMM) Annual General Meeting held earlier today are set out in the attached document. All resolutions were passed on a show of hands. For further information please contact: Campbell, Vice President of Busin
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting SYDNEY, AUSTRALIA November 12, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Com
Read more →IMMPImmutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Operational Update Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patients AIPAC Phase IIb re
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA November 1, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an operational
Read more →IMMPRules 4.7.3 and 4.10.3 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity: Immutep Limited (ASX:IMM) ABN / ARBN: Financial year ended: 90 009 237 889 30 June 2018
Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Immutep Limited (ASX:IMM) ABN / ARBN: Financial year ended: 90 009 237 889 30 June 2018 Our corporate governance statement2 for the above period above can be http://www.immutep.com/about-us
Read more →IMMPLETTER FROM THE CHAIRMAN Dear Fellow Shareholder, I invite you to join our Board and management team at Immutep s Annual General Meeting (AGM) to be held on Friday, 16 November 2018, in Sydney. An agenda for the AGM acco
LETTER FROM THE CHAIRMAN Dear Fellow Shareholder, I invite you to join our Board and management team at Immutep s Annual General Meeting (AGM) to be held on Friday, 16 November 2018, in Sydney. An agenda for the AGM accompanies this letter and the business of the AGM is set ou
Read more →IMMPimmutep LAG-3 IMMUNOTHERAPY I ANNUAL REPORT 2018 Reporting period: Year ended 30 June 2018 Previous corresponding period: Year ended 30 June 2017 ABN 90 009 237 889 TABLE OF CONTENTS CORPORATE DIRECTORY 3 CHAIRMAN S LETT
LAG-3 IMMUNOTHERAPY I ANNUAL REPORT 2018 Reporting period: Year ended 30 June 2018 Previous corresponding period: Year ended 30 June 2017 ABN 90 009 237 889 CONTENTS CORPORATE DIRECTORY 3 CHAIRMAN S LETTER 4 REVIEW OF OPERATIONS 5 DIRECTOR S REPORT 9 CORPORATE GOVERNANCE STATEME
Read more →IMMPRule 2.7, 3.10.3, 3.10.4, 3.10.5 APPENDIX 3B & CLEANSING NOTICE Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be give
Rule 2.7, 3.10.3, 3.10.4, 3.10.5 APPENDIX 3B & CLEANSING NOTICE application for quotation of additional securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be mad
Read more →IMMPImmutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting SYDNEY, AUSTRALIA October 2, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company dev
Read more →IMMPImmutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference SYDNEY, AUSTRALIA September 26, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy
Read more →IMMPImmutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
Read more →IMMPth 2 The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they
Patients* No. Clinical Trials* 26 Outlook 27 Outlook Immutep is well funded with a cash runway to calendar Q4 2019, well beyond the final progression free survival data from its Phase IIb AIPAC breast cancer trial. Potential News Flow and Milestones Clinical Other AIPAC fully rec
Read more →IMMP(Code: ASX: IMM; NASDAQ: IMMP) 3 September 2018 PROGRESS TOWARDS CLINICAL DEVELOPMENT OF IMP761 A LAG-3 AGONIST ANTIBODY SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep , the Company ),
Media Release (Code: ASX: IMM; NASDAQ: IMMP) CLINICAL DEVELOPMENT OF IMP761 A LAG-3 AGONIST ANTIBODY SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep , the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmu
Read more →IMMPProgress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody
Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government AUSTRALIA August 21, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing
Read more →IMMPImmutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference SYDNEY, AUSTRALIA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech August 16, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for
Read more →IMMPImmutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) TACTI-mel Patient Recruitment Complete and Operational Update Patient recruitment completed for Part B of ongoing TACTI-mel Phase I clinical trial Progress on Immutep s TA
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) TACTI-mel Patient Recruitment Complete and Operational Update SYDNEY, AUSTRALIA August 7, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatmen
Read more →IMMPTACTI-mel Patient Recruitment Complete and Operational Update
TACTI-mel Patient Recruitment Complete and Operational Update
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 30 July 2018 IMMUTEP S LAG-3 IMMUNOSTIMULANT PRODUCT CANDIDATE, EFTI, RECEIVES IND APPROVAL FROM U.S. FDA On schedule to initiate the TACTI-002 Phase II clinical study in
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUNOSTIMULANT PRODUCT CANDIDATE, EFTI, RECEIVES IND APPROVAL FROM U.S. FDA On schedule to initiate the TACTI-002 Phase II clinical SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is please
Read more →IMMPImmutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 2 July 2018 IMMUTEP SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce that it has submitted its Investigational New Drug ( IND ) applic
Read more →IMMPImmutep Submits Investigational New Drug (IND) Application with FDA
Immutep Submits Investigational New Drug (IND) Application with FDA
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 19 June 2018 MID-POINT OF PATIENT ENROLMENT REACHED IN AIPAC TRIAL SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to an
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) MID-POINT OF PATIENT ENROLMENT REACHED IN AIPAC TRIAL SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to announce that it has reached the mid-point in patient enrolment for its
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 4 June 2018 IMMUTEP PRESENTATIONS AT ASCO SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to confirm that it is involved
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP PRESENTATIONS AT SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) is pleased to confirm that it is involved in three poster presentations at the American Society of Clinical Oncolog
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast New data presented shows ORR of 61% (11/18 patients) SYDN
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast New data presented shows ORR of 61% (11/18 patients) SYDNEY, AUSTRALIA May 30, 2018 Immutep Limited (ASX: IMM; NA
Read more →IMMPPositive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
Read more →IMMPTwo ACTive Immunotherapies In Melanoma (TACTI-mel): Results Of A Phase I Trial With Metastatic Melanoma Patients Treated With A Soluble LAG-3 Receptor (LAG-3lg Or Eftilagimod Alpha) As An Antigen Presenting (APC) Activat
Two ACTive Immunotherapies In Melanoma (TACTI-mel): Results Of A Phase I Trial With Metastatic Melanoma Patients Treated With A Soluble LAG-3 Receptor (LAG-3lg Or Eftilagimod Alpha) As An Antigen Presenting (APC) Activator Combined With Pembrolizumab Fr d ric Triebel MD, PhD Thi
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast Chief Medical Officer Dr. Frederic Triebel to Present at the 3 rd Annual Advances in Imm
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast Chief Medical Officer Dr. Frederic Triebel to Present at the 3rd Annual Advances in Immuno-Oncology Congress SYDNEY, AUSTRALIA May 17, 2018 Immu
Read more →IMMPImmutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 4 May 2018 IMMUTEP TO PRESENT AT 2018 ASCO ANNUAL MEETING SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) today announced that it wil
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP TO PRESENT AT 2018 SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for Clinical Oncology (ASCO) Annual M
Read more →IMMPImmutep to Present at 2018 ASCO Annual Meeting
Immutep to Present at 2018 ASCO Annual Meeting
Read more →IMMPImmutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million
SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April 2018. The Company received applications from eligible shareholders for 300,561,089
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 13 April 2018 IMMUTEP COMPLETES $6.31 MILLION SHARE PURCHASE PLAN; RAISES TOTAL OF $13.16 MILLION SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or t
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP COMPLETES $6.31 MILLION SHARE PURCHASE PLAN; RAISES TOTAL OF $13.16 MILLION SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) advises that its Share Purchase Plan ( SPP ) closed as pl
Read more →IMMPImmutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million
Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 3 April 2018 Operational Update First two patients of the additional cohort of the Phase I, TACTI-mel trial have commenced treatment; data to be reported mid-2018 AIPAC tr
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), provides an operational update on the Company s ongoing development activities for its lead product candidates, eftilagimod alpha ( efti or IM
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 22 March 2018 IMMUTEP COMMENCES PATIENT DOSING IN ADDITIONAL TACTI-MEL COHORT SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) has a
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP COMMENCES PATIENT DOSING IN ADDITIONAL TACTI-MEL COHORT SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) has announced the initiation of patient dosing in the new cohort of the TAC
Read more →IMMPUpdated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
Read more →IMMPImmutep Commences Patient Dosing In Additional TACTI-mel Cohort
Immutep Commences Patient Dosing In Additional TACTI-mel Cohort
Read more →IMMPForm 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme Immutep Limited ACN/ARSN 009 237 889 1. Details of substantial holder (1) Name National Nominees Ltd ACF Australian
Notice of initial substantial holder To Company Name/Scheme Immutep Limited ACN/ARSN 009 237 889 1. Details of substantial holder (1) Name National Nominees Ltd ACF Australian Ethical Investment Limited ABN 51 004 278 899 The holder became substantial on 14/03/2018 2. De
Read more →IMMPMarch 2018 Dear Fellow Shareholder It is with pleasure that I write to invite certain eligible shareholders of Immutep to participate in Immutep s Share Purchase Plan ( SPP ), as announced on 12 March 2018. Eligible shar
Dear Fellow Shareholder It is with pleasure that I write to invite certain eligible shareholders of Immutep to participate in Immutep s Share Purchase Plan ( SPP ), as announced on 12 March 2018. Eligible shareholders are being offered the opportunity to subscribe for ordinary
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 12 March 2018 IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Co
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ) has announced that it has entered into a clinical trial collaboration and supply ag
Read more →IMMPImmutep Raises A$6.85M Through Institutional Placement
Immutep Raises A$6.85M Through Institutional Placement
Read more →IMMPImmutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 6 March 2018 IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep , the Company ) announce
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep , the Company ) announces the grant of patent no. 9,908,936 entitled Antibody molecules to LA
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 5 March 2018 Immutep receives A$686,704 R&D Tax Incentive SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce tha
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep receives A$686,704 SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), is pleased to announce that it has received a A$686,704 cash rebate from the Australian Federal Government s R&D t
Read more →IMMPImmutep receives A$686,704 R&D Tax Incentive
Immutep receives A$686,704 R&D Tax Incentive
Read more →IMMPIMMUTEP LIMITED ABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2017 (previous corresponding period: half-year ended 31 December 2016) To be read in conjunction with the 30 Jun
Interim Financial Report (previous corresponding period: half-year ended 31 December 2016) To be read in conjunction with the 30 June 2017 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: IMM) Appendix 4D Interim Financial Report Results for Annou
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 9 February 2018 Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or t
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Outcome from DSMB Safety Extension of TACTI-mel Phase I Clinical Trial SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), announced today that the Database Safety Monitoring Board ( DSMB ) co
Read more →IMMPOutcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 1 February 2018 IMMUTEP LIMITED ANNOUNCES MILESTONE PAYMENT FROM CHINESE PARTNER EOC PHARMA SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced today that
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) IMMUTEP LIMITED ANNOUNCES MILESTONE PAYMENT FROM CHINESE PARTNER EOC PHARMA SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced today that it has received a milestone payment from the Company s Chinese partner
Read more →IMMPImmutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma
Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma
Read more →IMMPInvestor Updates DECEMBER 2017 IN THIS ISSUE: MESSAGE FROM THE CHAIR MESSAGE FROM THE CEO SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING & BIO EUROPE 2017 BOARD OF DIRECTORS AND CLINICAL ADVISORY BOARD RU
MESSAGE FROM THE CHAIR MESSAGE FROM THE CEO SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING & BIO EUROPE 2017 BOARD OF DIRECTORS AND CLINICAL ADVISORY BOARD Message from the Chair As your new Company Chairman, I would like to take this opportunity to welcome you
Read more →IMMPASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) 12 December 2017 Operational Update SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), has provided an update on the Company s two ongoin
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), has provided an update on the Company s two ongoing clinical trials with eftilagimod alpha (LAG-3Ig or IMP321). Immutep is pleased to advise tha
Read more →IMMPASX/Media Release 4 December 2017 RELEASE OF SECURITIES FROM ESCROW; APPENDIX 3B & CLEANSING NOTICE Sydney, 4 December 2017 Immutep Limited (ASX:IMM) (the Company) advises that 1,538,462 fully paid ordinary shares will b
RELEASE OF SECURITIES FROM ESCROW; APPENDIX 3B & CLEANSING NOTICE Sydney, 4 December 2017 Immutep Limited (ASX:IMM) (the Company) advises that 1,538,462 fully paid ordinary shares will be released from escrow on 18 December 2017. There are no other restrictions that apply to th
Read more →IMMPASX/Media Release 28 November 2017 PRIMA BIOMED BECOMES IMMUTEP Sydney, 28 November 2017 We refer to shareholder approval granted at the Company s Annual General Meeting held on 17 November 2017 to change the name of the
PRIMA BIOMED BECOMES Sydney, 28 November 2017 We refer to shareholder approval granted at the Company s Annual General Meeting held on 17 November 2017 to change the name of the Company from Prima BioMed Ltd to Immutep Limited . The Company is pleased to advise that the name
Read more →IMMPPrima BioMed Becomes Immutep
Prima BioMed Becomes Immutep
Read more →IMMPAppendix 3Z Final Director s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given
Director s Interest Notice Final Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and Introduced 30/9/2001. Name of entity PRIMA BIOMED LIMITED (ASX:
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 November 2017 PRIMA SECURES EUROPEAN PATENT GRANT FOR LEAD PRODUCT IMP321 IN CANCER SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company )
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA SECURES EUROPEAN PATENT GRANT FOR LEAD PRODUCT IMP321 IN CANCER SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the grant of patent number 2604275 entitled Use of Recombinant
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 November 2017 PRIMA BIOMED CHANGES ITS NAME TO IMMUTEP LTD SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) has announced a rebran
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED CHANGES ITS NAME TO IMMUTEP LTD SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd ( Immutep ) foll
Read more →IMMPFAQ – Change of company name from ‘Prima BioMed Limited’ to ‘Immutep Limited’
FAQ – Change of company name from ‘Prima BioMed Limited’ to ‘Immutep Limited’
Read more →IMMPPrima Secures European Patent Grant for Lead Product IMP321 in Cancer
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
Read more →IMMPChairman s Address 2017 Annual General Meeting Lucy Turnbull, AO 17 November 2017 Dear Fellow Shareholder, On behalf of our Board, I would like to welcome you to the Prima BioMed Annual General Meeting for 2017. As is cu
2017 Annual General Meeting Dear Fellow Shareholder, On behalf of our Board, I would like to welcome you to the Prima BioMed Annual General Meeting for 2017. As is customary I will highlight some of the key achievements during what has been an extremely busy year for our compa
Read more →IMMPASX Announcement 17 November 2017 Results of Annual General Meeting The results of Prima BioMed Limited (ASX:PRR) Annual General Meeting held earlier today are set out in the attached document. All resolutions were passe
Results of Annual General Meeting The results of Prima BioMed Limited (ASX:PRR) Annual General Meeting held earlier today are set out in the attached document. All resolutions were passed on a show of hands. information please contact: Campbell, Vice President of Business Dev
Read more →IMMPPrima BioMed Changes its Name to Immutep Ltd
Prima BioMed Changes its Name to Immutep Ltd
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 15 November 2017 EFTILAGIMOD ALPHA (LAG-3Ig or IMP321) PRE-IND MEETING WITH THE FDA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to a
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) (LAG-3Ig or IMP321) PRE-IND MEETING WITH THE FDA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND) meeting with the U
Read more →IMMPEftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 9 November 2017 NEW EFTILAGIMOD ALPHA (LAG-3Ig or IMP321) DATA FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING SYDNEY, AUSTRALIA Pri
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) NEW EFTILAGIMOD ALPHA (LAG-3Ig or IMP321) DATA FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce
Read more →IMMPNew Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 1 November 2017 DR. FRÉDÉRIC TRIEBEL PRESENTED AT THE WORLD IMMUNOTHERAPY CONGRESS 2017 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima )
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) FR D RIC TRIEBEL PRESENTED AT THE WORLD IMMUNOTHERAPY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that Dr. Fr d ric Triebel, Prima s Chief Scientific Officer and Medical Officer, gave an oral
Read more →IMMPDr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 October 2017 DR. FRÉDÉRIC TRIEBEL PRESENTING AT THE WORLD IMMUNOTHERAPY CONGRESS 2017 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prim
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) FR D RIC TRIEBEL PRESENTING AT THE WORLD IMMUNOTHERAPY CONGRESS 2017 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that Dr. Fr d ric Triebel, Prima s Chief Scientific Officer & Medical Officer
Read more →IMMPDr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
Read more →IMMPA MESSAGE FROM THE CHAIRMAN Dear fellow Shareholder, I invite you to join our Board and management team at Prima BioMed s Annual General Meeting (AGM) to be held on Friday, 17 November 2017, in Sydney. An agenda for the
A MESSAGE FROM THE CHAIRMAN Dear fellow Shareholder, I invite you to join our Board and management team at Prima BioMed s Annual General Meeting (AGM) to be held on Friday, 17 November 2017, in Sydney. An agenda for the AGM accompanies this letter and the business of the AGM
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 17 October 2017 IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PR
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) IMP321 NEW DATA ACCEPTED FOR PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2017 ANNUAL MEETING SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that new data investigating the use
Read more →IMMPIMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Read more →IMMPINVESTOR UPDATE by EDITION 21 OCTOBER 2017 Message from the CEO Business overview LAG-3 continues to capture the attention of the international pharmaceutical and investment communities. Immunotherapy is becoming Marc Vo
UPDATE by EDITION 21 OCTOBER 2017 Message from the CEO Business overview LAG-3 continues to capture the attention of the international pharmaceutical and investment communities. Immunotherapy is becoming Marc Voigt, CEO a standard of care for many cancer treatments as evidenced
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 8 September 2017 PRIMA SECURES JAPANESE PATENT GRANT FOR IMP731 ANTIBODY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA SECURES JAPANESE PATENT GRANT FOR IMP731 ANTIBODY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the grant of Japanese patent no. 6177735 entitled Cytotoxic anti-LAG-3 monocl
Read more →IMMPPrima Secures Japanese Patent Grant for IMP731 Antibody
Prima Secures Japanese Patent Grant for IMP731 Antibody
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 September 2017 PRIMA SECURES JAPANESE PATENT GRANT FOR LEAD PRODUCT IMP321 IN INFECTIOUS DISEASE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA SECURES JAPANESE PATENT GRANT FOR LEAD PRODUCT IMP321 IN INFECTIOUS DISEASE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the grant of patent number 6169734 entitled Use o
Read more →IMMPPrima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 30 August 2017 PRIMA BIOMED AND MONASH UNIVERSITY RECEIVE FUNDING GRANT FOR LAG-3 RESEARCH PROJECT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED AND MONASH FUNDING GRANT FOR LAG-3 RESEARCH PROJECT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces that the Australian Research Council (ARC) has awarded Prima and
Read more →IMMPPrima BioMed Ltd Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2017 Previous corresponding peri
Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2017 Previous corresponding period: Year ended 30 June 2016 Revenue from ordinary activities Down 100 % to Other
Read more →IMMPPrima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 21 August 2017 PRIMA BIOMED APPOINTS NON-EXECUTIVE DIRECTOR TO THE BOARD SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today annou
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED APPOINTS NON-EXECUTIVE DIRECTOR TO THE BOARD SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that Grant Chamberlain will join the Board as a Non-Executive Direc
Read more →IMMPPrima BioMed Appoints Non-Executive Director to the Board
Prima BioMed Appoints Non-Executive Director to the Board
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 16 August 2017 PRIMA BIOMED RECEIVES A $1.3 MILLION TAX REFUND FROM FRENCH GOVERNMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES A $1.3 FROM FRENCH GOVERNMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) is pleased to announce that it has received a 876,635 (A$1,306,266) cash rebate from the
Read more →IMMPPrima BioMed Receives A$1.3 Million Tax Refund from French Government
Prima BioMed Receives A$1.3 Million Tax Refund from French Government
Read more →IMMPINVESTOR UPDATE by EDITION 20 AUGUST 2017 Message from the CEO Dear Fellow Shareholders, As the global leader in LAG-3, we are firmly focused on creating shareholder value through the advancement of our LAG-3 based clini
Message from the CEO Dear Fellow Shareholders, As the global leader in LAG-3, we are firmly focused on creating shareholder value through the advancement of our LAG-3 based clinical and preclinical oncology and autoimmune pipeline. We are making meaningful progress on the deve
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 18 July 2017 Financial Update 2H17 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) would like to update shareholders on its current financial status subsequent
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Financial Update 2H17 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) would like to update shareholders on its current financial status subsequent to the closing of the recent U.S. capital raise and yesterday s annou
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 17 July 2017 PRIMA BIOMED ANNOUNCES SECOND MILESTONE PAYMENT FOR IMP701 PROGRAM SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES SECOND MILESTONE PAYMENT FOR IMP701 PROGRAM SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced it will receive a second undisclosed significant clinical m
Read more →IMMPFinancial Update 2H17
Financial Update 2H17
Read more →IMMPPrima BioMed Announces Second Milestone Payment for IMP701 Program
Prima BioMed Announces Second Milestone Payment for IMP701 Program
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 10 July 2017 PRIMA BIOMED ANNOUNCES APPROVAL FOR THE INITIATION OF THE INSIGHT CLINICAL TRIAL SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima the Company )
Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES APPROVAL FOR THE INITIATION OF THE INSIGHT CLINICAL TRIAL SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima the Company ) today announced that its collaboration partner, the Institute of Cli
Read more →IMMPPrima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
Read more →IMMPASX Release (Code: ASX: PRR; NASDAQ: PBMD) 4 July 2017 Appendix 3B US$5m Capital Raising Sydney, Australia Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) We refer to the Company s announcement on 30 J
ASX Release (Code: ASX: PRR; NASDAQ: PBMD) US$5m Capital Raising Sydney, Australia Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima or the Company) We refer to the Company s announcement on 30 June 2017 of the US capital raising of US$5 million. anticipation of closing the US
Read more →IMMPASX Release (Code: ASX: PRR; NASDAQ: PBMD) 6 July 2017 Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b) Sydney, Australia Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) On 30 June 2017, the Compan
ASX Release (Code: ASX: PRR; NASDAQ: PBMD) Disclosure Under Listing Rules 3.10.5A and Sydney, Australia Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima or the Company) On 30 June 2017, the Company announced that it had entered into a securities purchase agreement with certain
Read more →IMMPInterim Financial Report For the nine and three months periods ended 31 March 2017 (previous corresponding periods: nine and three months periods ended 31 March 2016) To be read in conjunction with the 30 June 2016 Form
Interim Financial Report For the nine and three months periods ended corresponding periods: nine and three months periods ended 31 March 2016) To be read in conjunction with the 30 June 2016 Form Contents Unaudited Consolidated Statement of Comprehensive Income 2 Unaudi
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 29 June 2017 PRIMA BIOMED ANNOUNCES PRICING OF US$5.0 MILLION REGISTERED DIRECT OFFERING OF ITS AMERICAN DEPOSITARY SHARES SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR;
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES PRICING OF US$5.0 MILLION REGISTERED DIRECT OFFERING OF ITS AMERICAN DEPOSITARY SHARES SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced it has entered
Read more →IMMPPrima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares
Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 26 June 2017 Operational Update SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company s two active clinical trials in IMP321.
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company s two active clinical trials in IMP321. Prima is pleased to advise that clinical studies of IMP321 are progressing well. TACTI-me
Read more →IMMPJune 2017 ASX Market Announcements Australia Securities Exchange Expiry of Options Waiver of Listing Rule 6.24 Prima BioMed Limited (the Company ) (ASX:PRR) notifies the holders of 77,378,690 quoted options (ASX:PRRO) (
Market Announcements Australia Securities Exchange Expiry of Options Waiver of Listing Rule 6.24 Prima BioMed Limited (the Company) (ASX:PRR) notifies the holders of 77,378,690 quoted options (ASX:PRRO) (Options) that the Options will expire at 5.00pm AEST on 19 June 2017. T
Read more →IMMPASCO Poster 2017
ASCO Poster 2017
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 June 2017 LAG-3Ig (IMP321) DEMONSTRATES POSITIVE SAFETY AND EFFICACY QUALITIES IN BREAST CANCER CLINICAL TRIAL Breast cancer clinical trial demonstrates LAG-3Ig (IMP321)
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) LAG-3Ig (IMP321) DEMONSTRATES POSITIVE SAFETY AND EFFICACY QUALITIES IN BREAST CANCER CLINICAL SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) has announced positive safety and efficacy da
Read more →IMMPLAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 1 June 2017 PRIMA BIOMED ANNOUNCES FORMATION OF CLINICAL ADVISORY BOARD New Clinical Advisory Board comprises team of internationally renowned clinicians Provides strategi
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES OF CLINICAL ADVISORY BOARD SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic res
Read more →IMMPPrima BioMed Announces Formation of Clinical Advisory Board
Prima BioMed Announces Formation of Clinical Advisory Board
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 18 May 2017 DATA FROM PRIMA BIOMED AIPAC CLINICAL TRIAL TO BE PRESENTED AT 2017 ASCO CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or th
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) DATA FROM PRIMA BIOMED AIPAC TO BE PRESENTED AT 2017 ASCO CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that an abstract and poster have been accepted for pres
Read more →IMMPData from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 19 April 2017 PRIMA BIOMED RECEIVES APPROVAL FOR THIRD COHORT OF PHASE I MELANOMA TRIAL SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Compan
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES COHORT OF PHASE I MELANOMA TRIAL SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that approval has been granted for the third cohort of its Phase I cl
Read more →IMMPPrima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 April 2017 PRIMA BIOMED RECEIVES A$492,144 TAX REFUND FROM AUSTRALIAN GOVERNMENT SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), i
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES A$492,144 TAX REFUND FROM AUSTRALIAN GOVERNMENT SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), is pleased to announce that it has received a A$492,144 cash rebate fr
Read more →IMMPPrima BioMed receives A$492,144 Tax Refund from Australian Government
Prima BioMed receives A$492,144 Tax Refund from Australian Government
Read more →IMMPPrima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 15 March 2017 PRIMA BIOMED COMPLETES RECRUITMENT FOR SECOND PATIENT COHORT IN MELANOMA TRIAL AND WILL PRESENT AT ICI CONFERENCE IN BOSTON SYDNEY, AUSTRALIA Prima BioMed Lt
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED COMPLETES RECRUITMENT FOR SECOND PATIENT COHORT IN MELANOMA TRIAL AND WILL PRESENT AT ICI CONFERENCE IN BOSTON SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces that the
Read more →IMMPINVESTOR UPDATE by PRIMA BIOMED EDITION19 MARCH 2017 Marc Voigt, CEO Lucy Turnbull, AO Message from CEO & Chairman Dear Fellow Shareholders, In mid-January we were in San Francisco during the annual JP Morgan global heal
UPDATE by PRIMA BIOMED EDITION19 Marc Voigt, CEO Lucy Turnbull, AO Message from CEO & Chairman Dear Fellow Shareholders, In mid-January we were in San Francisco during the annual JP Morgan global healthcare conference, where it was very evident that the overall understanding
Read more →IMMPUSA Patent Grants for IMP321 in Cancer
USA Patent Grants for IMP321 in Cancer
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 1 March 2017 USA PATENT GRANTS FOR IMP321 IN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) USA PATENT GRANTS FOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent number 9,579,382 entitled Use of Recombinant LAG-3 or the Derivatives thereof for Elici
Read more →IMMPABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2016 (previous corresponding period: half-year ended 31 December 2015) To be read in conjunction with the 30 June 2016 Annual Re
Interim Financial Report For the Half-Year Ended (previous corresponding period: half-year ended 31 December 2015) To be read in conjunction with the 30 June 2016 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: PRR) Appendix 4D Interim Financial
Read more →IMMPFirst Half 2017 Operational Update
First Half 2017 Operational Update
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 24 February 2017 First Half 2017 Operational Update Highlights - Positive recruitment rates for TACTI-mel and AIPAC clinical trials - Operational cash reach extended to fi
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) would like to update shareholders on recent developments with the company regarding active clinical trials, current partnership developments, and cash reach in conjunc
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 13 February 2017 PRIMA BIOMED RECEIVES ~A$860,000 TAX CREDIT PAYMENT FROM FRENCH GOVERNMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Co
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES ~A$860,000 TAX CREDIT PAYMENT FROM FRENCH GOVERNMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), is pleased to announce that its French subsidiary, Immutep S.A.
Read more →IMMPPrima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 23 January 2017 PRIMA BIOMED TO PRESENT AT 2ND ANNUAL CANCER IMMUNOTHERAPY CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO PRESENT CANCER IMMUNOTHERAPY CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces that the submission titled TACTI-mel, Two ACTive Immunotherapies in Melano
Read more →IMMPPrima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
Read more →IMMPPrima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 18 January 2017 PRIMA BIOMED TO MAINTAIN NASDAQ LISTING SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the Company has received notification from the Listin
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO MAINTAIN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the Company has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company s Ame
Read more →IMMPPrima BioMed to Maintain NASDAQ Listing
Prima BioMed to Maintain NASDAQ Listing
Read more →IMMPPrima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 January 2017 PRIMA BIOMED COMMENCES RECRUITMENT FOR SECOND COHORT OF MELANOMA TRIAL SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company )
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED COMMENCES RECRUITMENT FOR SECOND COHORT OF MELANOMA TRIAL SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that the first patient has been dosed for the second co
Read more →IMMPNASDAQ: PBMD, ASX: PRR JANUARY 2017 CORPORATE PRESENTATION Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:P
NASDAQ: PBMD, ASX: PRR JANUARY 2017 CORPORATE Notice: Forward Looking Statements the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information
Read more →IMMPPrima BioMed enters new Material Transfer Agreement with Cytlimic
Prima BioMed enters new Material Transfer Agreement with Cytlimic
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 January 2017 PRIMA BIOMED ENTERS NEW MATERIAL TRANSFER AGREEMENT WITH CYTLIMIC SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology com
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ENTERS NEW MATERIAL TRANSFER AGREEMENT WITH CYTLIMIC AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, today announced that it has entered into a new collaboration agreement wit
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 3 January 2017 Prima Announces New Product Candidate IMP761 A LAG-3 Agonist Antibody SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announ
Media Release (Code: ASX: PRR; NASDAQ: PBMD) Product Candidate IMP761 A LAG-3 Agonist Antibody SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal a
Read more →IMMPPrima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody
Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 January 2017 PRIMA BIOMED COMMENCES RANDOMISED PHASE IIb CLINICAL TRIAL FOR IMP321 IN BREAST CANCER SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED COMMENCES RANDOMISED PHASE IIb CLINICAL TRIAL FOR IMP321 IN BREAST CANCER SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced the first patient has been dosed as pa
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 29 December 2016 PRIMA BIOMED ANNOUNCES FIRST CLINICAL DATA FROM COMBINATION OF IMP321 WITH ANTI-PD1 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES FROM COMBINATION OF IMP321 WITH ANTI-PD1 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 December 2016 PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES AIPAC CLINICAL TRIAL IN BREAST CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced interim data from the AIPAC Phase IIb clinical trial for IMP321
Read more →IMMPPrima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 December 2016 PRIMA BIOMED RECEIVES UK APPROVAL FOR AIPAC STUDY Competent Authority and Ethics Committee approval received in the United Kingdom for AIPAC Recruitment o
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), announces that it has received approval from the Competent Authority and Ethics Committee in the UK for its Phase IIb, AIPAC clinical trial of
Read more →IMMPPrima BioMed Receives UK Approval for AIPAC Study
Prima BioMed Receives UK Approval for AIPAC Study
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 19 December 2016 Prima BioMed Announces ADR Ratio Change SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces a ratio change for
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Prima BioMed Announces ADR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces a ratio change for the Company s American Depositary Receipt ( ADR ) program. As a result, the number of
Read more →IMMPAppendix 3B New issue announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be
New issue announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s proper
Read more →IMMPChairman s Address 2016 Annual General Meeting Lucy Turnbull, AO 25 November 2016 Dear Fellow Shareholder, On behalf of our Board, I would like to welcome you to the Prima Biomed Annual General Meeting for 2016. The past
2016 Annual General Meeting Dear Fellow Shareholder, On behalf of our Board, I would like to welcome you to the Prima Biomed Annual General Meeting for 2016. The past year has again been a highly active one for Prima BioMed. Presently, our two clinical programs for our lead pr
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 23 November 2016 WUXI BIOLOGICS AND PRIMA SIGN MOU AND ANNOUNCE STRATEGIC DEVELOPMENT AND MANUFACTURING PARTNERSHIP SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD)
Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA SIGN MOU AND ANNOUNCE STRATEGIC DEVELOPMENT AND MANUFACTURING PARTNERSHIP SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) and WuXi Biologics (WuXi), a WuXi AppTec group company, and a leading open-access
Read more →IMMPSITC 2016 NATIONAL HARBOR, MD NOVEMBER 9-13, 2016 An APC activator (IMP321 or LAG-3Ig) combined with anti-PD-1 blockade Fr d ric Triebel, M.D., PhD. , Prima Biomed Ltd sitc Society for Immunotherapy of Cancer #SITC2016 S
An APC activator (IMP321 or LAG-3Ig) combined with anti-PD-1 blockade Fr d ric Triebel, M.D., PhD. , Prima Biomed Ltd Society for Immunotherapy of Cancer Three groups of patients responding to anti-PD-1 (IFN-y signature) A- Inflamed responders respond to anti-PD-1 B- Inflam
Read more →IMMPINVESTOR UPDATE by PRIMA BIOMED EDITION 18 NOVEMBER 2016 Marc Voigt, CEO Message from the CEO Dear Fellow Shareholders, In our August operational update we outlined the trial designs and timelines for our two clinical pr
our August operational update we outlined the trial designs and timelines for our two clinical programs, AIPAC and TACTI-mel, both of which are progressing on schedule. Data read out from the open-label, safety run-in cohorts of both trials is expected by the end of the current
Read more →IMMPACN 009 237 889 N OTICE OF 2016 A NNUAL G ENERAL M EETING Including Explanatory Notes and Proxy Form To be held on: 25 November 2016 11.00 am (AEDT) (registration commencing at 10.45pm) At: K&L Gates, Level 31, 1 O Conne
ANNUAL GENERAL MEETING Including Explanatory Notes and Proxy Form 11.00 am (AEDT) (registration commencing at 10.45pm) 31, 1 O Connell Street, Sydney, NSW, 2000, Australia This is an important document. It should be read in its entirety. If you are in doubt as to the course
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 13 October 2016 PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that th
Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announces that the submission titled LAG-3Ig (IMP321) in combination with anti-PD-1 therap
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 6 October 2016 PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the
Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA ABSTRACTS ACCEPTED FOR AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that an abstract for each of its two clinical trials for IMP321 has bee
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 4 October 2016 Appendix 3B & Cleansing Notice SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) Prima advises that in relation to the
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) Prima advises that in relation to the issuance of ordinary shares as further detailed in the attached Appendix 3B, the Company gives notice un
Read more →IMMPAnnual Report 2016 Reporting period: Year ended 30 June 2016 Previous corresponding period: Year ended 30 June 2015 ABN 90 009 237 889 PRIMA BIOMED TABLE OF CONTENTS 03 Corporate Directory 04 Chairman s Letter 05 Review
Year ended 30 June 2016 Previous corresponding period: Year ended 30 June 2015 03 Corporate Directory 04 Chairman s Letter 05 Review of Operations 27 Corporate Governance Statement 28 Auditor s Independence Declaration 30 Financial Statements 31 Consolidated Statement of
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 2 September 2016 Appendix 3B & Cleansing Notice SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) Prima advises that in relation to the
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) Prima advises that in relation to the issuance of ordinary shares as further detailed in the attached Appendix 3B, the Company gives notice unde
Read more →IMMPPrima BioMed Ltd Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2016 Previous corresponding peri
Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2016 Previous corresponding period: Year ended 30 June 2015 Revenue from ordinary activities Up 100 % to $ 175,052 Other income
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 25 August 2016 EUROPEAN PATENT GRANTS FOR IMP731 ANTIBODY SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of p
(Code: ASX: PRR; NASDAQ: PBMD) EUROPEAN PATENT GRANTS FOR IMP731 ANTIBODY SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent number 2142210 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 18 August 2016 Operational Update SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company s cash position and the recruitment pr
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company s cash position and the recruitment progress in its two active clinical trials in IMP321. As a result of careful financial manage
Read more →IMMPASX/Media Release (Code: NASDAQ: PBMD; ASX: PRR) 10 August 2016 PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), has recei
(Code: NASDAQ: PBMD; ASX: PRR) PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (th
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 4 th Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of E
Appendix 4C Quarterly report for entities admitted on the basis Appendix 4C 4th Quarter For Entities Admitted on the Basis of Introduced 31/3/2000. Amended 30/9/2001 Prima BioMed Ltd (ASX:PRR) ABN: Quarter Ended ( Current Quarter ) 90 009 237 889 30 June 2016 Consoli
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 July 2016. PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBM
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today announced a new collaborative study investigating the intra-t
Read more →IMMPPrima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors
Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 June 2016 PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321 SYDNEY, AUSTRALIA - Prima BioMed Ltd
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleas
Read more →IMMPPrima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321
Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 7 June 2016 PRIMA BIOMED TO MAINTAIN NASDAQ LISTING SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the Company has received notification from the Listing Qu
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO MAINTAIN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the Company has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company s Ame
Read more →IMMPABN 90 009 237 889 Interim Financial Report For the Half-Year Ended 31 December 2015 (previous corresponding period: half-year ended 31 December 2014) Index to Financial Statements ABN 90 009 237 889 Consolidated Stateme
Index to Financial Statements Interim Financial Report For the Half-Year Ended corresponding period: half-year ended 31 December 2014) Index to Financial Statements Consolidated Statement of Comprehensive Income (Unaudited) 1 Consolidated Balance Sheet (Unaudited) 2 Co
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 May 2016 PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC PROGRAM Sydys Licenses Clinical-Stage Immuno-oncology Assets in spin out trans
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC PROGRAM SYDNEY, AUSTRALIA and SEATTLE, WASHINGTON - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) and U.S.-based Sydys Corporation, Inc. (O
Read more →IMMPMessage from the Chair Dear Fellow Shareholders, The Prima board and management recently announced to you the successful partnering of CVac with US based Sydys Corporation (SYYC) that will see the continued Lucy Turnbull
Message from the Chair Dear Fellow Shareholders, The Prima board and management recently announced to you the successful partnering of CVac with US based Sydys Corporation (SYYC) that will see the continued Lucy Turnbull, AO clinical development of the CVac program in ovar
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 2 May 2016 JAPANESE PATENT GRANTS FOR IMP321 IN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of pate
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) JAPANESE PATENT GRANTS FOR IMP321 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent number 5908210 entitled Use of Recombinant LAG-3 or the Derivatives thereof
Read more →IMMPApril 2016 ASX Compliance Pty Ltd 20 Bridge Street Sydney NSW 2000 Prima BioMed Ltd ASX Price Query Response I refer to your letter dated 21 April 2016 in relation to the ASX price query. Prima BioMed Limited ( Prima Bio
Prima BioMed Ltd ASX Price Query Response refer to your letter dated 21 April 2016 in relation to the ASX price query. Prima BioMed Limited (Prima BioMed) provides the following responses to the questions in your letter. Response. No, Prima BioMed is not aware of any such infor
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 3 rd Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of E
Appendix 4C Quarterly report for entities admitted on the basis Appendix 4C 3rd Quarter For Entities Admitted on the Basis of Introduced 31/3/2000. Amended 30/9/2001 BioMed Ltd (ASX:PRR) ABN: Quarter Ended ( Current Quarter ) 90 009 237 889 31 March 2016 Consolidated
Read more →IMMPMarch 2016 IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) advises that safety and immune monitoring data from an investi
IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therape
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 8 March 2016 APPOINTMENT OF JOINT COMPANY SECRETARY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today announces that General Counsel and Company Secretary,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) APPOINTMENT OF JOINT SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today announces that General Counsel and Company Secretary, Deanne Miller, will be on maternity leave with effect from 16 March 2016. Mr Tom Bloom
Read more →IMMPASX / Med ia Relea s e (Code: NASDAQ: PBMD; ASX: PRR) 4 March 2016 PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), has re
(Code: NASDAQ: PBMD; ASX: PRR) PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (th
Read more →IMMPPrima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial Highlights First-Ever Chinese-Manufactured Biologic Dosed in a European Clinical Trial Prima BioMed Dosed First Pa
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial SYDNEY, March 2, 2016 /PRNewswire/ WuXi Biologics Co. Ltd., a wholly owned subsidiary of WuXi AppTec Co. Ltd. (WuXi), and Prima BioMed Ltd. (Prima) (ASX: PRR; NASDAQ: PBMD)
Read more →IMMPABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2015 (previous corresponding period: half-year ended 31 December 2014) To be read in conjunction with the 30 June 2015 Annual Re
For the Half-Year Ended corresponding period: half-year ended 31 December 2014) To be read in conjunction with the 30 June 2015 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: PRR) Interim Financial Report Results for Announcement to the Market
Read more →IMMPLucy Turnbull, AO Message from the Chair Dear Shareholders, Welcome to our first newsletter for 2016 in what I envisage will be a year of continued success for our Company. Over the past 12 months we and our partners hav
LAG-3 product in clinical to three products in four clinical trials: quite a remarkable achievement for a small biotech company. We have also received milestone payments from our partners GSK and Novartis as their products have entered Phase I trials. newsletter we profiled our
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 28 January 2016 US PATENT GRANTS FOR IMP731 ANTIBODY SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent n
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) US PATENT GRANTS FOR SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent number US 9,244,059 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the t
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 27 January 2016 PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site f
Read more →IMMPJanuary 2016 ASX Compliance Pty Ltd 20 Bridge Street SYDNEY NSW 2000 Dear Stephanie, Prima BioMed Limited ASX Price Query Response I refer to your letter dated 7 January 2016 in relation to the ASX Price Query. Prima Bio
Prima BioMed Limited ASX Price Query I refer to your letter dated 7 January 2016 in relation to the ASX Price Query. Prima BioMed Limited (Prima BioMed) provides the following responses to the questions in your letter. 1. Question: Is the Entity aware of any information concer
Read more →IMMPAppendix 4C Quarterly reports for entities admitted on the basis of commitments Appendix 4C 2 nd Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of
Appendix 4C Quarterly reports for entities admitted on the basis Appendix 4C 2nd Quarter For Entities Admitted on the Basis of Introduced 31/3/2000. Amended 30/9/2001 BioMed Ltd (ASX:PRR) ABN: Quarter Ended ( Current Quarter ) 90 009 237 889 31 December 2015 Consolid
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 December 2015 PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER Institutional Review Board approval now obtained at four clinical sites in Belgium and
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first trial site
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 11 December 2015 PRIMA BIOMED PROGRESSES JAPANESE COLLABORATION New Material Transfer Agreement (MTA) concluded with Yamaguchi University and NEC Corporation Parties have
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PROGRESSES JAPANESE COLLABORATION AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first an
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 26 November 2015 PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to advise that it
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to advise that it has received approximately $420k in cash rebate from the Australian feder
Read more →IMMPPrima BioMed Ltd 2015 Annual General Meeting Address by Russell Howard, Non-Executive Director Dear Fellow Shareholder, On behalf of our Board, I would like to welcome you to the Prima BioMed Annual General Meeting for 2
2015 Annual General Meeting Address by Russell Howard, Non-Executive Director Dear Fellow Shareholder, behalf of our Board, I would like to welcome you to the Prima BioMed Annual General Meeting for 2015. Prima s Chair, Lucy Turnbull and Deputy Chair, Albert Wong both send th
Read more →IMMPLucy Turnbull, AO Message from the Chair Dear Fellow Shareholders, As this constitutes the first newsletter since shareholders approved the A$15m investment in our Company by US-based Ridgeback Capital Investments, I wou
The Ridgeback investment provided significant funding for the exciting immuno-oncology programs we acquired late last year with the Immutep SA transaction. In addition, as stated at the EGM, I believe that having Ridgeback as a shareholder elevates the reputation of our Company
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 18 November 2015 PRIMA BIOMED UNVEILS PHASE I COMBINATION STUDY OF IMP321 + CHECKPOINT INHIBITOR Highlights - Prima to run a Phase I safety and dose finding study of IMP32
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED UNVEILS PHASE I COMBINATION STUDY OF IMP321 + CHECKPOINT INHIBITOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) today unveiled a new clinical trial of IMP321, to be called TACTI-mel , short for Two
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 November 2015 PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015 SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced that Dr. Fr d ric Triebel, Chief Scienti
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 30 October 2015 PRIMA BIOMED RAISES A$2.0 MILLION THROUGH PLACEMENT TO A LEADING AUSTRALIAN INSTITUTIONAL INVESTOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX:PRR; NASDAQ:PB
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RAISES A$2.0 MILLION THROUGH PLACEMENT TO A LEADING AUSTRALIAN INSTITUTIONAL INVESTOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD), a leading immuno-oncology company, announces that it has raised A$2
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 27 October 2015 PRIMA BIOMED GAINS BELGIAN REGULATORY APPROVAL TO COMMENCE A REGISTRATION PHASE IIB STUDY OF IMP321 Belgium s Federal Agency for Medicines and Health Produ
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) BELGIAN REGULATORY APPROVAL TO COMMENCE A REGISTRATION PHASE IIB STUDY OF IMP321 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce its first regulatory appro
Read more →IMMPACN 009 237 889 N OTICE OF 2015 A NNUAL G ENERAL M EETING Including Explanatory Notes and Proxy Form To be held on: 25 November 2015 1pm (AEDT) (registration commencing at 12.30pm) At: Minter Ellison, Level 40, Governor
ANNUAL GENERAL MEETING Including Explanatory Notes and Proxy Form (registration commencing at 12.30pm) Minter Ellison, Level 40, Governor Macquarie Tower 1 Farrer Place, Sydney, NSW, 2000, Australia This is an important document. It should be read in its entirety. If you are
Read more →IMMPOctober 2015 CHANGE OF ADDRESS In accordance with Listing Rule 3.14, Prima BioMed Limited (ASX: PRR; NASDAQ: PBMD) advises that effective today, our registered office and principal administrative office is now Level 12,
Listing Rule 3.14, Prima BioMed Limited (ASX: PRR; NASDAQ: PBMD) advises that effective today, our registered office and principal administrative office is now Level 12, 95 Pitt Street, Sydney, NSW, Australia 2000. Our new general telephone number and facsimile number are as set
Read more →IMMPOctober 2015 INFORMATION REQUIRED UNDER LISTING RULE 3.10.5A Further to the Appendix 3B lodged 13 October 2015 for the issue of 31,022,181 fully paid ordinary shares, the Company provides the following information requir
INFORMATION REQUIRED UNDER LISTING RULE 3.10.5A Further to the Appendix 3B lodged 13 October 2015 for the issue of 31,022,181 fully paid ordinary shares, the Company provides the following information required under ASX Listing Rule 3.10.5A The dilutive effective of the Placem
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 13 October 2015 PRIMA BIOMED RAISES A$1.55M THROUGH PLACEMENT TO SOPHISTICATED EUROPEAN HEALTHCARE INVESTOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) A$1.55M THROUGH PLACEMENT TO SOPHISTICATED EUROPEAN HEALTHCARE INVESTOR SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading immuno-oncology company, announces that it has raised 1M
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 9 October 2015 PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), is plea
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), is pleased to announce that it has received approximately 306,000 (A$475,000)
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 1st Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of En
Appendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 1st Quarter For Entities Admitted on the Basis of Introduced 31/3/2000. Amended 30/9/2001 Prima BioMed Ltd (ASX:PRR) Ended ( Current Quarter ) 90 009 237 889 30 September 2015 Consol
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 25 September 2015 PRIMA BIOMED TO PRESENT AT LEERINK PARTNERS RARE DISEASE ROUNDTABLE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company )
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRESENT AT LEERINK PARTNERS RARE DISEASE ROUNDTABLE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ), a leading immuno-oncology company, announces that Marc Voigt, CEO, will present an overvi
Read more →IMMPPrima BioMed Ltd Preliminary final report APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2015 Previous corresponding peri
Preliminary final report PRELIMINARY FINAL REPORT Name of entity: Prima BioMed Ltd ABN: 90 009 237 889 Reporting period: Year ended 30 June 2015 Previous corresponding period: Year ended 30 June 2014 Revenue from ordinary activities Down 33.3% to $2,092,867 Loss from o
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 14 August 2015 PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) to
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) today announced it will receive an undisclosed clinical milestone payment
Read more →IMMPPrima Biomed Announces Commencement of Milestones for IMP701 Program
Prima Biomed Announces Commencement of Milestones for IMP701 Program
Read more →IMMPJuly 2015 The Manager Australian Stock Exchange Company Announcements Office Level 4, Exchange Centre 20 Bridge Street Sydney NSW 2000 Dear Sir/Madam, Re: Results of 2015 Extraordinary General Meeting Resolution 1: That,
Australian Stock Exchange Company Announcements Level 4, Exchange Centre Re: Results of 2015 Extraordinary General Meeting pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, the Company ratifies the previous issue of 200,000,000 Warrants to the ve
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 4 August 2015 PRIMA BIOMED TERMINATES INVESTMENT FACILITY WITH BERGEN GLOBAL OPPORTUNITY FUND, LP SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TERMINATES INVESTMENT FACILITY WITH BERGEN GLOBAL OPPORTUNITY FUND, LP SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading immuno-oncology company, advised that its in
Read more →IMMPNotice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche B rse:YP1B.DE). These slides have been prepar
GlaxoSmithKline licensed from Immutep, rights to develop LAG 3 depleting antibodies for autoimmune disease 64m total deal package (~A$118m) + royalties GSK2831781 is currently in first time in human clinical trials (see NCT02195349 at clinicaltrials.gov) In January 2015, Prima an
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 31 July 2015 Chairman s address Prima Biomed Ltd 2015 Extraordinary General Meeting Lucy Turnbull AO Welcome to Prima Biomed Ltd s Extraordinary General Meeting of 2015. I
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Prima Biomed Ltd 2015 Extraordinary General Meeting Welcome to Prima Biomed Ltd s Extraordinary General Meeting of 2015. It is a great pleasure to see our shareholders here in attendance. We appreciate the support we have receiv
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 4th Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of En
Appendix 4C Quarterly report for entities admitted on the basis Appendix 4C 4th Quarter For Entities Admitted on the Basis Introduced 31/3/2000. Amended 30/9/2001 ABN: Quarter Ended ( Current Quarter ) 90 009 237 889 30 June 2015 Consolidated Statement of Cash Flows
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 24 July 2015 PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), announces that i
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), announces that it has successfully raised A$10M via a Share Purchase Plan (SPP). The
Read more →IMMPJuly 2015 Ms Stephanie So Senior Adviser, Listings Compliance (Sydney) ASX Compliance Pty Ltd 20 Bridge Street SYDNEY NSW 2000 Dear Ms So, Prima BioMed Limited ASX aware query I refer to your letter dated 8 July 2015 in
Senior Adviser, Listings Compliance (Sydney) ASX Compliance Pty Ltd Prima BioMed Limited ASX aware query refer to your letter dated 8 July 2015 in relation to the ASX aware query. Prima BioMed Limited ( Prima ) provides the following responses to the questions in your letter
Read more →IMMP(Code: ASX: PRR; NASDAQ: PBMD) 10 July 2015 SHARE PURCHASE PLAN OFFER DOCUMENTS Prima BioMed Ltd ( Prima or the Company ) is pleased to provide the attached offer documentation relating to its recently anno
Media Release (Code: ASX: PRR; NASDAQ: PBMD) SHARE PURCHASE PLAN OFFER DOCUMENTS Prima BioMed Ltd ( Prima or the Company ) is pleased to provide the attached offer documentation relating to its recently announced Share Purchase Plan ( SPP ), including a booklet which sets out
Read more →IMMPMessage from the Chair INVESTOR UPDATE Dear Fellow Shareholders, A lot has happened for Prima BioMed in the six months since our last newsletter. In December 2014 we completed the acquisition of Immutep, and since then o
from the Chair INVESTOR UPDATE Dear Fellow Shareholders, A lot has happened for Prima BioMed in the six months since our last newsletter. In December 2014 we completed the acquisition of Immutep, and since then our team has been hard at work getting ready Lucy Turnbull, AO for c
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 7 July 2015 PRIMA BIOMED ANNOUNCES SHARE PURCHASE PLAN Highlights: Share Purchase Plan ( SPP ) to allow eligible shareholders to subscribe for up to A$15,000 worth of new
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES SHARE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading immuno-oncology company, announces that it is offering existing eligible shareholders the opportunity to top up their exis
Read more →IMMPA MESSAGE FROM THE CHAIRMAN Dear Fellow Shareholders of Prima BioMed, It is with great pleasure that we invite you to attend an Extraordinary General Meeting of shareholders of our company, to be held in Sydney on 31 Jul
A MESSAGE FROM THE CHAIRMAN Dear Fellow Shareholders of Prima BioMed, pleasure that we invite you to attend an Extraordinary General Meeting of shareholders of our company, to be held in Sydney on 31 July 2015. meeting will be one of the more important to be held in Prima s 14
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 June 2015 PRIMA BIOMED TO PRESENT AT THE 2015 BIOSHARES BIOTECH SUMMIT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO PRESENT AT 2015 BIOSHARES BIOTECH SUMMIT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading immuno-oncology company, is pleased to announce that that Stuart Roberts
Read more →IMMPJune 2015 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act In relation to the ordinary share issuances detailed in the Appendix 3Bs released on 4 th , 5 th , 10
Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act In relation to the ordinary share issuances detailed in the Appendix 3Bs released on 4th, 5th, 10th and 11th June 2015, Prima BioMed Ltd ( the Company ) gives notice under sec
Read more →IMMPPrima BioMed Receives a Research Tax Credit Cash Rebate in France
Prima BioMed Receives a Research Tax Credit Cash Rebate in France
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 11 June 2015 PRIMA BIOMED RECEIVES A RESEARCH TAX CREDIT CASH REBATE IN FRANCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a le
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED RECEIVES A RESEARCH TAX CREDIT CASH REBATE IN FRANCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ), a leading immuno-oncology company, is pleased to announce that it has rec
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 4 June 2015 PRIMA BIOMED TO MAINTAIN NASDAQ LISTING SYDNEY, AUSTRALIA Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), announces that, further to the ann
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO MAINTAIN SYDNEY, AUSTRALIA Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), announces that, further to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from
Read more →IMMPForm 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme Prima Biomed Ltd ACN/ARSN 009 237 889 1. Details of substantial holder (1) Name Ridgeback Capital Investments L.P. &
Corporations Act 2001 Notice of initial substantial holder To Company Name/Scheme Prima Biomed Ltd ACN/ARSN 009 237 889 1. Details of substantial holder (1) Name Ridgeback Capital Investments L.P. & Ridgeback Capital Management L.P. & Wayne Holman ( Ridgeback Parties ) ACN
Read more →IMMPth May 2015 Company Announcements Office Australian Securities Exchange N o t i c e und e r S ec t io n 7 0 8 A ( 5 )( e ) C o r p o ra t i o n s Ac t On 27 th May 2015, Prima BioMed Ltd ( the Company ) issued 28,000,000
Company Announcements Office 27th May 2015, Prima BioMed Ltd ( the Company ) issued 28,000,000 fully paid ordinary shares to Ridgeback Capital Investments. These shares were issued due to the conversion of the convertible note held by Bergen Global Opportunity Fund, LP, under t
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 25 May 2015 PRIMA BIOMED TO PRESENT AT PROACTIVE S LUNCHEON BRIEFINGS IN SYDNEY AND MELBOURNE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a biotech comp
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO PRESENT AT LUNCHEON BRIEFINGS IN SYDNEY AND MELBOURNE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a biotech company working in the emerging field of immuno-oncology, announces that Stuart Robe
Read more →IMMPMay 2015 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 15 th May 2015, Prima BioMed Ltd ( the Company ) issued 22,936,950 fully paid ordinary shares in ac
Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 15th May 2015, Prima BioMed Ltd ( the Company ) issued 22,936,950 fully paid ordinary shares in accordance with the terms of its Share Purchase and Convertible Security Agr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 11 May 2015 PRIMA BIOMED ANNOUNCES JAPANESE COLLABORATION SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces a collaboration
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES JAPANESE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces a collaboration with NEC Corporation and Yamaguchi University for Immutep s IMP321 in combination w
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 29 April 2015 PRIMA BIOMED TO PRESENT AT CANARY NETWORKS BIOTECH AND HEALTHCARE INVESTOR ROADSHOW SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) announces t
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO PRESENT AT BIOTECH AND HEALTHCARE INVESTOR ROADSHOW SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) announces that Stuart Roberts, Head of Investor Relations for Prima, will provide an overview of
Read more →IMMPPrima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3
Prima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3
Read more →IMMPABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2014 (previous corresponding period: half-year ended 31 December 2013) To be read in conjunction with the 30 June 2014 Annual Re
Table of Contents For the Half-Year Ended corresponding period: half-year ended 31 December 2013) To be read in conjunction with the 30 June 2014 Annual Report. In compliance with Listing Rule 4.2A Table of Contents ASX/Media Release (ASX: PRR) Interim Financial Report Re
Read more →IMMPPRIMA BIOMED Nasdaq: PBMD, ASX:PRR Introductory Corporate Presentation 27 February 2015 Marc Voigt (CEO) and Stuart Roberts (Global Head of IR) www.primabiomed.com.au PRIMA BIOMED Nasdaq: PBMD, ASX:PRR Immuno-Oncology: A
Introductory Corporate Presentation Marc Voigt (CEO) and Stuart Roberts (Global Head of IR) www.primabiomed.com.au Immuno-Oncology: A cancer treatment Revolution programs: An important part of the Revolution Beneficiaries: Patients...and our shareholders 27 February 2015 Int
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 2nd Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of En
4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 2nd Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of Entity: Prima BioMed Ltd (ASX:PRR) ABN: Quarter Ended ( Current Quarte
Read more →IMMPJanuary 2015 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 23 rd January 2015, Prima BioMed Ltd ( the Company ) issued 15,323,414 fully paid ordinary shar
Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 23rd January 2015, Prima BioMed Ltd ( the Company ) issued 15,323,414 fully paid ordinary shares in accordance with the terms of its share purchase and convertible security
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 January 2015 $777K R&D TAX INCENTIVE REFUND RECEIVED SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to advise that it has received a
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) INCENTIVE REFUND RECEIVED SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to advise that it has received approximately $777k in cash rebate from the Australian Federal Government s R&D tax ince
Read more →IMMPASX / Med ia Relea s e (Code: NASDAQ: PBMD; ASX: PRR) 29 December 2014 PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), an
(Code: NASDAQ: PBMD; ASX: PRR) PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) ( Prima , the Company ), announces that it received a notice, dated December 23, 2014 (the Notice ), from the Listing Qualif
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 December 2014 PRIMA BIOMED ANNOUNCES IMMUTEP S IMP321 PATENT APPLICATION RECEIVES CANADIAN PATENT OFFICE NOTICE OF GRANT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR;
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES IMMUTEP S IMP321 PATENT APPLICATION RECEIVES CANADIAN PATENT OFFICE NOTICE OF GRANT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to announce that it has
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 17 December 2014 PRIMA BIOMED COMPLETES IMMUTEP ACQUISITION SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces that the acqui
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED COMPLETES SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) announces that the acquisition of Immutep SA ( Immutep ), the French privately owned biopharmaceutical company in the
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 15 December 2014 PRIMA INITIATES PANCREATIC CLINICAL TRIAL with CVAC SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that i
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA INITIATES PANCREATIC CLINICAL TRIAL with CVAC SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that it has received the necessary regulatory approvals for the commencement of
Read more →IMMPDecember 2014 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act Prima BioMed Ltd ( the Company ) has today issued 15,214,606 fully paid ordinary shares in accord
Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act Prima BioMed Ltd ( the Company ) has today issued 15,214,606 fully paid ordinary shares in accordance with the terms of its share purchase and convertible security agr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 December 2014 PRIMA ENHANCES CVAC MANUFACTURING AND LOGISTICS CAPABILITY SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) MANUFACTURING AND LOGISTICS CAPABILITY SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces several enhancements to its CVac manufacturing and logistics infrastructure. Prima will be a
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 14 November 2014 Chairman s address Prima BioMed Ltd 2014 Annual General Meeting Lucy Turnbull AO Welcome to the Prima BioMed Ltd Annual General Meeting for 2014. It is wo
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Prima BioMed Ltd 2014 Annual General Meeting Welcome to the Prima BioMed Ltd Annual General Meeting for 2014. It is wonderful to see you here today and thank you for your attendance. The past year has been extremely busy for Pri
Read more →IMMPCEO Presentation Annual General Meeting Marc Voigt, CEO 14 November 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 1 Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the busines
Annual General Meeting ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 Notice: Forward Looking Statements the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche B rse:YP1B.DE). These slides have been prepared as a p
Read more →IMMPP85 Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1 S.E. Gargosky and the CAN-004 Study Team Prima BioMed USA
Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1 S.E. Gargosky and the CAN-004 Study Team Prima BioMed USA and CAN-004 study team of Belgium, Belarus, Bulgaria, Germany
Read more →IMMPNovember 2014 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 6 th November 2014, Prima BioMed Ltd ( the Company ) issued 13,163,514 fully paid ordinary sha
Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 6th November 2014, Prima BioMed Ltd ( the Company ) issued 13,163,514 fully paid ordinary shares in accordance with the terms of its share purchase and convertible
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 6 November 2014 CVAC DEMONSTRATES OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER Overall Survival data from the CAN-003 trial continues to show benefit for se
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) is pleased to announce that CVac has demonstrated a clinically meaningful improv
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 21 October 2014 PRIMA BIOMED CONFERENCE CALL & WEBCAST TO DISCUSS ACQUISITION OF IMMUTEP SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Compa
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) CONFERENCE CALL & WEBCAST TO DISCUSS ACQUISITION OF IMMUTEP SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) advises that the Company will host a shareholder conference call and webcast to d
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C 1 st Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of E
Appendix 4C Quarterly report for entities admitted on the basis Appendix 4C 1st Quarter For Entities Admitted on the Basis Introduced 31/3/2000. Amended 30/9/2001 Name of Entity: Prima BioMed Ltd (ASX:PRR) ABN: Quarter Ended ( Current Quarter ) 90 009 237 889 3
Read more →IMMPPRIMA BIOMED LTD Australian Cancer Treatment Company ACN 009 237 889 NOTICE OF 2014 ANNUAL GENERAL MEETING Including Explanatory Notes and Proxy Form To be held on: Friday, 14 November 2014 11.00 am (AEDT) (registration
Explanatory Notes and Proxy Form To be held on: Friday, 14 November 2014 11.00 am (AEDT) (registration commencing at 10.30 am) At: K&L Gates, Level 31, 1 O Connell Street, Sydney, NSW, 2000, Australia This is an important document. It should be read in its entirety. If you are i
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 14 October 2014 PRIMA ANNOUNCES IMMUTEP S IMP321 PATENT APPLICATION RECEIVES AUSTRALIAN NOTICE OF ALLOWANCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) IMMUTEP S IMP321 PATENT APPLICATION RECEIVES AUSTRALIAN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to announce that Immutep S.A. ( Immutep ) has received a Notice of Allowanc
Read more →IMMPAnnual Report 2014 ABN 90 009 237 889 PRIMA BIOMED CONTENTS 03 Corporate Directory 04 Chairman s Letter 06 Review of Operations 11 Directors Report 21 Management Directory 40 Corporate Governance Report 49 Auditor s Inde
03 Corporate Directory 04 Chairman s Letter 06 Review of Operations 21 Management Directory 40 Corporate Governance 49 Auditor s Independence Declaration 52 Consolidated Statement of Comprehensive Income 53 Consolidated Balance Sheet Statement of Changes in Equity 55 Con
Read more →IMMPOctober 2014 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act On 2 nd October 2014, Prima BioMed Ltd ( the Company ) issued 29,592,588 fully paid ordinary share
Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act 2nd October 2014, Prima BioMed Ltd ( the Company ) issued 29,592,588 fully paid ordinary shares in accordance with the terms of its share purchase and convertible secu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 2 October 2014 PRIMA SECURES US$37.4M INVESTMENT AGREEMENT WITH US INSTITUTIONAL INVESTOR BERGEN Highlights Investment agreement for up to US$37.4 million to fund acquisit
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA SECURES US$37.4M INVESTMENT AGREEMENT WITH US INSTITUTIONAL INVESTOR BERGEN Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) is pleased to announce the execution of an investment agreement (the Agreement
Read more →IMMPPrima BioMed Announces Strategic Acquisition of Immutep SA
Prima BioMed Announces Strategic Acquisition of Immutep SA
Read more →IMMPCompany Announcements Australian Stock Exchange, Sydney 27 August 2014 Announcement of Results Year ended 30 June 2014 Please find attached the Appendix 4E and annual financial report for the year ended 30 June 2014. You
Company Announcements Australian Stock Exchange, Sydney Announcement of Results Year ended 30 June 2014 Please find attached the Appendix 4E and annual financial report for the year General Counsel & Company Secretary Preliminary final report PRELIMINARY FINAL REPORT Name
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 19 August 2014 CVAC CAN-003 ABSTRACT ACCEPTED FOR POSTER PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING SYDNEY, AUSTRALIA - Pri
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ABSTRACT ACCEPTED FOR POSTER PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) to
Read more →IMMPINVESTOR UPDATE by PRIMA BIOMED EDITION 12 JULY 2014 Message from the CEO CEO Marc Voigt Welcome to the second issue of the Prima BioMed Investor update for 2014. It gives me great pleasure to be addressing Prima BioMed
INVESTOR UPDATE by PRIMA BIOMED EDITION 12 JULY 2014 Message from the CEO Welcome to the second issue of the Prima BioMed Investor update for 2014. It gives me great pleasure to be addressing Prima BioMed shareholders for the first time as Chief First of all and before going i
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 22 July 2014 SUMMARY OF KEY EMPLOYMENT TERMS FOR PRIMA BIOMED S NEW CHIEF EXECUTIVE OFFICER SYDNEY, AUSTRALIA - As previously announced, the Board of Prima BioMed Ltd (ASX
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) SUMMARY OF KEY EMPLOYMENT BIOMED S NEW CHIEF EXECUTIVE OFFICER SYDNEY, AUSTRALIA - As previously announced, the Board of Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) appointed Mr Marc Voigt as CEO and Execu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 16 July 2014 PRIMA RECEIVES US PATENT GRANT FOR CVAC SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that the US patent num
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA RECEIVES US PATENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that the US patent number 8,771,701 titled Compositions for immunotherapy and uses thereof , which protects
Read more →IMMPAppendix 3X Initial Director s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents g
Initial Director s Interest Initial Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public. Introduced 30/9/2001. PRIMA BIOMED LTD (A
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 9 July 2014 PRIMA BIOMED APPOINTS NEW CHIEF EXECUTIVE OFFICER SYDNEY, AUSTRALIA - The Board of Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED APPOINTS NEW CHIEF EXECUTIVE OFFICER SYDNEY, AUSTRALIA - The Board of Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces that Marc Voigt has today been appointed as Chief Executive Officer
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 23 June 2014 PRIMA BIOMED S CAN-002 CVAC TRIAL PUBLISHED IN JOURNAL FOR IMMUNOTHERAPY OF CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED S CAN-002 CVAC TRIAL PUBLISHED IN JOURNAL FOR IMMUNOTHERAPY OF CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today announced that a research article titled A phase 2,
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 19 June 2014 PRIMA BIOMED TO PRESENT AT 2014 WAGO ANNUAL MEETING SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today advised that t
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO PRESENT AT 2014 SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today advised that the Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted th
Read more →IMMPPRIMA BIOMED DISCUSSES CAN-003 ABSTRACT PRESENTED AT ASCO TRANSCRIPT Speakers Dr. Heidi Gray Dr. Brad Monk Adam Holdsworth, ProActive Group Analysts Scott Hazelwood, Continual Capital Group Michael Rosenberg, Hudson Capi
PRIMA BIOMED DISCUSSES CAN-003 ABSTRACT PRESENTED AT ASCO TRANSCRIPT Adam Holdsworth, ProActive Group Scott Hazelwood, Continual Capital Group Michael Rosenberg, Hudson Capital Prima BioMed (ASX:PRR, 3rd June 11:00am AEST Good day ladies and gentlemen and welcome to the Pr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 2 June 2014 CVAC DEMONSTRATES POSITIVE TREND IN OVERALL SURVIVAL IN SECOND REMISSION OVARIAN CANCER Interim overall survival data from CAN-003 clinical trial demonstrates
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) CVAC DEMONSTRATES POSITIVE TREND IN SECOND REMISSION OVARIAN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce that CVac has demonstrated a positive trend in overall survival
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 30 May 2014 PRIMA BIOMED TO HOST CONFERENCE CALL TO DISCUSS ABSTRACT PRESENTED AT ASCO ON NEW INTERIM OVERALL SURVIVAL AND FINAL PROGRESSION FREE SURVIVAL DATA FOR THE COM
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO HOST CONFERENCE CALL TO DISCUSS ABSTRACT PRESENTED AT ASCO ON NEW INTERIM OVERALL SURVIVAL AND FINAL PROGRESSION FREE SURVIVAL DATA FOR THE COMPANY S CAN-003 TRIAL Webcast to Include Dr. Heidi Gray, Lead Invest
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 26 May 2014 PRIMA S CVAC PATENT APPLICATION RECEIVES U.S. NOTICE OF ALLOWANCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is plea
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) APPLICATION RECEIVES U.S. NOTICE OF ALLOWANCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to announce that the Company has received a Notice of Allowance from the United State
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 15 May 2014 CVAC DEMONSTRATES IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN SECOND REMISSION OVARIAN CANCER Final PFS data from CAN-003 trial of CVac indicate stronger trend
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) IMPROVEMENT IN PROGRESSION FREE SURVIVAL IN SECOND REMISSION OVARIAN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce that CVac demonstrated a clinically meaningful improvemen
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 09 May 2014 PRIMA BIOMED S CVAC GRANTED FAST TRACK DESIGNATION BY FDA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce today
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED S CVAC GRANTED FAST TRACK DESIGNATION BY FDA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) is pleased to announce today that the United States Food and Drug Administration ( FDA ) granted F
Read more →IMMPMessage from the CEO Welcome to the first issue of the Prima BioMed Investor Update for 2014. We have had a great start to 2014 here at Prima BioMed and are excited to share some news with you. CEO Matthew Lehman Clinica
Message from the CEO Welcome to the first issue of the Prima BioMed Investor Update for 2014. We have had a great start to 2014 here at Prima BioMed and are excited to share some news with you. CEO Matthew Lehman Clinical Trial Update As recently announced, we reached an imp
Read more →IMMPrd quarter results for FY 2014 (period ended 31 March 2014) Supplemental information to management discussion
3rd quarter results for FY 2014 (period ended 31 March 2014) Supplemental information to management discussion May 6, 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 29 April 2014 PRIMA BIOMED THIRD QUARTER CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today re
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) QUARTER CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today released its Appendix 4C Quarterly Report for the three month period ending 31 March 2014. T
Read more →IMMPDraft ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 28 April 2014 PRIMA BIOMED S CAN-004 PHASE 2 TRIAL FOR CVAC COMMENCES RECRUITMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) today annou
Draft ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) CAN-004 PHASE 2 TRIAL FOR CVAC COMMENCES RECRUITMENT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) today announced that enrolment has commenced for its amended phase 2 CAN-004 clinical trial in Eu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 7 April 2014 PRIMA BIOMED TO PRESENT AT 13 TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) to
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRESENT AT 13TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13t
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 28 March 2014 PRIMA BIOMED S CVAC DATA DEMONSTRATING IMPROVEMENT IN PFS IN SECOND REMISSION OVARIAN CANCER ACCEPTED FOR ORAL PRESENTATION AT ASCO SYDNEY, AUSTRALIA - Prima
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) CVAC DATA DEMONSTRATING IMPROVEMENT IN PFS IN SECOND REMISSION OVARIAN CANCER ACCEPTED FOR ORAL PRESENTATION AT ASCO SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ) announced today that the American Socie
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 25 March 2014 PRIMA BIOMED ANNOUNCES SIGNIFICANT UPDATES TO ITS CLINICAL ADVISORY BOARD: ERIC PUJADE-LAURAINE, CHRISTIAN MARTH, AND IGNACE VERGOTE JOIN ESTEEMED GROUP OF G
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED ANNOUNCES SIGNIFICANT UPDATES TO ITS CLINICAL ADVISORY BOARD: ERIC PUJADE-LAURAINE, CHRISTIAN MARTH, AND IGNACE VERGOTE JOIN ESTEEMED GROUP OF GYNECOLOGY ONCOLOGY ADVISORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 5 March 2014 $1.6 million R&D Tax Incentive Refund Received Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to advise that
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) $1.6 million R&D Tax Incentive Refund Received Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to advise that it has received approximately $1.6 million in cash rebate from the A
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 27 February 2014 PRIMA BIOMED TO PRESENT AT 24 TH ANNUAL WALL STREET ANALYST FORUM INSTITUTIONAL INVESTOR CONFERENCE SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ:
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRESENT AT 24TH ANNUAL WALL STREET ANALYST FORUM INSTITUTIONAL INVESTOR SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) will present a corporate overview and provide an update of its CVac dev
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 21 February 2014 PRIMA BIOMED AND NEOPHARM GROUP EXECUTE FINAL AGREEMENT FOR CVAC LICENSE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to a
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) NEOPHARM GROUP EXECUTE FINAL AGREEMENT FOR CVAC LICENSE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to announce that it has finalized an agreement with Neopharm Group ( Neopharm ) for an exclusiv
Read more →IMMPABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2013 (previous corresponding period: half-year ended 31 December 2012) To be read in conjunction with the 30 June 2013 Annual Re
For the Half-Year Ended corresponding period: half-year ended 31 December 2012) To be read in conjunction with the 30 June 2013 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: PRR) Appendix 4D Interim Financial Report Results for Announcement to
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 12 February 2014 PETE A. MEYERS TO JOIN PRIMA BIOMED S BOARD OF DIRECTORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PETE A. MEYERS TO JOIN PRIMA BIOMED S BOARD OF DIRECTORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) is pleased to announce that Pete A. Meyers will join Prima s Board as a Non-Executiv
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 6 February 2014 PRIMA BIOMED S CAN-004 CLINICAL TRIAL AMENDMENT APPROVED IN MULTIPLE JURISDICTIONS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima ,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) CAN-004 CLINICAL TRIAL AMENDMENT APPROVED IN MULTIPLE JURISDICTIONS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announced that multiple jurisdictions have approved its amended CAN-004 pr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 31 January 2014 PRIMA BIOMED TO PRESENT AT THE 16 TH ANNUAL BIO CEO & INVESTOR CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD;
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO PRESENT AT THE 16TH ANNUAL BIO CEO & INVESTOR CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced today that Matt
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 29 January 2014 PRIMA BIOMED SECOND QUARTER HIGHLIGHTS AND MANAGEMENT CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( P
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) SECOND QUARTER HIGHLIGHTS AND MANAGEMENT CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today released its Appendix 4C Quarterly Report for the second qu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 9 January 2014 PRIMA BIOMED CEO MATTHEW LEHMAN TO BE INTERVIEWED ON CLEAR CHANNEL BUSINESS TALK RADIO DFW 1190AM Mr. Lehman to be Interviewed Live on The Traders Network R
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) MATTHEW LEHMAN TO BE INTERVIEWED ON CLEAR CHANNEL BUSINESS TALK RADIO DFW 1190AM Mr. Lehman to be Interviewed Live on The Traders Network Radio Show by BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ), a leader in de
Read more →IMMPRule?2.7,?3.10.3,?3.10.4,?3.10.5? Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information?or?documents?not?available?now?must?be?given?to?ASX?as?soon?as?available.
Rule?2.7,?3.10.3,?3.10.4,?3.10.5? Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information?or?documents?not?available?now?must?be?given?to?ASX?as?soon?as?available.??Information?and?documents? given?to?ASX?become?ASX?s?prop
Read more →IMMPPRIMA BIOMED A Leader in Developing Immunocellular Therapeutics for Cancer Analyst Briefing Document 09 December 2013 Investment Highlights CVac immunotherapy is a potential game changer in the treatment of ovarian cance
A Leader in Developing Immunocellular Therapeutics for Cancer Analyst Briefing Document Investment Highlights CVac immunotherapy is a potential game changer in the treatment of ovarian cancer: Maintenance therapy for ovarian cancer after second line treatment is a significant
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 26 November 2013 EXPERT PANEL TO DISCUSS PRIMA BIOMED S CVAC CLINICAL TRIAL DATA IN OVARIAN CANCER SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASD
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) DISCUSS PRIMA BIOMED S CVAC CLINICAL TRIAL DATA IN OVARIAN SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) announced that its recently reported CVac c
Read more →IMMPAppendix 3Z Final Director s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director s Interest Notice Information or documents not available now must be g
Appendix 3Z Final Director s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 20 November 2013 PRIMA BIOMED S CEO TO PRESENT AT 11 th ANNUAL COMMERCIAL TRANSLATION OF REGENERATIVE MEDICINE MEETING SYDNEY, AUSTRALIA Prima BioMed L
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED S CEO TO PRESENT AT 11th ANNUAL COMMERCIAL TRANSLATION OF REGENERATIVE MEDICINE MEETING AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today annou
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 15 November 2013 Chairman s address Prima Biomed Ltd 2013 Annual General Meeting Lucy Turnbull AO Welcome to the Prima Biomed Ltd Annual General Meetin
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) Prima Biomed Ltd 2013 Annual General Meeting Welcome to the Prima Biomed Ltd Annual General Meeting for 2013. It is a pleasure to see our shareholders here in attendance today. We appreciate our investors sup
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 11 November 2013 PRIMA BIOMED UPDATES CVAC DEVELOPMENT PROGRAM; CLINICAL TRIAL FOCUS ON SECOND-REMISSION OVARIAN CANCER PATIENT POPULATION Prima BioMed
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 11 November 2013 PRIMA BIOMED UPDATES CVAC DEVELOPMENT PROGRAM; CLINICAL TRIAL FOCUS ON SECOND-REMISSION OVARIAN CANCER PATIENT POPULATION Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima
Read more →IMMPPRIMA BIOMED DISCUSSES Q1 OF FISCAL YEAR 2014 RESULTS AND CVAC PROGRAM UPDATE EARNINGS CALL TRANSCRIPT Executives Matthew Lehman, Chief Executive Officer Marc Voigt, Chief Financial Officer Sharron Gargosky, Chief Techni
PRIMA BIOMED DISCUSSES Q1 OF FISCAL YEAR 2014 RESULTS AND CVAC PROGRAM UPDATE EARNINGS CALL TRANSCRIPT Matthew Lehman, Chief Executive Officer Marc Voigt, Chief Financial Officer Sharron Gargosky, Chief Anton Uvarov, RM Capital Robin Davidson, Edison Investment Research Ber
Read more →IMMPst quarter results for FY 2014 (period ended 30 September 2013) Supplemental information to management discussion
1st quarter results for FY 2014 (period ended 30 September 2013) Supplemental information to management discussion November 7, 2013 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 PRIMABIOMED1 Important Notice The purpose of the presentation is to provide an update of the business of P
Read more →IMMPPRIMA BIOMED ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 1 November 2013 PRIMA BIOMED FIRST QUARTER REPORT, MANAGEMENT CONFERENCE CALL AND CVAC PROGRAM UPDATE Prima BioMed Ltd (ASX: PRR; NASDAQ:
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED FIRST QUARTER REPORT, MANAGEMENT CONFERENCE CALL AND CVAC PROGRAM UPDATE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) yesterday released its Appendix 4C Qu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 06 November 2013 PRIMA BIOMED AND NEOPHARM LTD ENTER INTO LICENSE FOR CVAC IN ISRAEL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Pr
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 06 November 2013 PRIMA BIOMED AND NEOPHARM LTD ENTER INTO LICENSE FOR CVAC IN ISRAEL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that it has ent
Read more →IMMPPRIMA BIOMED LTD Australian Cancer Treatment Company ACN 009 237 889 Notice of 2013 Annual General Meeting Including Explanatory Notes and Proxy Form To be held on: Friday, 15 November 2013 10.30 am (AEDT) (registration
Australian Cancer Treatment Company Annual General Meeting Including Explanatory Notes and Proxy Form Friday, 15 November 2013 10.30 am (AEDT) (registration commencing at 10.00 am) Radisson Blue Plaza Hotel Sydney, 27 O Connell Street, Sydney, NSW, 2000, Australia This is a
Read more →IMMPPRIMA BIOMED MANAGEMENT PRESENTS CVAC TM PHASE 2 TRIAL RESULTS - CALL TRANSCRIPT Prima BioMed (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 2 nd October 2013 8:00am AEST James Moses: Investor Relations Representative Good
PRIMA BIOMED MANAGEMENT PRESENTS CVACTM PHASE 2 TRIAL RESULTS - Prima BioMed (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 2nd October 2013 8:00am AEST James Moses: Investor Relations Representative morning ladies and gentlemen and welcome to Prima BioMed s presentation of the
Read more →IMMPCAN-003 Analysis Phase 2 trial of CVac for the treatment of ovarian cancer patients in first or second remission Supplemental information to management presentation on
Phase 2 trial of CVac for the treatment of ovarian cancer patients in first or second remission Supplemental information to management presentation on October 2, 2013 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 The purpose of the presentation is to provide an update of the busi
Read more →IMMPAnnual Report 2013 ABN 90 009 237 889 PRIMA BIOMED CONTENTS 03 Corporate Directory 04 Chairman s Letter 06 Review of Operations 13 Directors Report 21 Management Directory 39 Corporate Governance Report 48 Auditors Indep
03 Corporate Directory 04 Chairman s Letter 06 Review of Operations 21 Management Directory 39 Corporate Governance 48 Auditors Independence Declaration 51 Consolidated Statement of Comprehensive Income 52 Consolidated Balance Sheet Statement of Changes in Equity 54 Cons
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 18 September 2013 TOP-LINE ANALYSIS OF CVAC PHASE 2 TRIAL; OVARIAN CANCER CLINICAL DEVELOPMENT UPDATE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; N
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) TOP-LINE ANALYSIS OF OVARIAN CANCER CLINICAL DEVELOPMENT UPDATE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced top-line analysis of
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 11 September 2013 PRIMA BIOMED TO PRESENT AT WDM CAPITAL 1 st GLOBAL LIFE SCIENCES CONFERENCE IN WARSAW SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR;
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO PRESENT AT WDM CAPITAL 1st GLOBAL LIFE SCIENCES CONFERENCE IN WARSAW SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced to
Read more →IMMPCompany Announcements Australian Stock Exchange, Sydney 30 August 2013 Announcement of Results Year ended 30 June 2013 Please find attached the Appendix 4E and annual financial report for the year ended 30 June 2013. You
Company Announcements Australian Stock Exchange, Announcement of Results Year ended 30 June 2013 Please find attached the Appendix 4E and annual financial report for the year ended 30 June 2013. General Counsel & Company PRELIMINARY FINAL REPORT Name of entity: Prima BioMe
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 21 August 2013 PRIMA BIOMED TO PRESENT AT THE 15 th ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO PRESENT AT THE 15th ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced
Read more →IMMPPRIMA BIOMED Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 15 August 2013 PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS A
PRIMA BIOMED Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 15 August 2013 PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT AND APPENDIX 3B SYDNEY, AUSTRALIA - Prima BioMed Ltd (AS
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 14 August 2013 PRIMA BIOMED S CANVAS CLINICAL TRIAL APPROVED TO START IN KOREA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED S CANVAS CLINICAL TRIAL APPROVED TO START IN KOREA SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that the Korean
Read more →IMMPPRIMA BIOMED Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 8 August 2013 PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS AC
Australian Cancer Treatment Company Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT AND APPENDIX 3B SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154
Read more →IMMPth quarter results for FY 2013 (period ended 30 June 2013) Supplemental information to management discussion
4th quarter results for FY 2013 (period ended 30 June 2013) Supplemental information to management discussion August 6, 2013 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (AS
Read more →IMMPAppendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C - 4th Quarter Quarterly Report For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Name of
Appendix 4C Quarterly report for entities admitted on the basis of commitments Appendix 4C - 4th Quarter For Entities Admitted on the Basis of Commitments Introduced 31/3/2000. Amended 30/9/2001 Prima BioMed Ltd (ASX:PRR) Quarter Ended ( Current Quarter ) Consolidated Stat
Read more →IMMPPRIMA BIOMED LTD Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 19 July 2013 PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS
Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED ISSUES THE FOLLOWING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT AND APPENDIX 3B SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; IS
Read more →IMMPLevel 7, 151 Macquarie Street Sydney NSW 2000 Australia 11 July 2013 ASX Compliance Pty Ltd 20 Bridge Street SYDNEY NSW 2000 Dear Stephanie, Prima BioMed Limited ASX Price Query Response I refer to your letter dated 11 J
Level 7, 151 Macquarie Street Sydney NSW 2000 Australia ASX Compliance Pty Ltd Prima BioMed Limited ASX Price Query Response I refer to your letter dated 11 July 2013 in relation to the ASX Price Query. Limited (Prima BioMed) provides the following responses to the qu
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 4 July 2013 PRIMA BIOMED ACTIVATES STUDY SITES IN GERMANY AND MULTIPLE EUROPEAN COUNTRIES FOR CANVAS CLINICAL TRIAL SYDNEY, AUSTRALIA - Prima BioMed Lt
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) BIOMED ACTIVATES STUDY SITES IN GERMANY AND MULTIPLE EUROPEAN COUNTRIES FOR CANVAS CLINICAL TRIAL SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is p
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 25 June 2013 PRIMA BIOMED TO MOVE FORWARD WITH PHASE 2 CLINICAL PROGRAM FOR CVAC IN PANCREATIC, COLORECTAL, AND TRIPLE-NEGATIVE BREAST CANCERS SYDNEY,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO MOVE FORWARD WITH PHASE 2 CLINICAL PROGRAM FOR CVAC IN PANCREATIC, COLORECTAL, AND TRIPLE-NEGATIVE BREAST CANCERS AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Pr
Read more →IMMPMARKET RELEASE 24 June 2013 Prima Biomed Limited TRADING HALT The securities of Prima Biomed Limited (the Company ) will be placed in Trading Halt Session State at the request of the Company, pending the release of an an
Prima Biomed Limited Prima Biomed Limited (the Company ) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State unt
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 19 June 2013 CVAC CAN-003 TRIAL SELECTED FOR ORAL PRESENTATION AT THE EUROPEAN CANCER CONGRESS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ:
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) CAN-003 TRIAL SELECTED FOR ORAL PRESENTATION AT THE EUROPEAN CANCER CONGRESS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced that the
Read more →IMMPASX Announcement Release Code: PRR 18 June 2013 ENTITLEMENT OFFER TOP 20 AND DISTRIBUTION SCHEDULE Following the completion of Prima BioMed Ltd s ABN 90 009 237 889 ( Company ) entitlement offer of options ( Options ) an
ENTITLEMENT OFFER TOP 20 AND DISTRIBUTION SCHEDULE Following the completion of Prima BioMed Ltd s ABN 90 009 237 889 (Company) entitlement offer of options (Options) and, as required by paragraphs 35 and 36 of Appendix 3B of the ASX Listing Rules, please find attached to this a
Read more →IMMPASX Announcement Release Code: PRR 13 June 2013 Prima BioMed Ltd Completion of Entitlement Offer Prima BioMed Ltd ABN 90 009 237 889 ( Company ) is pleased to announce the successful completion of its 1 for 4 non-renounc
Prima BioMed Ltd Completion of Entitlement Offer Prima BioMed Ltd ABN 90 009 237 889 (Company) is pleased to announce the successful completion of its 1 for 4 non-renounceable entitlement offer (Entitlement Offer) of options (Options) to acquire fully paid ordinary shares in th
Read more →IMMPINVESTOR UPDATE by PRIMA BIOMED Edition JUNE 2013 10 Message from the CEO Exciting times for cancer immunotherapy Several of the Prima team attended the recent American Society for Clinical Oncology (ASCO) annual meeting
Message from the CEO Exciting times for cancer immunotherapy of the Prima team attended the recent American Society for Clinical Oncology (ASCO) annual meeting in Chicago. This is one of the largest such meeting in the world every year and an important event to catch up on impo
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 24 May 2013 Prima BioMed Ltd Mailing of Prospectus and Entitlement and Acceptance Form completed Prima BioMed Ltd ABN 90 009 237 889 ( Company ) advise
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) Mailing of Prospectus and Entitlement and Acceptance Form completed Prima BioMed Ltd ABN 90 009 237 889 (Company) advises that the prospectus (Prospectus) and a personalised entitlement and acceptance form (E
Read more →IMMPLevel 7, 151 Macquarie Street Sydney NSW 2000 Australia 17 May 2013 ASX Market Announcements ASX Limited Level 4, Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam Notice under section 708A(5)(e) of the Cor
151 Macquarie Street Sydney NSW 2000 Australia 17 May 2013 ASX Market Announcements ASX Limited Level 4, Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam Notice under section 708A(5)(e) of the Corporations Act and Appendix 3B This notice is given by Prima BioMed L
Read more →IMMPLevel 7, 151 Macquarie Street Sydney NSW 2000 Australia 15 May 2013 ASX Market Announcements ASX Limited Level 4, Exchange Centre 20 Bridge Street Sydney NSW 2000 Dear Sir/Madam Prima BioMed Ltd Completion of SPP Prima B
ASX Market Announcements Level 4, Exchange Centre Prima BioMed Ltd Completion of SPP Prima BioMed Ltd ABN 90 009 237 889 (Company) is pleased to announce the successful completion of the share purchase plan the terms of which were given to ASX Limited (ASX) on 11 April 2013 T
Read more →IMMPASX Announcement Release Code: PRR 14 May 2013 ENTITLEMENT OFFER LETTER TO SHAREHOLDERS As required by paragraph 3 of Appendix 7A to the ASX Listing Rules, Prima BioMed Ltd ABN 90 009 237 889 ( Company or Prima ) has tod
ENTITLEMENT OFFER LETTER TO SHAREHOLDERS As required by paragraph 3 of Appendix 7A to the ASX Listing Rules, Prima BioMed Ltd ABN 90 009 237 889 (Company or Prima) has today mailed the attached letter to all shareholders in relation to its recently announced entitlement offer (
Read more →IMMPPrima Biomed Australian Cancer Treatment Company ASX Announcement Release Code: PRR 13 May 2013 ENTITLEMENT OFFER PROSPECTUS AND APPENDIX 3B Prima BioMed Ltd ABN 90 009 237 889 (Company or Prima) is pleased to provide th
Prima Biomed Australian Cancer Treatment Company ASX Announcement Release Code: PRR 13 May 2013 ENTITLEMENT OFFER PROSPECTUS AND APPENDIX 3B Prima BioMed Ltd ABN 90 009 237 889 (Company or Prima) is pleased to provide the prospectus (Prospectus) relating to its recently announce
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 8 May 2013 RUSSELL J. HOWARD TO JOIN PRIMA BIOMED S BOARD OF DIRECTORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) HOWARD TO JOIN PRIMA BIOMED S BOARD OF DIRECTORS SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that Russell J. Howard, PhD, w
Read more →IMMPInvestor Update by PRIMA BIOMED National Ovarian Cancer Day May 8th SPECIAL EDITION MAY 2013 Prima BioMed News Update In addition to our regular quarterly Shareholder Newsletter, we are happy to bring you more frequent n
National Ovarian Cancer Day May 8th Prima BioMed News Update regular quarterly Shareholder Newsletter, we are happy to bring you more frequent news updates in this brief format. Prima is dedicated to consistent and clear communications with our investors. In addition to this ne
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 24 April 2013 PRIMA BIOMED UPDATES CLINICAL LEADERSHIP TEAM SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima ,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) BIOMED UPDATES CLINICAL LEADERSHIP TEAM SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that Holbrook Kohrt, MD, PhD and Pamela
Read more →IMMPPRIMA BIOMED Australian Cancer Treatment Company ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 24 April 2013 PRESENTATION AT ANNUAL MEETING OF INTERNATIONAL SOCIETY FOR CELLULAR THERAPY SYDNEY, AUS
Australian Cancer Treatment Company Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRESENTATION AT ANNUAL MEETING OF INTERNATIONAL SOCIETY FOR CELLULAR THERAPY SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 19 April 2013 PRIMA BIOMED QUARTERLY RESULTS AND CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company )
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED QUARTERLY RESULTS AND CONFERENCE CALL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today released its Appendix 4C Quarterly Report for the three month peri
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 17 April 2013 PRIMA BIOMED AWARDED JAPANESE PATENT FOR CVAC SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima ,
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED AWARDED JAPANESE PATENT FOR CVAC SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that it has been granted a patent
Read more →IMMPLevel 7, 151 Macquarie Street Sydney NSW 2000 Australia 11 April 2013 ASX Market Announcements ASX Limited Level 4, Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam Share Purchase Plan notice under ASIC CO
Level 7, 151 Macquarie Street ASX Market Announcements Purchase Plan notice under ASIC CO 09/425 Prima BioMed Ltd (ASX: PRR) (Prima) gives notice that within 24 hours it will make offers to issue shares under a share purchase plan without disclosure to investors under Part 6D
Read more →IMMPPRIMA BIOMED Australian Cancer Treatment Company ASX Announcement Release Code: PRR 11 April 2013 SHARE PURCHASE PLAN OFFER DOCUMENTS Prima BioMed Ltd ( Prima or the Company ) is pleased to provide the offer documentatio
PRIMA BIOMED Australian Cancer Treatment Company ASX Announcement Release Code: PRR 11 April 2013 SHARE PURCHASE PLAN OFFER DOCUMENTS Prima BioMed Ltd ( Prima or the Company ) is pleased to provide the offer documentation relating to its recently announced share purchase plan (
Read more →IMMPASX Announcement Release Code: PRR 8 April 2013 SHARE PURCHASE PLAN UPDATE Prima BioMed Ltd ( Prima or the Company ) is pleased to provide an update on its planned Share Purchase Plan ( SPP ). Having taken into account p
SHARE PURCHASE PLAN UPDATE Ltd ( Prima or the Company ) is pleased to provide an update on its planned Share Purchase Plan ( SPP ). Having taken into account potential market conditions and feedback from its shareholders, the Company has changed the way in which the offer price
Read more →IMMPASX Announcement Release Code: PRR 2 April 2013 PLANNED SHARE PURCHASE PLAN AND ENTITLEMENT OFFER OF LISTED OPTIONS; NOTICE OF EXTRAORDINARY GENERAL MEETING Prima BioMed Ltd ( Prima or the Company ) is pleased to announc
PLANNED SHARE PURCHASE PLAN AND ENTITLEMENT OFFER OF LISTED OPTIONS; NOTICE OF EXTRAORDINARY GENERAL MEETING Prima BioMed Ltd ( Prima or the Company ) is pleased to announce that it expects to offer existing eligible shareholders the It is intended for the new shares issued und
Read more →IMMPASX Announcement Release Code: PRR 28 March 2013 CHANGE IN SENIOR MANAGEMENT Prima BioMed Ltd (ASX:PRR) ( Prima , the Company ) has announced that Neil Frazer will step down as full time Chief Medical Officer effective a
CHANGE IN SENIOR MANAGEMENT Prima BioMed Ltd (ASX:PRR) ( Prima , the Company ) has announced that Neil Frazer will step down as full time Chief Medical Officer effective as of June 30, 2013. Dr. Frazer will continue to advise the Company as a consultant through December 31, 201
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 20 March 2013 3.8 MILLION EURO GRANT TO SUPPORT CVAC DEVELOPMENT; PRIMA MOVING FORWARD WITH PILOT TRIALS OF CVAC IN ADDITIONAL CANCER INDICATIONS Prima
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 3.8 MILLION EURO GRANT TO SUPPORT CVAC DEVELOPMENT; PRIMA MOVING FORWARD WITH PILOT TRIALS OF CVAC IN ADDITIONAL CANCER INDICATIONS Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 11 March 2013 PRIMA BIOMED TO PRESENT AT ISBIOTECH ANNUAL MEETING SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Pri
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO PRESENT AT ISBIOTECH ANNUAL MEETING SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) announces that its Vice President of Manufacturing, M
Read more →IMMPPRIMA BIOMED DISCUSSES FIRST HALF OF FISCAL YEAR 2013 RESULTS EARNINGS CALL TRANSCRIPT Executives Matthew Lehman, Chief Executive Officer Marc Voigt, Chief Financial Officer Sharron Gargosky, Chief Technical Officer Anal
PRIMA BIOMED DISCUSSES FIRST HALF OF FISCAL YEAR 2013 RESULTS EARNINGS CALL TRANSCRIPT Matthew Lehman, Chief Marc Voigt, Chief Financial Officer Sharron Gargosky, Chief Technical Officer Anton Uvarov, RM Capital Chris Kallos, Edison Luca Pancratov, Roth Capital Partners Re
Read more →IMMPImportant Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the i
Results to be read in conjunction with notes from the Company s Half Year Report and previous year s Annual Report, both published in compliance with ASX listing rule 4.2A. 9 Exciting year ahead Continued scale up of manufacturing and expanding our cell collection network Phase 2
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 5 March 2013 PRIMA BIOMED CONFERENCE CALL TO DISCUSS FIRST HALF OF FISCAL YEAR 2013 RESULTS Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B203
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED CONFERENCE CALL TO DISCUSS FIRST HALF OF FISCAL YEAR 2013 RESULTS Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced it will hold a conference c
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 28 February 2013 PRIMA BIOMED COMMENCES CANVAS CLINICAL TRIAL IN EUROPE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima, the Comp
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED COMMENCES CANVAS CLINICAL TRIAL IN EUROPE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima, the Company ) is pleased to announce that it has commenced recruitment of patients
Read more →IMMPABN 90 009 237 889 Appendix 4D Interim Financial Report For the Half-Year Ended 31 December 2012 (previous corresponding period: half-year ended 31 December 2011) To be read in conjunction with the 30 June 2012 Annual Re
Interim Financial Report For the Half-Year Ended (previous corresponding period: half-year ended 31 December 2011) To be read in conjunction with the 30 June 2012 Annual Report. In compliance with Listing Rule 4.2A ASX/Media Release (ASX: PRR) Appendix 4D Interim Financial
Read more →IMMPRule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX as soon as available.
Rule 2.7, 3.10.3, 3.10.4, 3.10.5 New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and ma
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 6 February 2013 R&D Tax Incentive Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to advise that it has
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to advise that it has received $1,442,120.40 in cash rebate from the federal government s R&D tax incentive progr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 4 February 2013 PRIMA BIOMED ANNOUNCES TWO ACCEPTED ABSTRACTS FOR PRESENTATION AT ISCT ANNUAL MEETING SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; N
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) BIOMED ANNOUNCES TWO ACCEPTED ABSTRACTS FOR PRESENTATION AT ISCT SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) announces that two abstracts related
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 29 January 2013 PRIMA BIOMED TO PRESENT AT THE 15 TH ANNUAL BIO CEO & INVESTOR CONFERENCE SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; I
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO PRESENT AT THE 15TH ANNUAL BIO CEO & INVESTOR CONFERENCE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced today that Matthew Lehman, its Chief
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 24 January 2013 PRIMA BIOMED TO HOST INVESTOR DAYS IN AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) i
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED TO HOST INVESTOR DAYS IN AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce upcoming investor days at several major Australian c
Read more →IMMPASX/Media Release (Code: PRR) 23 January 2013 QUARTERLY ACTIVITY REPORT For Quarter ending 31 December 2012 Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) today released its Appendix 4C Quarterly R
ASX/Media Release (Code: PRR) QUARTERLY ACTIVITY REPORT For Quarter ending 31 December 2012 Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) today released its Appendix 4C Quarterly Report for the three month period ending 31 December 2012. The cash balan
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 24 December 2012 ANNOUNCEMENT FROM MARTIN ROGERS The Company advises that non-executive director, Mr Martin Rogers, has disposed of part of his interest
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) ANNOUNCEMENT FROM MARTIN ROGERS The Company advises that non-executive director, Mr Martin Rogers, has disposed of part of his interest in Prima BioMed Ltd which he has advised were for personal reasons, includ
Read more →IMMPNovember 2012 The Manager Australian Stock Exchange Company Announcements Office Level 4, Exchange Centre 20 Bridge Street Sydney NSW 2000 Dear Sir/Madam, Re: Results of 2012 Annual General Meeting Resolution 1: That, fo
Australian Stock Exchange Company Announcements Office Level 4, Exchange Centre Annual General Meeting That, for the purposes of section 250R(2) of the Corporations Act 2001 (Cth) and for all other purposes, the 2012 Remuneration Report as published in the Directors Report of
Read more →IMMPASX Announcement (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 16 November 2012 CEO ADDRESS - PRIMA BIOMED LTD 2012 ANNUAL GENERAL MEETING I would like to say thank you to our shareholders for your continued support
ASX Announcement (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) CEO ADDRESS - PRIMA BIOMED LTD 2012 ANNUAL GENERAL MEETING I would like to say thank you to our shareholders for your continued support of Prima. I am happy to have the opportunity to speak to you today about Pr
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 14 November 2012 PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL Interim immune monitoring data demonstrate positive effe
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima, the Company ) today released interim immune monitoring data
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 26 October 2012 PRIMA NAMES NEW CHIEF FINANCIAL OFFICER AND NEW COMPANY SECRETARY IN MANAGEMENT REORGANISATION Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; I
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) PRIMA NAMES NEW CHIEF FINANCIAL OFFICER AND NEW COMPANY SECRETARY IN MANAGEMENT BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) ( Prima, the Company ) announced today the following changes in senior manage
Read more →IMMPASX/Media Release (Code: PRR) 26 October 2012 QUARTERLY ACTIVITY REPORT For Quarter ending 30 September 2012 Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) today released its Appendix 4C Quarterly
ASX/Media Release (Code: PRR) QUARTERLY ACTIVITY REPORT For Quarter ending 30 September 2012 Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) today released its Appendix 4C Quarterly Report for the three month period ending 30 September 2012. The cash bal
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 18 October 2012 PRIMA TO PRESENT AT ASX SMALL TO MID CAPS CONFERENCE IN HONG KONG Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) announces t
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) TO PRESENT AT ASX SMALL TO MID CAPS CONFERENCE IN HONG KONG Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) announces that its CEO Matthew Lehman will present a corporate update at the ASX Small to
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 15 October 2012 POSITIVE INTERIM DATA FROM CAN-003 TRIAL OF CVAC TM FOR OVARIAN CANCER Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) ( Pri
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) POSITIVE INTERIM DATA FROM CAN-003 TRIAL OF CVACTM FOR OVARIAN CANCER Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) ( Prima , the Company ) today announced positive trends in the interim data fro
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) 04 October 2012 PRIMA BIOMED RELEASES QUARTERLY SHAREHOLDER NEWSLETTER, UPDATE ON CANVAS STUDY PROGRESS Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US7
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034) PRIMA BIOMED RELEASES QUARTERLY SHAREHOLDER NEWSLETTER, UPDATE ON CANVAS STUDY PROGRESS Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) ( Prima, the Company ) today released its quarterly Sharehold
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20th September 2012 Prima BioMed to Present at BIOX Prima BioMed Ltd (Prima, the Company) announces that its CEO Matthew Lehman will present a corporate update at BIOX; No
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Prima BioMed to Present at BIOX Prima BioMed Ltd (Prima, the Company) announces that its CEO Matthew Lehman will present a corporate update at BIOX; Noble Financial Capital Markets Life Sciences Exposition to be held at the Univ
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 31 August 2012 Remuneration package for incoming CEO Mr Matthew Lehman On 24 May 2012 the Company announced that Mr Matthew Lehman would assume the role of Chief Executive
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) Remuneration package for incoming CEO Mr Matthew On 24 May 2012 the Company announced that Mr Matthew Lehman would assume the role of Chief Executive Officer effective 1 September 2012. Mr Lehman will receive a combination of fi
Read more →IMMPPrima BioMed Ltd Level 7, 151 Macquarie Street Sydney NSW 2000 Australia Tel.: +61 (0) 2 9276 1224 Fax: +61 (0) 2 9276 1284 www.primabiomed.com.au Company Announcements Australian Stock Exchange, Sydney 31 August 2012 An
Level 7, 151 Macquarie Street Tel.: +61 (0) 2 9276 1224 Fax: +61 (0) 2 9276 1284 www.primabiomed.com.au Company Announcements Announcement of Results Year ended 30 June 2012 Please find attached the Appendix 4E and annual financial report for the year ended 30 June 2012.
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 30 July 2012 PRIMA BIOMED TO RELEASE INTERIM CVAC CLINICAL DATA Prima BioMed Ltd (ASX: PRR, NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO RELEASE INTERIM CVAC CLINICAL DATA Prima BioMed Ltd (ASX: PRR, NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim results from its CVac clinical trial CAN-003 in October 2012. The Int
Read more →IMMPThe purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR and NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they c
Execute development plans : Data will be the main driver for future growth in company value Data establishes safety, efficacy, and commercial viability of our products Data is the basis for global regulatory approvals physician use Focus on data quality Focus on data integrity Co
Read more →IMMPASX/Media Release: (Code: ASX: PRR; NASDAQ: PBMD) 13 th June 2012 PRIMA BIOMED LTD SHAREHOLDERS BRIEFING WEBCAST & DIAL IN DETAILS Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) confirms the webcast and dial in details for th
ASX/Media Release: (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED LTD SHAREHOLDERS BRIEFING WEBCAST & DIAL IN DETAILS Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) confirms the webcast and dial in details for the shareholder briefing to be held on Friday 15th June 2012, at 9.30am (Sy
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 8 June 2012 PRIMA BIOMED DUBAI UPDATE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) advises that it will be winding down its business activities in Du
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED DUBAI UPDATE Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) advises that it will be winding down its business activities in Dubai due to regulatory delays and logistical challenges that would mak
Read more →IMMPJune 2012 Prima BioMed to list on the Frankfurt Stock Exchange SYDNEY, AUSTRALIA Australian biotechnology company Prima BioMed Ltd. (ASX: PRR, NASDAQ: PBMD) announced today that it is to list its American depository rece
Prima BioMed to list on the Frankfurt Stock Exchange SYDNEY, AUSTRALIA Australian biotechnology company Prima BioMed Ltd. (ASX: PRR, NASDAQ: PBMD) announced today that it is to list its American depository receipts (ADRs) on the Entry Standard of the Frankfurt Stock Exchange as
Read more →IMMPASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 31 May 2012 PRIMA BIOMED TO HOST SHAREHOLDER BRIEFING Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company) advises that it will hold a shareholder briefing with
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) PRIMA BIOMED TO HOST SHAREHOLDER BRIEFING Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company) advises that it will hold a shareholder briefing with the Company s CEO designate Matthew Lehman, current CEO Martin Rogers
Read more →IMMPASX/Media Release (Code: ASX:PRR; NASDAQ:PBMD) 24 May 2012 PRIMA BIOMED ANNOUNCES CHANGES TO THE BOARD AND SENIOR MANAGEMENT Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD) ( Prima or the Company ) advises of the following chang
ASX/Media Release (Code: ASX:PRR; NASDAQ:PBMD) PRIMA BIOMED ANNOUNCES CHANGES TO THE BOARD AND SENIOR MANAGEMENT Prima BioMed Ltd (ASX:PRR; NASDAQ:PBMD) ( Prima or the Company ) advises of the following changes to senior management and the board of directors. The Company s Ch
Read more →IMMPSOURCE: Prima BioMed
SOURCE: Prima BioMed May 02, 2012 09:10 ET Prima BioMed to Present at the 37th Annual Deutsche Health Care Conference AUSTRALIA (Marketwire May 2, 2012) Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) announced today that Dr. Neil Frazer, Chief Medical Officer, will present at the
Read more →IMMPASX/Media Release (Code: PRR) 27 April 2012 QUARTERLY ACTIVITY REPORT For Quarter ending 31 March 2012 Prima BioMed (Prima) (ASX: PRR; NASDAQ: PBMD) today released its Appendix 4C Quarterly Report for the three month per
ASX/Media Release (Code: PRR) QUARTERLY ACTIVITY REPORT For Quarter ending 31 March 2012 Prima BioMed (Prima) (ASX: PRR; NASDAQ: PBMD) today released its Appendix 4C Quarterly Report for the three month period ending 31 March 2012. The cash balance as of 31 March 2012 was A$
Read more →IMMPImportant Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR). These slides have been prepared as a presentation aid only and the information they
Ian Frazer Prof. Neil Foster developing dense gas technology to formulate oral HPV vaccine Program Status Studies with Eudragit coated lyzosyme completed feasibility studies with ovalbumin ongoing Animal studies initiated to evaluate immunogenicity 21 Financial Profile Financial
Read more →IMMPPrima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Read more →Competitive Position
How IMMP ranks across every disease it competes inCompetitive Position is a premium feature
See how IMMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial